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The  local  and  systemic  immune  responses  to  an  inactivated, 
intranasal  Influenza  vaccine  were  evaluated  In  healthy 
volunteers  found  to  have  either  no  antibody  or  low  titres 
of  antibody  to  Influenza  A/Victoria/3/75  (H3N2).  A  similar 
control  group  who  received  placebo  (  an  aerosol  with  the  same 
appearance  and  composition  as  the  vaccine  except  that  It  did 
not  contain  virus  )  intranasally  was  included.  Nine  of  twenty- 
two  recipients  and  none  of  twenty-one  placebo  recipients 
developed  circulating  H-I  antibody  to  the  vaccine.  However, 
six  volunteers  in  each  group  developed  a  four-fold  rise  in  local 
H-I  antibody  levels.  Four  vaccine  recipients  and  five  placebo 
recipients  developed  four-fold  rises  in  local  neutralising 
antibody  levels.  Four  months  after  the  intranasal  admin- 
istration  of  vaccine  or  placebo  all  subjects  were  challenged 
intranasally  with  an  attenuated  vaccine  against  the  same  virus. 
Five  placebo  recipients  and  four  vaccine  recipients  subsequently 
developed  circulating  H-I  antibody. 
The  Interpretation  of  results  was  complicated  by  a 
natural  outbreak  of  Influenza  in  the  community  at  the  same  time 
as  the  trial.  In  the  volunteers  the  inactivated  vaccine  showed 
a  serological  response.  There  was  a  slight  protective  effect 
against  the  challenge  vaccine  but  not  against  natural  Infection. 
However,  the  timing  of  natural  infection  was  unknown  and  it  Is 
likely  that  the  vaccine  had  insufficient  time  to  'take'. 
The  response  to  natural  infection  is  of  longer  duration 
than  that  induced  by  vaccination.  However,  antibody  levels 
(>,  1:  16  )  were  maintained  for  the  four  month  test  period. 
The  criteria  used  for  selection  of  volunteers  was 
questioned  and  the  recommendation  was  made  that,  in  future, 
sIgA  levels  as  well  as  serum  H-I  antibody  levels  should  be 
measured  prior  to  accepting  a  subject  for  a  vaccine  trial. The  predominant  respiratory  pathogens  in  a  community  were 
analysed  during  two  winter  periods  and  sIgA  production  during 
and  following  respiratory  Infection  was  evaluated.  Selected 
subjects  were  examined  over  the  two  year  period.  These  showed 
individual  and  variable  patterns  of  sIgA  production.  There 
was  no  difference  in  sIgA  production  between  patients  suffering 
from  repeated  respiratory  infections  whether  complicated  by 
allergies  or  not  when  compared  to  the  rest  of  the  General 
Practice  patients  studied. TABLE  OF  CONTENTS 
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PROPOSITUS 
The  alms  of  the  study  are  : 
Part  1.  Vaccine  Trial 
1.  to  study  the  protective  efficacy  of  an  inactivated 
Influenza  vaccine,  administered  by  single  dose  aerosol. 
Four  months  after  vaccination  the  degree  of  protection  to 
be  assessed  by  measuring  immunity  to  challenge  infection 
with  a  live,  attenuated  virus  vaccine  introduced  intra- 
nasally,  in  the  light  of  an  evaluation  of  the  volunteer's 
previous  experience  with  Influenza  virus  infections. 
2.  to  assess  over  the  same  period  the  persistence  of 
local  and  serum  antibodies  elicited  by  vaccination 
against  Influenza. 
3.  to  evaluate  the  correlation  between  the  level  of  local 
and  serum  antibodies  and  response  to  artificial  infection. 
Part  2.  The  Secretory  Immune  Response  to  Respiratory  Infections. 
1.  to  study  secretory  immunity  following  naturally  acquired 
Influenza  and  other  respiratory  viral  diseases  during  two 
winter  periods. 
2.  to  examine  the  dynamics  of  secretory  antibody  production 
in  terms  of  time  of  initiation,  variation  in  total  duration 
and  quantity  of  production  both  during  infection  with 
recognised  bacterial  and  viral  pathogens  and  particularly 
relating  to  previous  history  of  respiratory  infection. 
This  latter  to  include  possible  malfunctions  of  the 
secretory  system  as  may  happen  in  chronic  bronchitis  and 
emphysema. 2 
CHAPTER  1 
LITERATURE  REVIEW 
1.1  INTRODUCTION 
Our  understanding  of  the  aetiology  and  epidemiology  of 
the  respiratory  and  gastrointestinal  tract  diseases  caused 
by  viruses  far  exceeds  our  capacity  to  control  or  to  alter 
the  course  of  these  illnesses.  Effective  immunoprophylaxis 
still  represents  a  formidable  challenge. 
The  mucosal  surface  of  the  respiratory  tract  is  an 
extensive  area  that  must  be  protected  from  penetration  by 
pathogenic  organisms  and  from  toxic  agents  in  the  environment. 
Protection  Is  mediated  by  a  local  Immune  system  which  is 
independent  of  systemic  immunity  (Bienenstock  (1974); 
Tomasi  (1976);  Lamm  (1976).  )  In  contrast  to  serum  in  which 
IgG  is  the  predominating  immunoglobulin,  secretions  contain 
secretory  IgA,  an  11S  dimer  with  secretory  component  (S.  C)  and 
3-chain  forming  a  molecule  Ideally  suited  to  the  environment  In 
which  it  is  active.  Protection  occurs  at  the  level  of  the 
mucous  membrane  by  the  neutralisation  of  viruses  and  control 
of  bacterial  proliferation  by  limiting  mobility  and  adherence 
to  epithelial  cells  (Walker  and  Isselbächer,  (1977)  ). 
IgA  found  in  secretions  differs  from  serum  IgA  and  will 
be  extensively  reviewed  in  the  following  chapter.  The  role 
of  monomeric  serum  IgA  in  the  Immunological  defence  system 
is  poorly  understood.  Possible  functions  of  serum  IgA  have 
been  reviewed  recently  by  Schuurman  (1980)  and  will  not  be 
discussed  further. 3 
In  order  to  augment  the  ideas  reviewed  here,  which  are 
only  those  relevant  to  my  study,  the  reader  is  directed  to 
several  excellent  reviews  which  give  an  historical  consideration 
of  the  development  of  the  concept  of  local  immunity.  (Tomasi  aßä 
6cty  (1972)  and  Heremans  (1976)  ). 
1.2  MOLECULAR  STRUCTURE  OF  IgA 
The  human  IgA  monomer  present  in  serum  consists  of  two 
heavy  polypeptide  chains  and  the  two  light  chains  linked 
together  by  disulphide  bridges.  Antigenic  analysis  of  IgA 
myeloma  proteins  have  revealed  two  subclasses  characterised 
by  small  antigenic  differences  in  the  constant  part  of  the 
heavy  chain.  These  subclasses  are  called  IgAl  and  IgA2. 
IgA2  differs  strikingly  from  IgAl  in  the  hinge  region.  This 
leads  to  differences  in  susceptibility  to  digestion  by 
proteolytic  enzymes.  For  example,  the  protease  derived  from 
Streptococcus  sanguis  selectively  cleaves  IgAl  molecules 
whereas  IgA2  is  resistant  to  attack  by  this  enzyme  (Plaut  (1978)  ). 
At  present  IgAl  is  the  only  known  substrate  for  the  proteases 
produced  by  several  species  of  bacteria.  How  protease-- 
production  affects  the  pathogenicity  of  these  organisms  is  an 
area  stimulating  much  current  interest.  In  normal  serum 
about  90%  of  the  total  IgA  belongs  to  the  IgAl  subclass  and 
about  10%  to  the  IgA2  subclass. 
Human  serum  IgA  is  almost  completely  monomeric  with  a 
small  percentage  of  polymeric  IgA  which  is  composed  of  monomers 
linked  by  3-chain.  In  contrast  the  IgA  of  secretions  is 
largely  dimeric.  It  contains  3-chain  and  a  secretory  component 
(S.  C.  )  There  are  two  proposed  models  for  secretory  IgA  (figure  1). 4 
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Figure  1.  Proposed  models  for  secretory  IgA  (Tomasi,  1972) 
It  is  generally  agreed  that  the  3-chain  is  held  in 
disulphide  linkage  with  the  carboxy  terminal  area  of  the  heavy 
chains  of  the  two  IgA  molecules  which  are,  in  turn,  opposed 
by  the  tips  of  their  Fc  regions.  The  physical  arrangement 
is  brought  about  in  the  plasma  cells  which  synthesise  both 
IgA  and  3-chain.  The  evidence  for  the  intracellular 
formation  of  dimers  comes  from  studies  of  secretory  IgA  in  human 
colostrum.  It  was  shown  that  a  single  sIgA  molecule  contains 
either  14  or  -A  light  chains  and  mixed  molecules  are  not 
present  in  appreciable  quantities.  This  random  reassociation 
of  '1S  monomeric  units  in  the  interstitial  region  seems  unlikely. 
It  is  strongly  suggested  that  the  3-chain,  discovered  by 
Halpern  and  Koshland  (1970),  is  the  mediator  of  polymerisation 
in  both  IgA  and  IgM  (Parkhouse  and  Della  Corte  (  1974)  ). 
IgA  monomers  polymerise  in  a'  linear'  structure,  different 
from  the  cylindrical  structure  of  pentameric  IgM  (  Hauptmans 
2.  Compact  form. 
and  Tomasi  (  1975)  ). 5 
The  linear  structure  has  no  restriction  in  the  number  of 
polymers  per  IgA  molecule;  this  is,  in  turn,  reflected 
by  the  existence  of  serum  IgA  myeloma  proteins  with  a 
variable  degree  of  polymerisation.  (Roberts-Thomson  et  al 
(1970)). 
Secretory  component  Is  present  in  secretory  fluids,  both 
free  and  bound  to  immunoglobulins  (Brandtzaeg  et  al.  (1970)). 
It  is  largely  bound  covalently  to  IgA  but  is  only 
non  covalently  associated  with  IgM  (Welker  and  Underdown  (1975)). 
Secretory  component  has  a  high  glycine  content  which  makes 
the  molecule  very  flexible;  it  can,  therefore,  easily  coil 
around  two  adjacent  heavy  chains  in  the  IgA  molecule. 
(Heremans  (1974)  and  Mestecky  (1978)). 
With  the  use  of  Immunofluorescent  techniques  on  intestinal 
tissue,  it  has  been  shown  that  SC  Is  synthesised  in  the 
columnar  epithelial  cells  lining  the  mucous  membranes  while 
0-chain  containing  IgA  Is  synthesised  by  plasma  cells  in  the 
lamina  propria  (Brandtzaeg  and  Balkien  (  1976)  ). 
1.3  ORIGIN  OF  SECRETORY  IgA  (  sIgA) 
The  lymphoblast  precursor  cells  of  the  IgA  producing 
plasma  cells  are  probably  derived  from  gut  associated  lymphoid 
tissue  (G.  A.  L.  T.  )  primarily  Peyer's  patches  and  are  precommitted 
to  IgA  production  before  becoming  distributed  along  the 
mucosal  surface  (Cebra  et  al.  (1977)  ).  These  lymphoblasts 
belong  to  a  sub-population  of  B-cells  which  bear  no  IgM  but 
probably  have  IgA  on  their  membranes  (Craig  and  Cebra  (1975)). 
Immunisation  attempts  have  shown  that  an  antigen  applied 
to  the  mucous  membrane  penetrates  these  nembranes  and  encounters 
the  B-lymphocytes.  The  plasma  cells  which  result  from 
B-lymphocyte  stimulation  produce  IgA  and  this  is  actively 
transported  through  the  epithelial  cells  to  the  surface  of 
membrane  where  the  original  antigenic  stimulation  occurred. 6 
Numerous  examples  clearly  demonstrate  the  efficiency  of  this 
pathway  of  immunisation.  For  example,  stimulation  of  one 
eye  via  the  conjunctival  sac  led  to  the  appearance  of 
antibodies  in  tears  from  the  immunised  site  but  not  from  the 
other  eye.  (Centifanto  et  al.  (1970)).  Similarly  the 
application  of  poliovirus  antigen  into  the  large  intestine  of 
individuals  who  have  had  double-barrelled  colostomies  induced 
sIgA  antibodies  restricted  to  the  site  of  antigen  application 
but  failed  to  induce  antibodies  in  other  parts  of  the 
intestine,  in  glandular  secretions  or  in  nasal  secretions. 
(Ogra  et  al.  (1968)).  These  are  only  two  examples  of  the 
experiments  that  are  suggestive  of  an  IgA-associated  immune 
response  that  results  from  topical  antigen  application. 
Based  on  these  results  the  concept  of  secretory  IgA  mediated 
local  immunity  was  proposed.  (Reviews:  Tomasi  (1976)  and 
Heremans  (1974)). 
However,  these  experiments  did  not  satisfactorily 
explain  the  presence  of  antibodies,  naturally  or  artificially 
induced,  in  the  secretions  of  glands  that  are  remote  from 
mucous  surfaces  such  as  the  mammary  glands  or  the  salivary 
and  lachrymal  glands.  These  are  connected  to  the  mucous  surface 
by  ducts  of  various  lengths.  The  wide  range  of  sIgA  antibodies 
found  in  these  secretions  added  to  the  confusion. 
(Arnold  et  al.  (1976)). 
It  has  been  established  that  IgA  found  In  these  secretions 
is  produced  by  numerous  plasma  cells  which  are  distributed  in 
the  parenchyma  of  the  gland.  (Heremans  (1974)).  Since  IgA 
is  the  predominant  secretory  immunoglobulin  and  since  it  is 
actively  transported  in  secretions,  the  mechanism  of  the 
sIgA  mediated  response  In  glandular  secretions  is  open  to 
question.  If  antigens  that  are  present  on  a  remote  mucous 
surface  are  absorbed,  enter  the  circulation  and  are  carried 
to  the  lymphoid  system  of  a  gland  where  they  induce  an  Immune 
response,  as  demonstrated  by  the  appearance  of  sIgA  in  the 
secretion,  one  would  then  expect  a  parallel  serum  response. 7 
In  addition,  Montgomery  et  al.  (1976)  indicated  that  the 
presence  of  antibodies  in  sera  of  animals  Immunised 
systemically  did  not  prevent  a  subsequent  secretory  response 
induced  by  local  (oral)  ingestion  of  antigens. 
Thus  a  new  pathway  for  the  induction  of  the 
secretory  immune  response  has  been  formulated  from  the 
findings  of  Montgomery  et  al  (1974  and  1976)  and  Cebra's 
previous  observations  concerning  the  origin  of  IgA  precursor 
cells  and  their  homing  patterns.  (Craig  and  Cebra  (1971) 
and  Robertson  and  Cebra  (1976)).  According  to  this  theory 
a  population  of  lymphocytes  from  gut  or  bronchial  associated 
lymphoid  tissues  (GALT  and  BALI)  have  the  potential  for 
seeding  other  tissues  and  differentiating  into  IgA  producing 
plasma  cells.  (Craig  et  al.  (1971)  and  Rudzik  et  al.  (1975)). 
These  lymphocytes  also  carry  the  commitment  to  produce 
specific  antibodies  to  antigens  encountered  in  GALT  and  BALT. 
The  mechanisms  by  which  such  lymphocytes  are  sensitised  by 
antigen  and  how  mature  plasma  cells  subsequently  home  to  the 
mucosal  surfaces  are  not  yet  clearly  established.  Several 
theories  have  been  proposed  by  Bienenstock  (1978). 
Oral  immunisation  studies  have  shown  the  appearance  of 
antibodies  to  the  ingested  antigen  in  secretions  of  mammary 
(Montgomery  et  al  (1974),  salivary  and  lachrymal  glands. 
(Mestecky  (1978a)  ). 
The  available  information  concerning  the  origin  of  IgA 
producing  plasma  cells  and  the  spectrum  of  IgA-associated 
antibodies  found  in  external  secretions  suggest  strongly  that 
there  are  two  pathways  of  stimulation  for  a  secretory  antibody 
immune  response.  The  first  is  a  local  immune  response 
induced  by  topical  antigen  application,  the  second  mechanism 
of  induction  operates  through  the  sensitisation  of  GALT  and 
possibly  BALI. 8 
The  latter  pathway  of  stimulation  leads  to  the  appearance  of 
specific  IgA-associated  antibodies  in  secretions  of  mammary, 
salivary  andlachrymal  glands(and  perhaps  other  sites). 
This  in  turn  suggests  the  existence  of  a  common  mucosal 
secretory  system.  (Figure  2). 
The  factors  determining  which  type  of  secretory  response 
is  evoked  are  largely  inknown.  This  is  an  area  which  needs 
further  research.  It  offers  fascinating  possibilities  in  the 
field  of  vaccine  development. 
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Figure  2.  Pathway  for  Stimulation  of  the  sIgA  Associated 
Immune  Response. 
A.  Local  sIgA  response  restricted  to  the  site  of  antigen 
stimulation.  (  Mestecky  et  al.  (1978  b)  ). 9 
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Figure  2.  (  continued). 
B.  Lymphocytes  (L)  within  gut-associated  lymphoid  tissues  (GALT) 
primarily  Peyer's  Patches  (PP)  of  the  ileum  are  stimulated  by 
antigens  entering  from  the  intestinal  lumen:  I 
l.  via  specialised  epithelium  (M  cells)  across  conventional 
absorptive  cells  or  from  the  systemic  circulation.  Lymphoblasts 
migrate  to  mesenteric  nodes  for  further  maturation  and 
2.  enter  the  systemic  circulation  as  plasmablasts  to  redistribute 
along  intestinal  mucous  surfaces  and 
3.  produce  sIgA  antibodies  in  response  to  absorbed  antigens. 
(  Walker  and  Isselbacher  , 
(1977)) 10 
1.4  PRODUCTION  AND  TRANSPORT  OF  SECRETORY  IgA 
_ 
Irrespective  of  origin,  the  IgA  producing  cells,  once 
situated  at  the  sub-mucosal  surfaces  become  sites  of  secretory 
IgA  synthesis.  Local  synthesis  has  been  confirmed  both  by  In- 
vitro  organ  culture  and  by  Fluorescent  antibody  techniques. 
Secretory  component  synthesised  in  the  epithelial  cells  appears 
to  function  on  the  membrane  of  the  epithelial  cells  as  a 
receptor  for  IgA  dimers  bound  by  3-chain;  the  subsequent  assembly 
occurs  inside  the  cell  during  the  selective  transport  of  IgA 
to  the  mucous  surface.  (Brandtzaeg  (1978)  ).  The  completed 
secretory  immunoglobulin  molecules  are  released  from  the 
epithelial  cells  by  reverse  pinocytosis. 
In  the  absence  of  IgA,  for  example  in  selective  serum 
IgA  deficiency,  there  is  a  compensatory  increase  in  the 
secretion  of  another  polymeric  immunoglobulin  -  namely  IgM. 
This  antibody  is  synthesised  by  the  same  mechanism  as  sIgA. 
Polymeric  immunoglobulins,  in  association  with  S.  C.  appear  to 
represent  an  adaptation  of  immunoglobulins  for  optimum  function 
and  survival  in  secretions. 
The  role  of  the  secretory  component  In  transport  Is 
unclear.  (Lamm  (1976)).  It  has  been  suggested  that  this 
glycoprotein  represents  a  specific  receptor  site  for  polymeric 
Immunoglobulins  which  is  essential  for  it's  uptake  and 
transport  through  epithelial  cells.  An  alternative  role  may 
involve  protection  of  sIgA  against  proteolysis.  Linkage  of 
S.  C.  to  the  IgA  dimer  protects  it  both  against  breakdown  by 
lysosomal  enzymes  during  passage  through  the  epithelial  cells 
and  also  against  other  enzymes  present  on  the  mucous  surface. 
It  is  possible  that  accumulation  of  IgA  plasmacytes  at  the 
site  of  sIgA  production  is  the  consequence  of  a  selective 
homing  process  mediated  by  the  presence  of  S.  C.  on  the  surface 
of  exocrine  epithelial  cells.  (Brandtzaeg  (1973)  ). 11 
Regulation  of  B-cell  antibody  synthesis  appears  to  be 
mediated  by  T-cells  and  macrophages  as  well  as  by  humoral 
substances  derived  from  such  cells.  The  regulatory 
mechanisms  for  the  production  of  IgG  and  IgM  are  well 
documented.  Less  is  known,  however,  about  mechanisms 
for  sIgA  production.  Elson  et  al  (1978)  have  shown  that 
mitogenic  stimulation  of  T-cells  with  Concavellin  A  markedly 
suppressed  IgM  biosynthesis  in  all  tissues  studied  but  the 
effect  of  IgA  biosynthesis  varied  according  to  the  tissue 
examined  -  for  example  in  the  spleen  IgA  biosynthesis 
was  suppressed  whereas  in  Peyer's  Patches  production  was 
enhanced.  This  evidence  suggests  a  separate  T-cell  regulatory 
system  for  sIgA  production. 
1.5  PROPERTIES  OF SECRETORY  IgA 
In  describing  the  properties  of  sIgA  it  should  be  noted 
that  they  begin  at  birth.  The  essentially  sterile 
gastrointestinal  tract  will,  within  several  hours  of  birth, 
be  colonised  by  many  species  and  strains  of  bacteria. 
The  factors  influencing  the  resulting  'normal'  flora  are  many 
but  could  be  due  in  part  to  the  presence  of  sIgA  Ingested  in 
colostrum.  This  regulatory  function  of  sIgA  may  also  be 
reflected  in  the  colonisation  of  respiratory  and  genitourinary 
tracts. 
Colostrum  is  a  rich  source  of  antibodies;  many  of  the 
secretory  type.  These  antibodies,  together  with  maternal 
IgG,  which  has  crossed  the  placenta,  play  a  role  in  the 
development  of  resistance  to  infection  by  the  infant.  Some 
animals,  for  example  bovines,  are  born  agammaglobulinaemic 
because  maternal  IgG  does  not  cross  the  placenta.  If 
colostrum  is  with-held  many  of  the  calves  will  succumb  to 
infection  within  a  short  period  of  time.  Calves  therefore 
receive  all  of  their  immunologic  defences  post  partum. 12 
In  the  human,  the  situation  is  more  complex,  not  only 
because  gammaglobulins  cross  the  placenta,  but  because 
there  is  little  evidence  of  significant  adsorption  of 
antibodies  from  the  gastro-intestinal  tract  (G-I  tract) 
post  partum.  Therefore,  the  role  of  colostral 
antibodies  must  be  at  the  local  gastrointestinal  mucosal  level. 
G-I  tract  permeability  following  birth  is  a  species 
characteristic.  In  humans  the  G-I  tract  Is  impermeable  to 
intact  proteins;  In  other  animals  there  is  a  transient 
period  of  permeability  ranging  for  2-3  days  in  cows  and 
sheep  to  15  --  20  days  in  the  rat. 
The  human  neonate,  at  birth,  possesses  no  detectable 
IgA  either  in  serum  or  secretions.  In  saliva,  however, 
there  is  free  secretory  component.  The  infant,  therefore, 
appears  to  be  prepared  to  develop  a  competent  secretory 
Immunologic  system  and  this  further  supports  the  observation 
by  Tomas!  T.  R.  (1974)  that  the  sIgA  system  develops  earlier 
than  the  serum  IgA  system. 
As  yet,  it  has  not  been  established  whether  IgA  antibodies 
can  mediate  any  secondary  effect  or  functions  following 
interaction  with  antigen  or  whether  differences  exist  in  this 
aspect  between  IgA  subclasses.  Difficulties  are  encountered 
in  obtaining  preparations  of  sIgA  free  from  contaminating 
antibodies  of  other  classes  and  several  discrepancies  have  been 
reported  in  connection  with  the  properties  of  IgA  antibodies. 
It  is  unclear  whether  IgA  antibodies  can  fix  complement 
Götze  and  Muller-Eberhard  (1971)  have  shown  that  although 
IgA  immunoglobulins  cannot  fix  complement  by  the  classical 
pathway,  serum  type  IgA  1  and  IgA  2  and  secretory  IgA  proteins 
are  effective  activators  of  the  alternate  pathway  if  artificially 
aggregated.  However,  in  one  series  of  experiments  by 
Colten  and  Bienenstock  (1974)  the  interaction  of  sIgA  with 
antigen  on  the  surface  of  red  blood  cells  failed  to  activate 
the  alternate  pathway. 13 
In  addition,  it  is  not  certain  whether  all  the  necessary 
complement  components  are  present  in  external  secretions  or, 
if  so,  that  they  can  function  in  such  an  environment. 
(Ballow  (1974)).  Secretory  IgA  antibodies  have  been 
reported  to  interact  with  complement  and  lysozyme  together 
so  as  to  bring  about  bacteriolysis  (Hill  and  Porter  (  1974)  ). 
Opsonisation  is  a  phenomenon  that  can  either  be 
mediated  directly  by  the  Fc  portion  of  an  antibody  or 
indirectly  via  complement.  In  the  case  of  IgA  antibodies, 
the  abilityto  opponise  is  controversial.  (Kaplan  (1972)). 
More  recently  Reynolds  et  al.  (1978)  have  shown  that 
IgG  is  the  most  important  opsonic  antibody  in  the  lower 
respiratory  tract  and  that  sIgA  is  relatively  ineffective  as 
an  opsonin. 
The  ability  of  sIgA  to  counteract  infectious 
micro  organisms  is  well  established.  The  following  section 
will  demonstrate  however  that  this  is  probably  not  its 
sole  protective  function.  Under  natural  conditions, 
especially  in  the  C-I  tract,  IgA  antibodies  are  undoubtedly 
being  formed  against  a  great  many  environmental  and  ingested 
antigens.  This  problem  is  demonstrated  by  observations 
that  IgA  deficient  persons  tend  to  have  increased  levels  and 
incidence  of  humoral  antibodies  directed  toward  antigens 
derived  from  food  and  intestinal  organisms.  (Buckley  &  Dees 
(1969)).  It  is  presumed  that  these  antibodies  are  formed 
because  the  defective  IgA  system  allows  molecules  which 
would  normally  be  prevented  from  absorbing,  to  penetrate  the 
Intestinal  lining.  It  has  been  further  postulated  that 
the  absorption  of  excess  foreign  substances  is  a  factor  in 
the  high  incidence  of  autoimmune  phenomena  in  these 
individuals.  (Lamm.  (1976)).  It  may  be  that  the  ability 
of  sIgA  to  combine  with  antigens  and  to  prevent  absorption 
may  explain  the  predominance  of  the  IgA  class  in  external 
secretions. 14 
Although  the  inflammatory  reaction  is  thought  to 
play  a  protective  and  therefore  a  beneficial  role,  it  is 
often  an  inappropriate  and  poorly  controlled  mechanism. 
Many  of  the  consequences  of  inflammation  are  deleterious 
to  the  host.  For  example,  in  the  case  of  allergic 
inflammation,  it  would  seem  that  the  body  would  be  better  off  if 
sucfi  _an 
immune  response  did  not  occur.  (Thomas  (1971)'. 
and  Lamm  and  Stetson  (1972)).  When  immune  reactions  are 
mediated  by  antibody,  the  inflammatory  consequences  are 
due  in  great  measure  to  the  "effect  functions"  of  the 
Fc  regions.  (e.  g.  complement  fixation,  anaphylaxis, 
chemotaxis  etc).  The  a-  chain  constant  regions  do  not 
mediate  an  effect  or  function  of  major  significance  in  vivo. 
This  lack  may  be  an  evolutionary  process  selected  to  avoid 
the  undesirable  consequences  of  antigen-antibody  reactions. 
IgA  blocking  antibodies  have  a  protective  role  in  that  they 
complete  for  antigens  with  reagins  of  the  IgE  class(  Turk  et  al. 
(1970)  and  Stokes  et  al.  (1974)).  The  latter  report  suggests 
that  in  Atopic  allergy  there  is  an  overstimulation  of  the 
IgE  system  because  of  a  qualitative  defect  in  IgA 
production. 15 
1.6  RECOVERY  FROM  AND  RESISTANCE  TO  VIRAL  INFECTIONS 
For  a  clearer  understanding  of  the  importance  and 
functions  of  secretory  immunoglobulins  it  would  be  appropriate 
to  consider  their  phylogenetic  place  amongst  mechanisms 
protective  against  viral  infections. 
Recovery  from  and  resistance  to  viral  infection  are 
determined  by  the  interaction  of  specific  and  non-specific  host 
factors.  Their  functions  are  to  prevent  establishment  of 
infection  and  if  infection  has  already  started,  to  interfere 
with  virus  replication  to  limit  the  spread  of  infection  and 
finally  to  eliminate  the  virus.  To  acheive  this  a  complex 
host  defence  mechanism  is  required. 
In  primary  infection  of  the  respiratory  tract, 
non-specific  host  resistance  factors  represent  the  main  line  of 
defence  during  the  first  few  days  of  infection.  These 
consist  of  the  physical  barriers  to  virus  penetration,  such 
as  intact  epithelium  and  the  integrity  of  the  mucous  layer, 
the  upwards  current  of  mucus  caused  by  ciliated  epithelium 
together  with  phagocytosis  by  wandering  mucophages.  The 
latter  factor  may  not  be  effective  against  Influenza  and  other 
respiratory  viruses  which  infect  only  the  lining  epithelial 
cells  and  have  no  subepithelial  invasion  but  is  almost 
certainly  vital  In  terms  of  priming  the  lymphocytes. 
Another  series  of  non  specific  antiviral  activities  is 
introduced  soon  after  the  initiation  of  infection  which  in 
the  case  of  myxo  and  paramyxoviruses  involves  lysis  of  mucus 
by  virus-produced  neuraminidase.  These  are  local  interferon 
production,  elevated  body  temperature  possibly  related  to 
Interferon  production  and  acid  pH  formation  at  the 
inflammatory  site.  Thus  by  interfering  with  the  early  stage 
of  virus  attack,  the  non  specific  host  defences  may  be 
important  in  determining  the  outcome  of  a  viral  infection. 16 
Final  recovery  from  a  fully  established  infection,  however, 
is  influenced  by  the  specific  immune  responses  and  although 
active  from  an  early  stage  can  only  be  measured  some  days 
after  the  initiation  of  infection. 
The  specific  host  immune  responses  are  probably  the  main 
mechanism  of  host  defence  against  reinfection  with  the  same 
or  antigenically  related  organisms.  These  are  the  cell- 
mediated  immune  response  mounted  by  cells  of  the  lymphoid 
system  and  the  humoral  immune  response  expressed  as  circulating 
antibody.  Cell-mediated  immunity  is  mediated  by  sensitised 
T-lymphocytes  and  antibodies,  which  neutralise  extracellular 
virus,  are  produced  by  B-lymphocytes.  Strong  interactions 
occur  between  the  B  and  T-cell-mediated  immune  responses  to 
viral  infections  and  other  factors  such  as  complement, 
polymorphonuclear  leukocytes  and  other  secondary  effectors. 
Secretory  immunity  refers  to  both  antibody  and  cell- 
mediated  reactions  which  occur  at  mucosal  surfaces. 
Systemic  antibody  and  systemic  cell-mediated  immunity  have  long 
been  accepted  entities,  whereas  local  antibody,  primarily 
secretory  IgA  has  been  vigorously  studied  only  in  the  last 
decade  or  two.  (Tomasi  (1972)  ). 
Much  of  the  research  concerned  with  examining  the 
production  of  secretory  antibodies  following  virus  infection 
has  been  carried  out  during  vaccination  programmes. 
Inactivated  Influenza  virus  vaccine  is,  at  present,  the  only 
respiratory  virus  vaccine  available.  However,  despite  the 
fact  that  vaccines  have  been  available  for  more  than  thirty 
years  Influenza  remains  the  only  major  epidemic  disease  which 
has  not  been  brought  under  control.  A  thorough  investigation 
of  the  different  antibody  responses  is  essential  before  the 
efficacy  of  these  vaccines  can  be  evaluated. 17 
In  Poliomyelitis  the  role  of  secretory  antibodies 
has  been  made  clear  by  the  work  of  Ogra  and  Karzon  (1971). 
Their  findings  can  be  summarised  as  follows:  circulating 
IgG  type  poliomyelitis  antibodies 
a)  protect  against  the  paralytic  symptoms  of  the  infection 
and  b)  have  little  or  no  influence  on  the  multiplication 
of  the  virus  in  the  mucosal  cells  of  the  digestive  tract, 
its  subsequent  isolation  from  the  infected  individual  or  its 
circulation  throughout  the  community. 
By  contrast,  secretory  antibodies 
a)  prevent  the  development  of  paralytic  symptoms  by 
neutralising  the  virus  at  the  portal  of  entry  and  b)  prevent 
the  virus  from  multiplying  In  the  mucosal  cells  of  the 
intestine;  stop  its  excretion  from  the  Infected  individual 
and  also  stop  its  subsequent  spread  in  the  community.  For 
these  reasons  as  far  as  Poliomyelitis  is  concerned 
circulating  IgG  antibodies  may  be  thought  of  as  the  primary 
factor  in  host  Immunity  whereas  secretory  antibodies  are  the 
primary  factor  in  collective  immunity.  These  observations 
will  then  be  useful  in  forming  an  understanding  of  the  role 
of  secretory  antibodies  in  protection  against  other  viruses 
and  In  particular  Influenza. 
Two  main  criteria  are  generally  used  to  determine  the 
importance  of  antibodies  in  protection  against  infectious 
diseases.  The  first  is  the  correlation  between  antibody 
level  and  susceptibility  to  infection.  The  other  relates 
to  the  possibility  of  preventing  its  symptoms  by  administering 
antibodies. 
The  role  of  serum  antibodies  in  protecting  against 
Influenza  has  not  been  defined  completely.  Francis  in  1937 
was  the  first  to  show  that  circulating  antibody  levels 
correlated  with  immunity  and  several  epidemiological  surveys 
between  1960  -  70  have  shown  that  a  fall  In  'herd'  serum  antibody 
levels  to  influenza  virus  variants  is  considered  to  be  the  main 
reason  for  the  occurrence  of  epidemics.  (Gordon  and  Belova  (1973); 
Foy  et  al.  (1973)and  Stiver  et  al.  (1973)). 18 
However,  several  studies  have  shown  significant 
numbers  of  people  with  high  titres  of  antibody  becoming 
ill  and  vice  versa.  (Davenport  (1961)and  Morris  et  al, 
(1966)). 
Recently  Butler  (cited  in  Kilbourne  et  al.  (1973)) 
has  suggested  that  Influenza  immunity  as  assessed  by  a 
H-I  serum  antibody  titre  of  1:  32  and  higher  does  not 
necessarily  indicate  that  these  antibodies  are  able  to 
protect  against  Infection.  The  antibody  level  may  only 
reflect  the  person's  general  immune  status. 
The  role  of  secretory  antibodies  in  protecting 
seemed  to  have  been  established  by  Francis  in  1943. 
However,  the  research  necessary  for  optimising  the  application 
of  inactivated  influenza  virus  vaccines  is  an  ongoing  problem. 
More  recent  confirmation  of  anti-influenza  immunity  in 
ferrets  was  carried  out  by  Shore  et  al.  (1972).  The 
resistance  of  these  animals  to  reinfection  gave  a  positive 
correlation  with  levels  of  secretory  antibody;  titres 
of  circulating  antibodies  did  not  correlate. 
Several  investigators  have  observed  that  local 
application  of  inactivated  influenza  vaccine  stimulates  the 
production  of  neutralising  IgA  antibodies  in  nasal  secretions 
and  induces  protective  immunity.  (Waldman  et  al.  (1968, 
1969  and  1970  );  Kasel  et  al,  (1969  );  Waldman  and  Coggins  (1972); 
Liem  et  al.  (1973  a);  Andre  et  al.  (1976)).  Studies  by 
Perkins  et  al.  (1969)  have  shown  that  local  immunisation 
against  rhinovirus  is  important  and  that  significant 
protection  against  viral  challenge  followed  in  those  vaccinees 
who  developed  secretory  IgA  nasal  antibodies.  Both  parenteral 
and  aerosol  vaccine  groups  had  serum  antibody  titres  after 
immunisation. 19 
However  in  other  studies  (Tyttdl  et  al.  (1970  ); 
Edmondson  et  al.  (1971);  Stuart-Harris  (1973))protection 
conferred  after  vaccination  by  the  intranasal  route  was 
found  to  be  poor;  possibly  due  to  differences  in  the 
method  used  for  the  administration  of  vaccine. 
(Liem  et  al.  (1973  b)). 
Parenteral  administration  of  inactivated  influenza 
vaccine  provokes  a  secretory  immune  response  simultaneously 
with  the  serum  response  under  certain  circumstances. 
In  1973,  Dowdle  showed  that  if  the  concentration  of  antigen 
In  high,  secretory  and  circulating  antibodies  will  be 
detected.  The  strain  of  virus  used,  recipient's  age  and 
previous  antigenic  experience  are  also  important.  Children 
below  the  age  of  2  years  respond  poorly  even  when  high  doses 
of  inactivated  virus  antigen  are  used. 
Passive  immunity  can  be  induced  rapidly  by  the 
Intramuscular  or  intravenous  administration  of  antibody  formed 
in  other  individuals.  However,  this  Immunity  tends  to  be 
short-lived.  The  parenteral  administration  of  antibodies 
Isolated  from  the  sera  of  donors  Immunised  with  Influenza 
vaccine  has  been  used  widely  in  the  treatment  of  patients  , 
especially  small  children  with  'hypertoxic'  forms  of  Influenza, 
If  these  antibodies  are  administered  in  the  early  stages  of 
the  disease  (days  1  and  2)_  they  prevent  toxicity,  shorten  the 
duration  of  fever  and  prevent  the  development  of  pneumonia. 
N&chaev  et  al.  (1938)  were  the  first  to  administer 
hyperimmune  serum  intranasally  for  medical  purposes.  This 
route  of  administration,  like  the  parenteral  route  is  effective 
in  terms  of  reduced  numbers  of  cases,  fewer  complications 
when  disease  occurs  and  a  shortened  duration  of  disease. 20 
The  available  literature  concerning  Influenza 
vaccination  is  vast  and  confusing.  Four  types  of 
Influenza  vaccine  are  currently  available.  They  are 
attenuated  or  inactivated  and  are  administered 
parenterally,  intranasally  or  both.  In  addition  adjuvants 
can  be  used.  In  the  numerous  studies,  researchers  have 
examined  serum  and  secretory  responses.  Problems  have 
arisen  in  the  timing  of  the  trials  (i.  e.  problems  with 
outbreaks  of  wild  type  influenza)  and  In  the  methodology 
of  secretion  collection  and  testing  for  antibody  content. 
It  Is  virtually  Impossible  to  draw  comparisons  between  trials 
due  to  the  high  number  of  variables. 
What  is  clear,  however,  is  that  since  secretory  immune 
responses  are  important  in  protection  against  respiratory 
viral  infections,  a  knowledge  of  the  optimal  methods  of 
stimulating  such  antibodies  on  mucosal  surfaces  is  essential 
in  determining  the  best  procedures  for  immunisation. 
Recent  data  suggests  that  the  secretory  component  of 
sIgA  may  itself  play  an  important  role  in  protection.  An 
example  was  reported  recently  by  Strober  et  al.  (1976) 
They  recorded  the  case  of  a  15  year  old  boy  with  chronic 
intestinal  Candidiasis  who  had  normal  serum  IgA  levels  but 
who  lacked  IgA  in  his  secretions.  He  appeared  to  be 
deficient  in  secretory  component.  It  is  thought  that 
secretory  component  may  either  provide  a  homing  signal  for 
IgA  cells  or  may  provide  a  stimulus  for  differentiation 
or  proliferation  of  IgA  precursor  cells  which  move  into 
mucosal  areas.  An  SC  deficiency  in  mucosal  cells  may 
therefore  induce  defective  homing  of  IgA  producing  cells, 
resulting  in  the  lack  of  secretory  IgA  synthesis  and  lack  of 
protection  against  local  infection  which  was  observed  in 
this  patient. 21 
1.7  QUANTITATION  OF  SECRETORY  IgA  IN  SECRETIONS 
In  contrast  to  the  measurement  of  serum  IgA  by 
standard  serological  methods,  the  quantitation  of  secretory 
IgA  in  biological  secretions  Is  an  area  of  complexity  and 
uncertainty.  Some  of  the  major  difficulties  are 
summarised  below. 
a.  Expressing  the  concentration  of  secretory  IgA 
The  concentration  of  IgA  in  secretions  can  be  expressed 
as  a  percentage  of  total  protein  or,  alternatively,  as  the 
IgA  to  albumin  ratio.  This  latter  method  is  convenient  when 
the  sample  differs  from  the  original  fluid  by  an  unknown 
factor,  for  instance,  with  nasal  fluid  that  has  to  be  collected 
by  washing  the  nostrils  with  a  standardised  amount  (eg.  10  ml) 
of  an  isotonic  solution. 
Unfortunately  there  is  no  satisfactory  technique  for 
measuring  total  protein  concentrations  in  complex  mixtures  such 
as  saliva.  Inaccuracies  occur  through  the  use  of  single 
standards  such  as  albumin  or  I 
-globulin  which  give  results 
which  are,  at  best,  r  elative.  When  colorimetric  reactions 
(Folin  or  Bluret)  are  used  technical  difficulties  may  result 
in  the  colour  development  (Kabat  &  Mayer;  (  1967)).  In  practice 
this  means  that  none  of  the  available  methods  provide  absolute 
values  for  the  total  protein  content  of  a  secretion  (Tomasi 
1972)'. 
An  additional  complication  exists  in  the  fact  that  for  many 
secretions  the  total  protein  concentration  varies  widely  within 
the  same  individual  and  depends  upon  the  rate  of  fluid  secretion. 
In  addition  to  measuring  the  total  protein  content  of  a 
secretion,  it  is  desirable  to  determine  the  volume  of  secretion 
collected  over  a  given  time  period.  The  immunoglobulin 
concentration  can  be  expressed,  as  with  urine,  in  milligrams 
excreted  per  1000ml  or  per  24  hours. 22 
As  expected,  where  flow  rate  has  been  measured,  it 
has  been  found  that  the  IgA  concentration  of  some 
secretions  drops  significantly  with  increasing  rates 
of  secretion.  ßrandtzaeg  (1970)  showed  that  the  IgA 
concentration  of  parotid  saliva  fell  3-4  fold  while 
the  rate  of  secretion  (ug/minute/gland)  was  3  times 
increased  after  stimulation.  Following  prolonged 
continuous  secretory  stimulation  IgA  secretion  rates  remain 
essentially  unchanged. 
Another  aspect  of  this  problem  Is  that  there  is  a 
large  variation  in  the  monomer  to  polymer  ratio  of  IgA  in 
various  secretions.  This  ratio  ranges  from  1:  20  to  1:  1 
(Brandtzaeg,  (1970)).  The  molecular  weight  of  precipitating 
antigen  influences  the  result  of  measurement  techniques  in 
gel  (such  as  single  radial  immunodiffusion)  and  marked 
deviations  may  be  observed  in  the  determination  of  IgA 
as  a  consequence. 
In  view  of  these  problems  quantitative  levels  of  IgA 
in  secretions  should  therefore  be  considered  as  a  mere 
qualitative  indication  of  its  presence  (Samson,  (1973)). 
b. 
. 
Collection  of  specimens 
Two  methods  have  achieved  common  usage  to  collect 
respiratory  tract  secretions;  squeezing  the  adsorbed  secretion 
from  cotton  wool  tamons(Burnet  et  al.  (1939);  Francis  et  al.  (1943); 
McKerscher,  (1972)and  Smith,  (1975))and  washing  the  mucous 
surface  with  an  isotonic  solution.  (Remington  et  al.  (1964)  and 
Shvartsman  and  Zykov,  (1976)).  Both  methods  were  used  in  this 
project  and  are  outlined  in  detail  in  Chapter  2.  (2.1.1  and 
2.2.1) 23 
Tears  may  be  collected  on  standard  sized  hard  filter 
paper  strips  held  in  the  corner  of  the  eye  or  into  standard 
sized  polypropylene  sponges  which  when  sufficiently  wetted 
are  transferred  to  small  vials  containing  a  measured  amount 
(0.1  -  0.2  ml)  of  isotonic  solution.  A  rough  quantitation 
of  tears  collected  can  be  achieved  by  these  methods.  The 
volume  of  fluid  collected  can  be  estimated  either  from  the 
length  of  paper  which  has  been  wetted  or  from  the  contents 
of  the  sponge.  Tears  have  also  been  collected  by  using 
cotton  tipped  applicator  sticks  of  uniform  dimensions  held  in 
the  inner  canthus  of  the  eye  after  tears  have  been  stimulated 
with  vapour  from  freshly  peeled  onions. 
Saliva  from  the  parotid  gland  may  be  collected  using  one 
of  a  number  of  different  devices  which  have  in  common  a  cap 
which  is  fitted  with  two  concentric  rings-to  cover  Stensen's 
duct.  The  outer  ring  communicates  by  a  tube  to  a  device  for 
applying  mild  suction  in  order  to  hold  it  in  position  over  the 
orifice  of  Stensen's  duct  and  to  prevent  contamination  of  the 
parotid  saliva  with  other  oral  secretions.  The  inner  ring  is 
the  collection  chamber  which  allows  parotid  secretions  to  flow 
via  a  tube  to  a  collecting  vessel.  (Shannon  and  Chauncey  (1967)). 
c.  Losses  in  storage  and  concentration 
During  storage  losses  of  sIgA  of  the  order  of  10  -  20% 
may  occur  at  -70°C  after  a  few  months.  Free  secretory 
component  concentrations  appear  to  be  less  affected  by  storage 
(Brandtzaeg  and  Baklien  (1976)). 
Freezing  at  -70°C  and  thawing  once  or  twice  seems  to  have 
little  discernible  effect  on  the  titres  of  antibody  activity 
measurable  in  nasal  secretions  and,  since,  these  secretions 
are  often  contaminated  with  bacteria  prompt  freezing  is  a  most 
useful  way  to  store  secretions  until  they  can  be  studied. 
However  hyaluronic  acid  derivatives  become  insoluble  as  a 
result  of  one  freeze-thaw  cycle  and  freezing  is  to  be  avoided 
if  these  substances  are  to  be  studied  (Rossen  et  al.  (1971)  ). 24 
Since  many  external  secretions  contain  concentrations  of 
immunoglobulins  (particularly  IgG  or  IgM)  too  low  to  measure 
by  most  of  the  commonly  used  techniques,  it  is  necessary  to 
concentrate  fluids.  Lyophilisation  has  been  used 
extensively.  The  dried  fluids  are  reconstituted  up  to  one 
tenth  of  the  initial  volume  or  up  to  the  concentration 
corresponding  to  20  mg.  of  IgA  in  100  ml. 
The  use  of  lyophilisation  in  practice  is  questionable. 
According  to  several  authors  cited  in  Rossen,  (1971)  from 
30  -  70%  of  IgA  is  denatured  by  lyophilisatio.  n. 
It  has  proved  generally  more  suitable  to  concentrate 
secretions  using  some  means  of  withdrawing  water  and 
electrolytes  through  a  semipermeable  membrane.  A  variety 
of  hyogroscopic  agents  are  also  available,  for  example, 
Sephadex  G-200  (Pharmacia)  and  Lyphogel  (Fisher  Scientific  Co.  ), 
for  removal  of  water  for  concentration.  These  have  the 
disadvantage  of  high  cost  and  the  possibility  that  'something 
else'  may  be  removed. 
Despite  the  range  of  available  methods  for  the  primary 
treatment  of  secretions  most  investigators  have  limited  this 
to  homogenising  and  removal  of  insoluble  particles  by 
centrifugation. 
d.  Methods  of  secretory  IgA  assay 
The  methods  available  for  the  detection  and  assay  of  IgG 
antibody  to  viral  antigens  are  of  two  types,  those  which  are 
multicomponent  systems  and  those  which  are  based  on  two 
component  systems.  Amongst  the  multicomponent  methods  are 
several  which  hove  been  used  routinely  for  many  years,  including 
virus  neutralisation  tests,  haemagglutination-inhibition 
tests  (H.  I),  complement  fixation  (C  F),  Immunofluorescence  (I.  F) 
Radioimmunoassay  (R.  I.  A.  )  and  more  recently  enzyme  linked 
immunosorbent  assays  (E.  L.  I.  S.  A.  )  Essentially  these  systems 
depend  on  testing  serial  dilutions  of  test  sera  with  known 
doses  of  virus  or  viral  antigen  and  employing  an  appropriate 
indicator  system  to  measure  the  degree  of  reaction  of  antigen 
with  specific  antibody. 25 
Several  two  component  systems  have  been  accepted  for 
routine  use.  These  are  immunodouble  diffusion  (I.  D.  D.  ) 
single  radial  diffusion  (S.  R.  D.  )  and  immunoelectrophoresis 
(I.  E.  )  techniques.  These  techniques  depend  on  antigen- 
antibody  reactions  in  gel. 
The  quantitation  of  secretory  IgA  in  nasal  secretions 
can  be  carried  out  using  techniques  which  are  basically 
the  same  as  those  outlined  above  for  sera.  The  possible 
techniques  will  be  described  with  particular  reference  to 
the  problems  arising  when  secretory  IgA  is  under  test. 
1)  Neutralisation  tests: 
These  are  the  most  sensitive  of  the  'classical' 
immunological  reactions.  Infectious  virus  when  combined 
with  specific  antibody  is  unable  to  be  taken  in  by 
susceptible  cells  and  is  said  to  be  'neutralised'.  In 
principle  virus  and  secretion  are  mixed,  allowed  to  react 
for  an  appropriate  time  and  the  mixture  inoculated  into  a 
host  system  which  can  then  be  examined  for  signs  of  infection. 
Tests  are  usually  carried  out  in  animals,  embryonated  eggs 
or  monolayers  of  cells.  The  advantage  of  sensitivity  is 
set  against  the  disadvantage  that  these  tests  are  tedious 
and  time  consuming  to  perform. 
11)  Haemagglutination  Inhibition  Tests  :  (H.  I.  ) 
H.  I  is  a  technique  used  either  to  diagnose  infection  or 
to  indicate  the  Immune  status  of  an  Individual.  It  is  also 
used  to  identify  the  haemagglutinin  subtype  of  influenza  viruses. 
Inhibition  of  haemagglutination  results  when  antibody 
attaches  to  the  virus  haemagglutinin.  This  either  blocks 
red  blood  cell  reactive  sites  on  the  virion  or  eliminates 
the  virus  from  competition  for  red  blood  cells  by  forming  virus 
antibody  complexes. 26 
Although  H.  I  is  a  simple,  highly  reproducible  test 
suitable  for  mass  investigation  it  has  a  major  disadvantage 
Haemagglutination  of  viruses  may  be  inhibited  by  normal 
components  of  sera  from  a  wide  variety  of  animals.  These 
non-specific  inhibitors  can  lead  to  false  positive  H.  I  tests. 
They  are  usually  glycoproteins  and  comprise  of  three  groups, 
alpha,  beta  and  gamma,  according  to  virus  types  and 
subtypes  affected. 
Receptor-destroying  enzyme  (R.  D.  E.  )  of  Vibrio  cholerae 
and  potassium  periodate  are  most  commonly  used  for  destroying 
non-specific  inhibitors. 
In  the  use  of  the  H.  I  test  for  determining  antibody 
concentrations  in  nasal  secretions,  there  are  problems  that 
have  not  yet  been  solved.  Whether  non  specific  inhibitors 
are  present  remains  controversial  as  does  the  treatment  of 
specimens  prior  to  testing  (Schuartsman(1976)). 
Ili) 
_jadioimmunoassay 
(R.  I.  A.  ) 
R.  I.  A.  has  become  a  highly  specialised  technique.  The 
basis  of  the  assay  is  that  the  concentration  of  an  unknown 
antigen  is  determined  by  measuring  its  ability  to  compete 
with  a  fixed  amount  of  radiolabelled  antigen  for  a  limiting 
amount  of  antibody.  Standard  curves  of  this  inhibition  are 
produced  using  known  amounts  of  unlabelled  antigen.  Total 
amounts  of  IgA  in  secretions  can  be  measured  using  this 
technique.  R.  I.  A.  Is  highly  sensitive.  However  complex 
equipment  is  necessary  and  because  of  the  medical  hazards 
posed  by  the  use  of  isotope  labels,  highly  trained  personnel 
are  required. 27 
iv)  Immunofluorescence  (I.  F.  ) 
Fluorescent  dyes  such  as  fluorescein  and:;  rhodamine  can 
be  coupled  to  antibodies  without  destroying  their  specificity 
In  1941  Coons  showed  that  such  conjugates  would  combine  with 
antigen  present  in  a  tissue  section  and  that  the  bound  dye 
could  be  visualised  in  the  ultra-violet  microscope,  using 
appropriate  filters,  through  the  emission  of  fluorescence. 
In  this  way  the  distribution  of  antigen  throughout  a  tissue 
and  within  cells  can  be  demonstrated.  The  method  can  also 
be  used  for  the  detection  of  antibodies  directed  against 
antigens  already  known  to  be  present  In  a  given  tissue  section 
or  cell  preparation.  The  end-point  being  that  dilution  of 
antiserum  showing  a  50%  reduction  in  brightness.  This  rapid, 
elegant  technique  has  the  slight  disadvantage  of  depending 
on  the  subjective  visual  assessment  of  fluorescence  unless 
a  photometer  is  available.  This  Instrument  Is  beyond  the 
financial  capabilities  of  most  laboratories. 
If  this  technique  is  used  to  measure  secretory  IgA 
against  a  specific  viral  antigen  there  are  slight  technical 
problems  due  to  the  non  availability  of  appropriate  commercial 
antisera  and  conjugates.  In  addition  nasal  washings  tend  to 
be  heavily  mucoid.  Mucus  gives  a  high  undesirable  background 
fluorescence  and  introduces  the  possibility  of  'missing' 
low  antibody  levels. 
v)  Enzyme-linked  Immunosorbent  Assay  (E.  L.  I.  S.  A.  ) 
Serological  methods  are  playing  an  increasingly  important 
role  both  in  the  diagnosis  and  in  the  epidemiological  study 
of  disease.  Simple,  inexpensive  methods  for  large-scale 
application  are  urgently  needed.  The  enzyme  immunoassay 
methods  were  developed  by  Engvall  and  Perlman  (1971  and  1972). 
The  methods  are  based  on  the  use  of  antibodies  or  antigens 
which  are  linked  to  an  insoluble  carrier  surface. 28 
This  is  then  used  as  a  base  for  the  binding  of  the  relevant 
antigen  or  antibody  from  the  test  solution.  The  complex 
is  then  detected  by  means  of  an  enzyme-labelled  antibody 
or  antigen.  The  ensuing  degradation  of  the  enzyme  substrate, 
measured  photometrically,  is  proportional  to  the  concentration 
of  the  unknown  'antibody'  or  'antigen'  in  the  test  solution. 
Under  laboratory  conditions  these  methods  can  be  as  sensitive 
as  R.  I.  A.,  but  can  also  be  adapted  as  simple  field-screening 
procedures. 
Äkerlund  (  1977  )  used  the  technique  to 
quantitate  secretory  IgA  in  biological  secretions.  Despite 
rapid  advances  there  are  still  several  problem  areas. 
Firstly  the  purity  of  the  antigen  would  appear  to  be  critical 
and  secondly  the  guide  lines  for  defining  an  end-point  titre 
are  very  vague. 
In  the  future,  ELISA  systems  will  surely  be  used  routinely 
as  a  supplement  to  virus  isolation  and  immunofluorescence 
techniques  to  detect  viral  antigens  in  clinical  specimens. 
(Bishai  et  al.  (1981)).  A  variation  of  the  method  allows  ELISA 
to  detect  specific  secretory  IgA  in  human  sera  as  a  diagnostic 
test  for  viruses.  Rotavirus  antibody  can  also  be  detected 
in  this  way.  (Grauballe  et  al.  (1981)). 
Precepitation  Reactions  in  Gels 
i)  Immuno  Double  Diffusion  (I.  D.  D.  ) 
When  an  antigen  solution  is  mixed  in  'optimal'  proportions 
with  homologous  antiserum,  a  precipitate  is  formed.  The 
precipitation  reaction  can  be  visualised  in  gels.  In  the 
double  diffusion  method  of  0uchterlony  (1970),  antigen  and 
antibody  placed  in  wells  cut  in  an  agar  gel,  diffuse  towards 
each  other  and  precipitate  to  from  an  opaque  line  in  the  region 
where  they  meet  in  optimal  proportions.  A  preparation 
containing  several  antigens  will  give  rise  to  multiple  lines. 29 
I.  D.  D.  techniques  are  of  considerable  value  as  qualitative 
tests  for  the  identification  of  antibodies  in  test  sera  but 
are  not  readily  adaptable  to  quantitative  studies. 
ii)  Single  Radial  Immunodiffusion  (S.  R.  D.  ) 
The  single  radial  immunodiffusion  test  provides  a  simple 
assay  system  for  antibodies  or  antigens  based  on  the  principles 
first  described  by  Mancini  in  1965.  For  antibody  measurement 
antigen  is  incorporated  uniformly  throughout  a  matrix  (usually 
a  gel)  and  antibody  is  added  to  a  well  cut  in  the  gel. 
The  antibody  diffuses  rapidly  and  at  optimum  proportions  of 
antigen/antibody  a  visible  zone  of  precipitate  forms.  The 
size  of  the  zone  is  proportional  to  the  concentration  of 
antibody  applied  to  the  gel  in  a  given  time  period.  Therefore 
using  serum  dilutions  of  known  concentration  a  standard  graph 
of  zone  size  against  antibody  concentration  can  be  produced 
and  used  to  determine  antibody  concentration  of  unknown 
specimens. 
This  method  is  commonly  used  for  the  determination  of 
secretory  IgA  In  concentrated  fluids. 
iii)  Single  Radial  Haemolysis  (S.  R.  H.  ) 
A  technique  which  has  recently  been  accepted  in  the 
diagnostic  laboratory  is  single-radial  haemolysis.  The 
method  utilises  the  ability  of  specific  antibodies  in  the 
presence  of  complement  to  lyse  eythrocytes  which  have  been 
sensitised  by  treatment  with  certain  viral  antigens 
eg.  Rubella,  Influenza.  When  performed  in  agarose  gels 
the  technique  enables  antibody  to  be  quantitated  by  measurement 
of  the  size  of  zones  of  haemolysis  surrounding  wells  in  the 
gel  to  which  antisera  have  been  added. 30 
The  value  of  the  S.  R.  H.  technique  for  the  measurement 
of  secretory  IgA  has  not  been  documented  but  Schild  et  al.  (1975). 
Indicated  that  its  sensitivity  in  detecting  serum  antibody 
to  haemagglutinin  is  equivalent  to  or  greater  than 
conventional  H.  I  tests. 
The  method  is  simple,  rapid  and  does  not  require 
pre-treatment  of  sera  since  it  is  not  affected  by  non-specific 
inhibitors  in  animal  sera.  This  technique  is  suitable  for 
large  scale  serological  surveillance  for  antibody  to  the 
haemagglutinin  antigen  such  as  is  required  when  a  new 
influenza  variant  emerges. 
iv)  Immunoelectrophoresis 
Immunoelectrophoresis  has  proved  to  be  a  valuable  tool 
in  the  qualitative  investigation  of  proteins,  particularly 
human  serum  immunoglobulins.  Classically,  the  technique 
involves  the  separation  of  proteins  held  in  a  gel  support 
medium  by  passing  an  electric  field  across  the  gel. 
Visualisation  of  the  separated  proteins  is  achieved  by  using 
specific  antisera.  Initial  separation  of  the  proteins  depends 
on  the  charge  carried  by  each  protein.  Polyclonal 
immunoglobulins  being  of  varying  amino-acid  composition  will 
exhibit  a  spectrum  of  mobility  moving  as  a  broad  band  on 
electrophoresis  and  producing  a  pattern  of  smooth  arcs  with 
monospecific  antisera  to  IgG,  IgA  and  IgM. 
Further  developments  of  the  principle  have  combined 
electrophoresis  with  immunoprecipitation  in  which  movement 
in  an  electric  field  drives  the  antigen  directly  into  contact 
with  antibody.  Counter  current  electrophoresis  may  be 
applied  to  antigens  which  migrate  towards  the  positive  pole 
in  agar.  This  qualitative  technique  is  considerably  more 
sensitive  than  double  diffusion  (Ouchterlony  (1967)). 
Rocket  electrophoresis  is  a  quantitative  method  in  which 
antigen  diffuses,  under  the  influence  of  an  electric  field, 
into  a  layer  of  agar  containing  specific  antiserum.  The 
antigen-antibody  rocket-shaped  precipitate  length  is  proportional 
to  the  concentration  of  antigen  in  the  well  and  to  the  duration 
of  electrophoresis.  The  method  is  more  sensitive  than  simple 31 
radial  diffusion  and  can  be  used  to  measure  immunoglobulins 
in  small  samples  of  dilute  and  unconcentrated  biological 
fluids. 
Standards 
Whatever  method  of  gel-technique  adopted  it  is  essential 
to  use  an  appropriate  standard  for  the  immunoglobulin  under 
study  because  these  techniques  are  very  sensitive  to 
differences  In  molecular  size  of  the  antigen.  This  is 
particularly  Important  for  IgA  which  occurs  in  several  molecular 
sizes  in  secretory  fluids.  The  major  species  of  IgA  In  most 
fluids  Is  115  and  so  it  is  best  to  use  an  11S  standard 
Isolated  from  saliva  or  milk  (colostrum)  when  a  technique 
such  as  radial  diffusion  or  electro-immunodiffusion  is  used 
for  quantitation  since  these  depend  on  size.  Using  a  75 
(serum)  IgA  standard  the  concentration  of  IgA  in  secretions 
will  be  underestimated  approximately  3-4  fold. 
Pooled  serum  may  be  used  as  a  working  standard  but  prior 
calibration  is  necessary  with  115  secretory  IgA  from  colostrum 
or  saliva.  (Brandtzaeg  et  al.  (1970)  and  Tomasi  (1972)  ). 32 
CHAPTER  2 
MATERIALS  AND  METHODS 
2.1  VACCINE  TRIAL 
The  present  study  was  carried  out  in  Girvan,  South  Ayrshire, 
Scotland.  The  study  was  started  on  28th  November,  and  completed 
on  3rd  May,  the  following  year.  (  1977  -  78  ). 
Details  about  the  composition  of  the  vaccine  used  in  the  study, 
the  experimental  design  and  the  procedure  for  the  study  are  given  in 
Appendix  II. 
47  subjects  were  selected  on  the  basis  of  low  serum  H.  I  antibody 
titres  and  44  of  them  entered  the  study.  One  subject  (no.  1719) 
was  withdrawn  from  the  study  a  few  weeks  after  vaccination  (hysterical 
reaction,  admitted  to  hospital)  of  the  remaining  43  subjects, 
22  received  Influvac  Spray  and  21  received  placebo  under  double-blind 
conditions. 
6  weeks  after  vaccination,  blood  samples  and  nasal  washings  were 
obtained  from  all  43  subjects. 
4  months  after  vaccination,  41  subjects  were  challenged. 
2  subjects  (one  in  each  group,  nos.  1745  and  1732)  left  the  study  for 
private  reasons  and  did  not  receive  the  live  vaccine.  One  challenged 
subject  (no.  1729)  did  not  provide  a  final  blood  sample  (admitted 
to  hospital  with  myocardial  infarction). 33 
2.1.1  COLLECTION  OF  SPECIMENS 
a)  Nasal  Washings 
Nasal  washings  were  collected  by  the  following  standard 
technique.  The  volunteer  was  asked  to  sit  with  his  neck 
hyperextended  and  5ml  of  phosphate  buffered  saline  (P.  B.  S.  ) 
at  pH  7.2  were  instilled  into  each  nostril  using  a  10ml 
disposable,  plastic  syringe  fitted  with  a  Yale  Microlance 
21G12  needle  in  a  protective  guard  with  the  tip  removed. 
During  this  process  the  volunteer  continuously  pronounced  the 
letter  'K'  to  prevent  P.  B.  S.  entering  the  alimentary  system. 
The  volunteer  then  brought  his  head  forward  and  forcibly 
expelled  the  washing  into  a  beaker  placed  firmly  against  his 
top  lip.  This  procedure  was  repeated  until  a  volume  of  5m1 
of  washings  was  collected.  The  washings  were  aspirated 
with  a  pipette  and  centrifuged  at  1500g  for  15  minutes  to 
remove  insoluble  material.  All  nasal  washings  were  tested 
for  the  presence  of  blood  contamination  using  Labstix 
(Ames Co,  Div.  of  Miles  Lab.  Ltd)  This  'dip  and  read'  test 
took  30  seconds  and  registered  whether  or  not  blood  was  present 
by  changing  from  yellow  to  blue.  The  depth  of  colour  was 
dependent  on  the  amount  of  blood  present.  No  specimens 
registered  a  positive  result.  The  supernatants  were 
stored  at-200C  prior  to  determination  of  antibody  titres  by 
several  methods. 
b)  Blood  Samples 
8m1  of  blood  were  collected  into  sterile  dry  containers, 
allowed  to  clot,  and  centrifuged  at  2500g  for  5  minutes. 
Separated  serum  samples  were  stored  in  ampoules  at  -20°C 
prior  to  antibody  testing. 34 
2.1.2  ANTIBODY  MEASUREMENT  IN  NASAL  WASHINGS 
a)  Total  Secretory  IgA  and  IgG 
Radioimmunoassay 
The  Radioimmunoassay(R.  I.  A.  )results  presented  in  this 
thesis  were  obtained  by  courtesy  of  Dr.  D.  B.  L.  McClelland, 
Director,  South  East  Scotland  B.  T.  S.,  Royal  Infirmary, 
Edinburgh.  Total  amounts  of  secretory  IgA  and  IgG  in  the 
nasal  washings  were  estimated  using  the  .  -chain  and  ö 
-chain  assays 
in  routine  use  at  Edinburgh  Royal.  The  basis  of  this  highly 
specialised  technique  is  that  the  concentration  of  an  unknown 
antigen  (i.  e.  secretory  IgA)  is  determined  by  measuring  its 
ability  to  compete  with  a  fixed  amount  of  radiolabelled 
antigen  for  a  limiting  amount  of  antibody.  Standard  curves 
of  this  inhibition  are  produced  using  known  amounts  of 
unlabelled  antigen. 
In  this  particular  assay  system  the  antibody  was 
immobilised  in  an  insoluble  support  (Sepharose  4B  particles). 
This  aids  the  separation  of  bound  antigen  from  free  antigen. 
The  purer  the  antibody  used,  the  more  efficient  the  system. 
It  should  be  noted  that  the  following  standards  were  used: 
o&.  -  chain  assay: 
X  -chain  assay: 
Human  colostrum  secretory  IgA 
Purified  IgG  from  the  pooled  sera. 
(Yap  et  al.  (1979)). 35 
2.1.2 
b)  Specific  Secretory  ISA 
i)  Quantitative  Haemadsorption 
This  technique  was  used  to  assay  the  neutralising  antibodies 
present  in  unconcentrated  nasal  washings  against  Influenza 
type  A/Victoria  (H3N2).  The  reasons  for  choosing  this  method 
were  specificity  and  reliability  plus  the  ability  to  correlate 
the  results  with  those  from  previous  trials  and  from  two  trials 
running  concurrently  in  Rome  and  Zagreb. 
The  technique  used  was  evolved  by  Dr.  N.  B.  Finter  (1967) 
and  was  a  modification  of  a  previous  method  of  Interferon  Assay. 
(Finter,  1964). 
The  principles  involved  in  Quantitative  Haemadsorption  are 
that  red  blood  cells  are  added  to  virus-infected  cell  cultures, 
excess  red  cells  are  washed  away  and  the  haemadsorbed  red  cells 
are  then  lysed  by  adding  distilled  water.  Each  culture  thus 
provides  a  solution  of  haemoglobin  at  a  concentration  which  is 
proportional  to  the  number  of  haemadsorbed  red  cells,  and  which 
can  be  measured  with  a  spectrophotometer.  In  this  way  relative 
amounts  of  growth  of  a  haemadsorbing  virus  can  be  measured 
precisely.  This  report  describes  the  use  of  this  quantitative 
haemadsorption  (QH)  method  in  the  assay  of  neutralising  antibodies. 
Materials 
Virus:  Influenza  type  A/Victoria/3/75  (H3N2)  supplied 
by  W.  H.  O.  Geneva. 
Specimens:  Nasal  Washings  from  human  volunteers  (see 
Protocol,  Appendix  II) 36 
Tissue  Cells:  Monolayers  of  secondary  African  Green  Monkey 
Kidney  (AgMK)  Cells  (supplied  by  Flow 
Laboratories,  Irvine)  in  4"  x  12"  glass 
tubes  plugged  with  silicone  stoppers. 
Blood  Cells:  Human  0  red  blood  cells  supplied  by 
West  of  Scotland,  B.  T.  S.,  Law  Hospital. 
Assay  for  Neutralising  Antibodies 
I.  Nasal  washings  were  inactivated  at  56°C  for  30  minutes 
2.  Serial  doubling  dilutions  of  0.5m1  volumes  were  made 
using  199  and  Hepes,  serum  free  medium  as  diluent. 
3.  To  each  dilution  0.5m1  virus  was  added  at  the 
predetermined  concentration  (1:  100). 
4.  The  virus/antibody  mixtures  were  incubated  at  room 
temperature  for  90  minutes. 
5.  From  each  dilution  of  virus/antibody  mixture,  0.2m1 
amounts  were  inoculated  into  four  tubes  of  AgMK  cells. 
6.  The  mixtures  were  adsorbed  at  40C  for  1  hour  prior  to 
adding  maintenance  medium. 
7.  The  cultures  were  incubated  at  37°C  for  22  hours,  in 
a  stationary  position. 
8.  Following  incubation  the  medium  was  decanted  from  each 
tube  and  replaced  with  2m1  of  0.4%  human  0  red  blood 
cells  (r.  b.  c) 
9.  The  tubes  were  placed  at  40C  for  30  minutes  to  allow 
haemadsorption  to  take  place. 
10.  The  r.  b.  c.  were  in  turn  decanted  and  the  tubes  were 
washed  with  chilled  P.  B.  S.  to  remove  excess  r.  b.  c. 
(twice) 37 
11. 
12. 
The  haemadsorbed  cells  were  lysed  by  adding  4m1 
distilled  water.  The  tubes  were  agitated  gently 
and  left  for  30  minutes  at  room  temperature. 
The  concentrations  of  haemoglobin  in  the  resulting 
solutions  were  measured  in  an  Unican  SP800 
spectrophotometer  at  a  wavelength  of  410nm. 
The  following  controls  were  included: 
i)  Virus  controls:  These  were  four  tubes  of 
AgMK  cells  which  were  inoculated 
with  virus  and  diluent  only  and 
represent  100%  haemadsorption. 
Cell  Controls:  These  were  four  tubes  of  cells 
containing  two  volumes  of  diluent 
and  detected  any  non-specific 
adsorption  of  r.  b.  c. 
Selection  of  the  amount  of  virus  for  the  Quantitative 
Haemadsorption  Assay 
1.4-fold  dilutions  of  0.5m1  volumes  were  made  using 
199  and  Hepes,  serum-free  medium  as  diluent. 
2.  O.  lml  of  each  vurus  dilution  was  inoculated  into  four 
tubes  of  AgMK  cells  (including  controls). 
3.  The  virus  was  adsorbed  at  4  °C  for  1  hour  prior  to 
adding  maintenance  medium. 
4.  The  tubes  were  incubated  at  37°C,  stationary  for  a 
convenient  time  (i.  e.  22  hours). 
5.  Haemadsorption  was  carried  out  as  described  above 
(steps  8-  12). 38 
6.  The  resulting  optical  density  readings  were  plotted 
on  a  graph  against  the  log  concentration  of  the  virus. 
For  use  in  the  test,  the  dilution  of  virus  was  chosen 
which  gave  near  maximum  readings  for  QH  at  the 
selected  time. 
The  results  obtained  with  Influenza  type  A/Victoria" 
in  AgMK  cells  are  shown  in  figure  3.  A  suitable 
dilution  of  virus  was  1:  100.  The  original  dilution 
chosen  was  1:  20,  however,  during  preliminary  testing 
of  the  nasal  washings  it  became  apparent  that  the 
antibody  content  of  the  nasal  washings  was  low  and 
consequently  a  higher  dilution  of  virus  was  required  to 
increase  the  sensitivity  of  the  assay. 
Methods  used  in  presenting  results 
An  example  assay  of  neutralising  antibody  in  nasal  washing 
specimens  is  shown  in  figure  4.  The  optical  density  (O.  D.  ) 
readings  at  410nm  have  been  plotted  against  the  corresponding 
log  10  serum  dilutions. 
There  were  two  sets  of  controls  in  each  assay. 
1.  Uninfected:  To  detect  non-specifically  bound  red 
blood  cells.  This  normally  very  weak 
solution  of  haemoglobin  was  used  to  zero 
the  spectrophotometer  and  from  a  base- 
line  for  measuring  the  ODs  of  test 
samples. 
2.  Infected:  To  provide  a  maximum  OD  value  for  a 
solution  of  haemoglobin  resulting  from 
the  lysis  of  haemadsorbed  red  blood 
cells. 39 
The  difference  between  the  O.  D.  readings  with  these  controls 
represents  the  excess  haemoglobin  due  to  growth  of  the  virus. 
The  scale  for  expresssing  other  O.  D.  readings  as  a  percentage 
of  this  difference  is  shown  on  the  right-hand  ordinate  in 
figure  4. 
From  a  number  of  similar  assays  it  has  been  found  that  when 
the  results  obtained  with  a  wide  range  of  antibody  dilutions 
were  plotted,  an  S-shaped  curve  could  be  fitted  to  the  points. 
Such  a  curve  had  a  linear  portion  over  a  range  of  O.  D.  readings 
corresponding  to  approximately  25%  to  75%  excess  haemoglobin. 
A  straight  line  has  correspondingly  been  fitted  to  the 
relevant  points  in  figure  4. 
The  end-point  of  neutralising  antibody  activity  was  taken 
as  the  log10  serum  dilution  at  which  there  was  a  50%  reduction 
in  the  excess  haemoglobin  due  to  virus  growth. 
The  end  point  from  figure  41s  1.17  log  QH  50  units. 40 
Use  of  a  Reference  Nasal  Washing 
On  the  basis  of  the  following  (Finter,  1967) 
'Within  a  single  assay,  parallel  dose-response  curves 
are  obtainable  for  all  sera  (here  nasal  washings) 
tested  together.  Hence  if  the  dose-response  curve  was 
precisely  determined  for  any  one  nasal  washing  used  as  a 
reference  (eg.  1717  (IV)  ),  the  relative  titre  of  another 
nasal  washing  tested  in  the  same  assay  could  be  obtained 
from  the  result  at  any  single  dilution  giving  an  O.  D. 
reading  within  the  linear  25%  to  75%  excess  haemoglobin 
range'. 
Screening 
Dilutions  of  1:  20  were  tested  against  1717  IV  Reference 
nasal  washing.  Within  a  batch  the  dilutions  can  be  compared 
with  the  reference  and  depending  on  the  displacement  from 
the  reference,  can  be  assigned  a  titre  of  log  QH  50  unit/ml. 
The  screening  was  carried  out  in  If  batches  and  the  reference 
assayed  4  times.  If  one  assigns  an  arbitary  value  of  1.28 
log  QH  50  units/ml  (the  value  obtained  in  one  of  the  assays) 
as  the  titre  of  the  reference  nasal  washing  then  the  titres 
of  the  reference  obtained  in  other  3  assays  can  be  corrected 
against  this  titre  and  the  3  correction  factors  added  to  the 
nasal  washing  titres  within  each  batch  in  an  effort  to 
standardise  the  test.  Any  specimens  which  gave  either  no 
or  questionable  results  were  titrated  and  reassayed. 41 
The  Virus,  Influenza  type  A/Victoria/3/75  (H3N2)  was  used 
in  several  of  the  assays  described  in  this  chapter.  Stock 
was  prepared  as  follows: 
EGG  INOCULATION 
This  simple  technique  was  used  to  produce  large  quantities 
of  Influenza  Type  A/Victoria/3/75  virus. 
Method 
Fertilised  eggs  which  had  been  incubated  for  10  -  12  days 
were  'candled'  (le.  examined  in  a  darkened  room  over  a  bright 
lamp)  to  check  that  the  embryo  was  alive  and  to  mark  the 
position  of  the  air  sac  and  main  blood  vessels.  The  shells 
were  sterilised  by  swabbing  with  merthiolate.  Using  a 
dental  drill  fitted  with  a  carborundum  disc,  a  small  area  of 
membrane  was  exposed  on  the  side  of  the  egg  in  an  area  free  of 
blood  vessels.  An  incision  was  made  in  the  shell  over  the 
air  sac  to  release  any  pressure  produced  by  subsequent  ' 
inoculation.  The  syringe  was  filled  with  virus  suspension 
and  O.  lml  was  injected  into  the  egg  through  the  exposed 
membrane  and  into  the  allantoic  cavity.  Both  openings  were 
then  sealed  with  tape  and  the  eggs  incubated  for  48  hours. 
Harvesting 
Following  incubation  the  eggs  were  chilled  at  4°C  for  one  hour 
to  prevent  haemorrhage  during  harvesting. 
The  shell  over  the  air  sac  was  removed  to  expose  the  shell 
membrane  which  together  with  the  chorioallantoic  membrane  was 
removed  using  sterile  forceps. 42 
The  exposed  allantoic  fluid  was  removed  using  a 
Himmelweit  pipette  and  placed  in  a  sterile  universal  container. 
The  fluid  was  clarified  by  centrifugation.  The  resulting 
supernatant  was  tested  for  viral  activity  by  a  haemag- 
glutination  test.  Those  which  showed  a  good  yield 
(i.  e.  titre  128)  were  pooled,  ampouled  into  lml  amounts 
and  stored  in  liquid  nitrogen  (-196°C) 
The  concentration  of  virus  defined  above  was  used  in  all 
the  tests  described  which  depend  on  the  use  of  Influenza  virus. 
2.1.2  ii)  Haemagglutination  Inhibition 
The  Haemagglutination  Inhibition  Test  was  used  as  a  simple, 
rapid  technique  for  the  measurement  of  type  specific  antibody 
present  in  unconcentrated  nasal  washings. 
The  principles  involved  are  that  a  standardised  amount  of 
virus  is  added  to  dilutions  of  nasal  washings  under  test 
and  incubated  under  standard  conditions  of  temperature  and 
time.  The  erythrocytes  of  an  appropriate  animal  species  are 
added  as  an  indicator  of  the  amount  of  haemagglutinin 
neutralised  by  antibody. 
Antigen  Preparation  -  Influenza  type  A/3/75  grown  in  allantoic 
fluids. 
Antigen  titration: 
Preparation  of  1%  human  0  red  blood  cell  suspension:  - 
Fresh  human  O.  r.  b.  c.  were  washed  3  times  in  PBS  by  adding 
buffer  and  centrifuging  for  10  minutes  at  2000  r.  p.  m. 
The  cells  were  packed  by  centrifuging  in  a  calibrated 
tube  at  3000  r.  p.  m.  for  15  minutes.  The  cells  were 
resuspended  in  buffer  to  give  a  1%  suspension. 43 
2.  Using  a  V-well  microtitre  plate  (Dynatech)  doubling 
dilutions  of  antigen  were  made  in  PBS  using  a  microdiluter 
(0.025ml  volumes)  and  0.025ml  of  PBS  added  to  each  well. 
3.0.025m1  of  1%  r.  b.  c.  were  added  to  each  well  and  the 
plates  agitated  gently. 
4.  A  control  of  PBS  +  1%  r.  b.  c.  should  be  included. 
5.  The  plates  were  covered  and  left  at  room  temperature  for 
two  hours. 
6.  Reading  the  plates 
Positive:  Agglutination 
i.  e.  a  carpet  of  cells  covering  the 
base  of  the  well. 
Negative:  A  button  of  cells  on  the  base  of  the 
well. 
End  point:  Last  well  to  show  agglutination. 
This  dilution  represents  1  unit  of 
antigen.  The  antigen  should  be  used 
at  4  units  in  the  test. 
Test  System 
Using  V-well  microtitre  plates  (Dynatech)  and  volumes  of 
0.025m1. 
1.  The  nasal  washings  were  heat  inactivated  at  56°C  for 
30  minutes  and  titrated  in  PBS  to  give  a  doubling 
dilution  series  ranging  from  1/2  to  1/2046. 
2.  Influenza  type  A  virus  suspension  was  added  at  a 
concentration  of  4  haemagglutination  units. 
3.  The  plates  were  covered  and  incubated  at  room  temperature 
for  1  hour. 
4.1  volume  of  human  O.  r.  b.  c.  was  added  to  each  well  and 
the  plates  were  incubated  for  2  hours  at  room  temperature. 
A 44 
5.  The  plates  were  examined  and  end-points  read.  The 
end-point  was  taken  as  the  last  dilution  showing 
significant  inhibition  of  haemagglutination. 
Controls 
Virus  dilutions  were  prepared  in  buffer  at  4,2,1,1  and  0 
Haemagglutination  units  with  buffer  replacing  serum  dilutions. 
1  volume  of  1%  r.  b.  c.  was  added  and  incubated  with  the  test. 
Readings  are  graded  as  0  for  no  agglutination  (button 
formation)  to  4  for  complete  agglutination  (shield  formation) 
Virus  controls  should  show  full  agglutination  for  1  HA 
unit  and  partial  agglutination  at  I  HA  unit.  One  well 
containing  0.025m1  buffer  in  place  of  virus  is  included  as 
a  cell  control. 
2.1.3.  ANTIBODY  MEASUREMENT  IN  SERUM  SPECIMENS 
a)  Total  Serum  IgA  and  IgM 
Radial  Immunodiffusion 
The  Radial  Immunodiffusion  test  was  used  to  measure  the  total 
concentrations  of  IgA  and  M  in  serum  specimens.  The  plates 
used  in  the  test  were  supplied  by  the  Hyland  Division  of 
Travenol  Laboratories. 
Single  radial  immunodiffusion  methods,  introduced  in  1965  by 
O.  L.  Fahey  and  E.  M.  McKelvey,  are  specific  for  the  quantitation 
of  immunoglobulins  in  biological  fluids.  The  'precision' 
method  was  used,  as  follows.  The  wells  were  filled  with  a 
constant  volume  of  serum  and  zones  measured  after  precipitation 
was  complete  (48  hours  or  longer).  The  zones  were 
characterized  by  the  presence  of  a  bright  ring  at  the  outer 
edge  of  the  precipition  zone. 45 
Reference  curves  were  obtained  by  plotting  the  zone  diameters 
squared  against  the  immunoglobulin  concentrations  contained 
in  the  multi-component  immunology  reference  sera.  This 
relationship  is  generally  linear  except  where  zone  diameters 
are  small  relative  to  the  well  diameters.  Immunoglobulin 
concentrations  in  the  test  sera  are  then  determined  from  these 
reference  curves. 
Materials 
1.  Immunopiates  (Hyland) 
Set  of  plates  containing  antiserum  specific  for  human  IgA 
it  if  ""  If  human  IgM 
2.  Multi-component  Immunology  Reference  serum.  3  vials, 
0.5m1  each 
3.  ['recision  pipette  (3ml)  with  disposable  tips 
(SMI  Micro/Pettor  (Hyland)  ). 
Method 
1.  The  immunodifftision  plate  was  allowed  to  come  to  room 
temperature  in  its  unopened  pouch. 
2.  The  plate  was  removed  from  the  pouch.  The  cover  was 
removed  and  the  plate  allowed  to  air  dry  at  room  temperature 
until  no  excess  moisture  remained  in  the  wells.  The  cover 
was  replaced  firmly  until  plate  was  used. 
3.  The  first  three  wells  of  one  plate  were  used  for  the 
3  reference  sera:  the  remaining  wells  on  that  plate  were 
used  for  test  specimens.  Additional  plates  with  the  same 
lot  number  used  in  the  same  run  required  only  one  reference 
serum  per  plate. 
4.  With  a  clean  tip  attached  to  the  precision  pipetter 
3)A1  of  the  serum  were  added.  Entrapping  air  bubbles  in 
the  pipetter  tip  must  be  avoided  to  ensure  that  the  correct 
volume  is  expressed. 46 
5.  Serum  was  added  to  the  well  by  touching  the  pipetter 
tip  to  the  bottom  of  the  well  and  releasing  the  serum  while 
slowly  raising  the  tip.  Care  must  be  taken  not  to  damage 
the  well  during  this  procedure.  The  introduction  of  air 
bubbles  prevents  proper  diffusion  into  the  gel  so  they  must 
be  avoided. 
6.  The  remaining  wells  were  filled  in  the  same  manner. 
7.  Once  the  serum  had  begun  to  diffuse  (le.  when  the 
serum  level  began  to  drop)  the  cover  was  replaced  firmly 
on  the  plate. 
8.  Incubation  was  at  37°C  in  a  moist  container  for 
48  to  52  hours. 
9.  The  diameter  of  each  precipiton  zone  was  measured  to 
the  nearest  0.1mm  and  recorded. 
10.  A  standard  curve  was  drawn  and  the  concentrations  of 
test  sera  calculated. 
2.1.3 
b)  Specific  Serum  IgG 
Fluorescent  Antibody  Technique 
The  Fluorescent  Antibody  Technique  (F.  A.  T.  )  was  used  to 
measure  the  specific  serum  IgG  levels  against  influenza  A/ 
Victoria/3/75  (H3N2).  It  is  a  simple,  sensitive  method 
which  enables  rapid  detection  of  specific  serum  antibodies. 
A  fluorescent  dye  such  as  fluorescein  is  coupled  to 
antibodies  without  loss  of  specificity.  Such  conjugates  can 
combine  with  viral  antigens  present  in  fixed  cell  preparations 
and  the  bound  antibody  visualised  in  an  Ultra  violet  microscope 
through  the  emission  of  fluorescence.  Using  an  indirect 
method  the  test  can  be  used  to  measure  the  concentration  of 
serum  antibodies  to  specific  viruses. 47 
Preparation  of  Infected  Cells  on  Microscope  Slides 
1.  Influenza  type  A  virus  was  inoculated  at  a  predetermined 
optional  concentration  into  preformed  monolayers  of  Rhesus 
monkey  kidney  cells  in  glass  tubes  and  incubated  for  18  hours. 
(The  concentration  of  virus  and  time  of  incubation  were 
chosen  to  give  a  high  degree  of  brightness  in  50  per  cent 
of  the  cells). 
2.  The  medium  was  discarded  and  replaced  with  1'ml  of  a 
Trypsin/Versene  mixture  containing  0.25  per  cent  Trypsin 
(Flow  Laboratories)  and  0.02  per  cent  Versene  (BDH  Chemicals  Ltd) 
in  equal  proportions. 
3.  The  tubes  were  incubated  at  37°C  for  5-  10  minutes  until 
a  single  cell  suspension  was  formed. 
4.  The  cells  were  pooled  into  a  conical  centrifuge  tube, 
stoppered  and  centrifuged  at  1500g  for  5  minutes. 
5.  The  supernatant  was  discarded  into  chloros  and  the 
deposit  resuspended  in  a  small  volume  of  PBS  to  give  an 
optimal  cell  suspension  of  approximately  5x  105  cells  per  ml. 
6.  The  cells  were  spotted  onto  precleaned  glass  microscope 
slides  using  glass  capillary  tubes  (Microcaps:  Drummond 
Scientific  Corporation). 
7.  The  spots  were  allowed  to  air  dry  and  the  slides  then 
fixed  in  acetone  for  5  minutes  at  room  temperature. 
8.  A  test  slide  was  stained  to  ensure  that  the  quality 
of  the  batch  was  acceptable.  The  rest  of  the  slides  were 
then  stored  at  -700C  until  used. 48 
Staining  Procedure 
1.  Microtitre  plates,  microdiluters  and  calibrated  droppers 
(0.025  ml  volumes)  were  used  to  titrate  sera  in  a  doubling 
dilution  series  from  1/2  to  1/256  in  PBS. 
2.  Slides  were  retrieved  from  cold  storage  and  brought  to 
room  temperature. 
3.  The  slides  were  allowed  to  dry  then  serum  dilutions  were 
overlaid  onto  the  infected  cells. 
4.  Incubation  was  at  37°C  for  30  minutes  in  a  moist  chamber. 
5.  Washing  procedure:  the  slides  were  rinsed  In  PBS, 
washed  In  PBS  for  10  minutes  (5  minutes  x  2)  rinsed  in  distilled 
water  and  air  dried. 
6.  Coat  antihuman  IgG  conjugate.  (Kallestad  Laboratories) 
was  overlaid  and  the  slides  were  incubated  for  a  further 
30  minutes  at  37°C  in  a  moist  chamber. 
7.  The  washing  procedure  as  described  in  5  was  repeated. 
8.  The  slides  were  examined  under  a  Leitz  Ortholux  microscope 
fitted  with  a  mercury  vapour  illumination  source. 
When  fluorescein  is  the  dye  used,  positive  fluorescence  is 
a  bright  apple-green  colour.  In  contrast  negative  specimens 
have  dull  green  and  non-fluorescent  staining. 
The  end  point  is  judged  to  be  the  dilution  of  antibody 
showing  a  50  per  cent  reduction  in  the  intensity  of  fluorescence. 49 
c)  Specific  Serum  Haemagglutinating  Antibody 
Haemagglutination  Inhibition  Test 
The  principles  and  methods  are  the  same  as  used  for 
measuring  specific  secretory  IgA  in  nasal  washings. 
Serum  requires  pre-treatment  however,  with  an  enzyme 
mixture  such  as  Cholera  Filtrate  to  remove  non-specific 
inhibitors.  Two  of  these  enzymes  R(eceptor)  D(estroying) 
E(nzyme)  and  mucinase,  eliminate  non-specific  inhibitors 
of  influenza-virus  haemagglutin.  This  application  was  first 
described  by  Mulder  and  Van  der  Veen  (1948) 
Serum  Pre-treatment  (Removal  of  Non-specific  Inhibition) 
1.  A  vial  of  Cholera  Filtrate  (Philips-Duphar  ß.  V.  ) 
was  reconstituted  by  adding  5  ml  of  distilled  water. 
2.5  volumes  of  reconstituted  Cholera  filtrate  were  mixed 
with  1  volume  of  serum. 
3.  Incubation  was  at  37°C  for  18  hours  to  destroy 
non-specific  inhibitors. 
4.  Before  proceeding  with  the  titration  the  incubation 
mixture  was  inactivated  at  56°C  for  60  minutes. 50 
2.2  GENERAL  PRACTICE  STUDY 
The  study  was  carried  out  in  a  General  Practice  on  the 
South  side  of  Glasgow.  The  study  took  place  during 
the  winter  months  of  1977  -  78  and  1978  -  79. 
146  patients  suffering  from  clinical  acute  respiratory 
infections  were  included  in  the  survey.  They  ranged  in 
age  from  6  months  to  80  years  and  sexes  were  approximately 
equally  distributed.  Each  patient  was  assessed 
clinically  and  was  re-examined  seven  days  later. 
2.2.1  COLLECTION  OF  SPECIMENS 
At  each  consultation  nasal  mucus  samples  were  collected 
by  the  following  standard  method.  Cotton-tipped  swabs 
were  inserted  into  each  nostril  as  far  as  possible  and  left 
30  seconds  in  'situ'.  The  swabs  acted  as  irritants  and 
promoted  rapid  production  of  nasal  mucus.  Each  swab  was 
rotated,  withdrawn  and  immediately  immersed  and  shaken  in 
2  ml  sterile  phosphate  buffered  saline  (PBS)  at  pH  7.2 
and  at  ambient  temperature.  Swabs  from  the  nose  were  also 
taken  for  virus  and  bacterial  culture,  Into  appropriate 
transport  medium  at  40C.  In  all  cases  transportation  to 
the  laboratory  of  the  collected  specimens  took  place  within 
2  hours. 
The  preliminary  specimens  in  this  study  were  nasal  washings 
However,  this  technique  discouraged  volunteers  from  taking 
part  in  the  study  so  the  above  method  was  preferred. 51 
2.2.2  PROTEIN  DETERMINATION 
Lowry  Protein  Estimation 
Modification  of  the  method  of  Lowry  et  al.  (1951)  devised  to 
enable  evaluation  of  results  in  the  Multiskan  Elisa  Reader 
(Flow  Laboratories)  and  simplify  the  handling  of  large  numbers 
of  specimens. 
Materials 
A.  2%  Sodium  Carbonate  and  0.1  N  Sodium  hydroxide. 
B.  2%  Sodium  tartrate  Solution  prepared  in  distilled  water. 
C.  1%  Copper  sulphate  solution  in  distilled  water 
Folin  colcalteau  reagent. 
Method 
Prepare  solution  A 
Solution  B. 
Modification:  - 
100  ml  of  A 
1  ml  of  B 
1ml  of  C 
Folin  ciocalteau  reagent  to  1N 
(ie.  dilute  1/3) 
Standard  Curve 
1.  Doubling  dilutions  of  a  stock  solution  of  Bovine  serum 
albumin,  fraction  V  (BDH  Chemicals)  containing  200mg  ldl. 
2.  Dilutions  were  made  in  a  flat  bottomed  microtitre 
plate  (Dynatech  M129  A)  in  volumes  of  0.05  ml  using  a 
multichannel  pipette. 
3.0.25  ml  of  solution  were  added  and  left  for  exactly 
10  minutes. 52 
4. 
5. 
6. 
7. 
0.25  ml  of  solution  B  were  added  and  left  for  at  least 
20  minutes. 
Samples  were  read  at  619  nm  in  the  Multiskan  reader 
using  distilled  water  as  a  blank. 
A  standard  graph  was  drawn  of  protein  concentration 
(mg/dl)  against  absorbances  (absorbance  units,  AU). 
0.05m1  of  nasal  washing  were  used  undiluted  in  this 
test  and  the  protein  concentration  determined  by 
reference  to  the  standard  curve. 
32  specimens  were  screened  per  plate. 
2.2.3  SECRETORY  IgA  DETERMINATION 
Rocket  Electrophoresis 
This  rapid,  reliable  and  relatively  simple  method  was  used 
for  the  determination  and  quantitation  of  a  single  protein 
(ie.  secretory  IgA  (sIgA))in  a  mixture.  Antigen  (sIgA)  moves 
in  a  layer  of  buffered  agar  containing  monospecific  antibody 
to  sIgA  in  an  appropriate  electric  field.  A  stainable 
precipitate  occurs  in  a  'rocket'  shape  add  the  length  of  the 
'rocket'  correlates  with  the  amount  of  antigen  (sIgA)present. 
Under  standard  conditions  of  time  and  electric  field  strength 
the  method  is  suitable  for  measurement  of  tiny  quantities 
of  immunoglobulin  in  dilute  and  unconcentrated  biological 
fluids.  (Merrill  et  al  (1976)  ). 
Materials 
Instrumentation  :- 
Electrophoresis  equipment  from  Hoechst  Pharmaceuticals 
(Behring  Diagnostics). 53 
Reagents 
Antiserum:  sheep  antiserum  secretory  IgA  plus 
secretory  piece  supplied  by  Dakopatts  A/S  Denmark. 
Agarose:  1%  Indubiose  in  buffer,  supplied  by 
l'Industrie  Biologique  Francaise. 
Buffer:  Michaelis  buffer  pH  8.6  (Serva  Labs) 
Stain:  Coomassie  Stainer  and  destainer  as 
described  in  Dakopatts  Manual  (Working  procedures  for 
DAKO  immunoglobulins). 
Standards 
Low  level  human  IgA  reference  serum  (pooled  human  serum): 
Hyland  Laboratories. 
Secretory  Immunoglobulin  A  (Colostrum):  Seward  Laboratories. 
1.  Production  of  antiserum  containing  gel  plates: 
A  1%  agarose  solution  was  prepared  with  barbital  buffer,  pH  8.6 
The  specific  antiserum  was  added  at  a  temperature  of  approximately 
55°C.  The  solution  was  then  uniformly  distributed  on 
10  x  10  cm  glass  plates  on  the  horizontal  table.  It  is 
advisable  to  precoat  the  plate  with  a  thin  coat  of  agarose  to 
enhance  the  bonding  of  gel  to  plate.  Once  the  gel  had  set, 
wells  were  cut  using  a  gel  punch  and  template  (3mm  in  diameter 
and  8mm  apart). 
2.  Electrophoresis  Conditions: 
1.  The  plates  were  laid  on  the  carrier  plate  of  the  electro- 
phoresis  chamber  and  connecting  bridges  of  surgical  lint 
moistened  with  buffer  were  established.  The  wicks  should  not 
overlap  the  edges  of  the  slide  or  crooked  precipitates  may 
result. 54 
2.  The  current  was  switched  on  and  the  voltage  across 
the  gel  adjusted  to  about  1  volt  per  cm.  3u1  of  samples 
were  applied  to  the  wells  using  a  micropipette.  The  current 
through  the  gel  should  prevent  rings  of  diffusion  around 
the  wells. 
3.  The  potential  gradient  in  the  gel  was  adjusted  to 
7  volts  per  cm,  the  lid  of  the  apparatus  replaced  and  the 
electrophoresis  run  for  3.5  hours.  To  keep  the  temperature 
in  the  gel  suitably  constant  the  heat  produced  during 
electrophoresis  must  be  eliminated.  This  was  achieved  by 
using  an  inbuilt  cooling  system.  The  carrier  plate  which 
holds  the  gels  is  made  of  plastic  with  channels  for  water 
cooling.  For  the  time  period  used,  tap  water  was  found 
to  be  a  suitable  coolant  with  a  reasonably  constant  temperature 
of  15°C. 
Washing  and  Staining 
1.  On  completion  of  electrophoresis,  the  wells  were  filled 
with  water  and  the  gel  covered  with  a  piece  of  wet  filter  paper, 
taking  care  to  avoid  trapping  air  bubbles.  A  2cm  thick  layer 
of  soft  cellulose  tissue  was  placed  on  the  slide  and  a  pressure 
of  about  10glcm2  maintained  for  15  minutes.  Effective 
squeezing  of  the  gel  was  achieved  and  the  liquid-phase  of  the 
gel  containing  non-precipitated  proteins  was  eliminated. 
2.  The  filter  paper  was  peeled  off  carefully.  Any  adhering 
fluff  was  removed  by  a  light  touch  and  running  water. 
3.  The  gel  was  dried  under  a  current  of  warm  air. 
4.  The  gel  was  stained  by  immersion  in  the  coomassie  solution 
for  2-3  minutes. 55 
5.  The  gel  was  then  washed  in  the  destainer  until  the 
background  was  slightly  bluish,  three  changes  of  destainer 
were  needed.  The  destaining  was  done  in  about  6  minutes. 
6.  The  gel  was  allowed  to  dry. 
Construction  of  the  Calibration  Curve 
The  rocket  heights  were  measured  with  an  accuracy  of  0.5mm. 
A  linear  or  near-linear  curve  was  obtained  by  plotting  the 
height  of  the  standard  rockets  against  the  amount  of  antigen 
applied  to  the  wells.  By  interpolation  on  the  curve  unknown 
samples  were  quantitated.  It  should  be  noted  that  at  the 
onset  of  measuring  sIgA  by  Rocket  electrophoresis  the 
secretory  IgA  standard  (Seward  Laboratories)  was  not  in 
production  and  the  low  level  serum  IgA  standard  (Hyland  Labs) 
was  used.  When  the  secretory  standard  became  available 
the  serum  standard  was  calibrated  against  the  secretory 
standard  and  new  values  assigned  to  the  secretory  IgA 
concentrations.  However,  for  measurement  of  differences  in 
sIgA  concentration  it  was  decided  to  compare  differences  in 
rocket  height  to  minimise  discrepancies  due  to  the  small  rocket 
height  of  some  of  the  samples. 
2.2.4  BACTERIOLOGICAL  AND  VIROLOGICAL  STUDIES. 
The  bacteriology  results  were  provided  by  courtesy  of  the 
Bacteriology  Department,  Belvidere  Hospital. 
The  virology  testing  was  performed  by  myself  and  by 
colleagues  in  the  Virology  Department,  Belvidere  Hospital. 
Testing  was  performed  using  the  standard  techniques  in 
current  use. BEST  COPY 
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CHAPTER  3 
RESULTS 
3.1  VACCINE  TRIAL 
3.1.1  ANALYSIS  OF  SERUM  H-I  ANTIBODY  LEVELS 
The  age  and  sex  of  each  subject  are  outlined  in  Table  I. 
The  ages  ranged  from  19  -  72  years  and  the  male  -  female  ratio 
was  45%  -  55%. 
H.  I.  antibody  titres  against  A/Victoria/3/75  in  sera 
obtained  2  weeks  before  vaccination  (1),  6  weeks  after 
vaccination  (II),  4  months  after  vaccination  just  before 
challenge  (III)  and  6  weeks  after  challenge  (IV)  are  shown  In 
table  2.  Corresponding  titres  against  B/Hong  Kong/8/73 
are  shown  in  Table  3. 
In  the  placebo  group  no  subject  showed  a  rise  in  titre  6 
weeks  after  receiving  the  placebo,  indicating  that  there  was 
little  or  no  influenza  activity  in  the  study  population  in 
that  time  interval.  9  out  of  22  subjects  seroconverted  in 
the  Influvac  Spray  group  indicating  that  the  vaccine  was 
slightly  immunogenic.  The  geometric  mean  titre  rose  from 
8  to  21  which  is  statistically  significant  (P  =  0.005). 
In  the  time  Interval  between  the  second  blood  sample  at 
6  weeks  post-vaccination  and  challenge,  5  subjects  in  each 
group  showed  significant  antibody  rises  indicating  that  they 
had  been  naturally  infected  by  influenza  virus.  5  of  these 
10  subjects  (3  in  the  Influvac  Spray  group  and  2  in  the  placebo 
group)  also  reported  flu-like  disease  in  the  corresponding 
period.  Only  one  more  subject  (no.  1701)  complained  of 
flu-like  symptoms  during  the  same  time  interval. 59 
Thus  a  small  outbreak  of  influenza  occurred  during  the 
course  of  the  study.  There  is  no  evidence  that  Influvac  Spray 
gave  any  protection  against  natural  infection.  In  fact  one 
subject  (no.  1723)  who  had  seroconverted  after  vaccination  was 
infected.  It  is  also  possible  that  the  initial  rise  in 
titre  was  due  to  natural  infection  and  not  the  vaccine. 
After  challenge  a  further  eleven  subjects  seroconverted 
(7  in  placebo  group  and  4  In  Spray  group).  If  the  10  subjects 
who  were  apparently  naturally  Infected  are  withdrawn  from  the 
study  (since  they  would  be  expected  to  be  Immune  to  a  challenge 
infection)  the  following  protection  rate  can  be  calculated  for 
Influvac  Spray 
4/16 
Protection  Rate  =  (1  - 
_77-14-  )x  100  =  50% 
With  regard  to  the  response  after  vaccination  to 
B/Hong  Kong/8/73,  it  can  be  seen  in  Table  3  that  only  one 
subject  in  the  Influvac  Spray  group  produced  a  significant  rise 
in  serum  H.  I.  -  antibody  titre. 
The  geometric  mean  serum  H.  I.  -antibody  titre  rose  in  the 
Influvac  Spray  group  from  50  to  62  after  vaccination  whereas 
in  the  placebo  group  the  corresponding  values  were  22  and  19. 
No  adverse  reactions  related  to  the  vaccine  were  reported 
after  vaccination.  7  subjects  reported  common  cold  (4  in 
placebo  group,  3  in  Influvac  Spray  group)  and  1  subject  in 
the  Influvac  Spray  group  reported  sore  throat. 
The  subjects  were  originally  selected  because  they  had  low 
levels  of  serum  HI-antibodies  against  Influenza/A/Victoria/3/75. 
(Titre  <  40).  No  account  was  taken  of  initial  levels  of 
secretory  IgA.  Table  4  shows  HI-antibody  titres  of  subjects  with  low 
initial  levels  of  secretory  IgA  measured  by  the  Haemagglutination 
Inhibition  test.  (Titre  <  16).  Table  5  is  a  repeat  of  table  4 
with  the  exclusion  of  those  subjects  who  were  serologically 
demonstrated  to  have  contracted  wild  type  influenza  virus  during  the 
course  of  the  study. 60 
No  subject  seroconverted  in  the  placebo  group  whereas 
7/11  subjects  seroconverted  in  the  Influvac  Spray  group 
indicating  that  the  vaccine  was  more  immunogenic  in  this 
group.  The  geometric  mean  titre  rose  from  8  to  26.  This 
is  statistically  significant  (P  =  0.01/0.005).  After 
challenge  a  further  8  subjects  seroconverted  (6  in  placebo 
group  and  2  In  the  spray  group). 
2/10 
Protection  rate  =  (1  -  6/12)  x  100%  =  60% 
Table  6  shows  the  HI-antibody  titres  when  the  subjects 
have  moderate  to  high  levels  of  secretory  IgA  (titrev.  l6). 
Table  7  is  a  repeat  of  this  group  with  the  influenza 
sufferers  excluded.  Although  this  group  is  small  it  can 
be  shown  statistically  that  the  Influvac  spray  does  not  cause 
a  significant  increase  in  serum  antibody  levels  (P  =  0.15). 
The  geometric  mean  titre  rises  from  10  to  17. 
After  challenge  there  were  3  seroconversions  (2  in  the 
Spray  group  and  1  in  the  placebo  group).  Unfortunately  there 
were  too  few  subjects  in  the  placebo  group  to  calculate  the 
protection  rate. 61 
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Note  in  Tables  2  through  26 
I=  pre-vaccination 
II  =  post-vaccination 
III  =  pre-challenge 
IV  =  post-challenge 
F=  Subject  reported  flu-like  illness  in  this  time  interval 
*=  significant  rise 
NE  =  subject  did  not  enter  the  study 
GMT  =  Geometric  mean  titre 63 
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If  subjects  are  selected  with  low  levels  of  secretory  antibodies 
as  measured  by  the  Quantitative  Haemadsorption  test  (table  8) 
and  with  the  exclusion  of  those  subjects  who  were  demonstrated 
serologically  to  have  contracted  wild  type  influenza  virus 
during  the  course  of  the  study,  the  results  are  as  follows: 
No  subject  seroconverted  in  the  placebo  group  whereas  5/11 
subjects  seroconverted  in  the  Influvac  Spray  group  i.  e.  vaccine 
is  more  immunogenic  in  this  group  (see  table  9).  The  geometric 
mean  titre  rose  from  8  to  20.1.  This  is  statistically 
significant  (P  =  0.05/0.025)  After  challenge  a  further  11 
subjects  seroconverted  (7  in  the  placebo  group  and  4  in  the 
Spray  group). 
4/11 
protection  rate  =  (1  -  771-2)  x  100%  =  37.7% 
The  response  to  the  attenuated  challenge  vaccine  is  also 
significant  (P  =  0.05)  One  patient  (1730)  shows  a  significant 
rise  twice.  Table  10  shows  the  subjects  who  have  moderate 
to  high  levels  of  secretory  IgA  (titre  >-l  QH  log  50/ml)-and  with 
the  Influenza  sufferers  excluded.  This  time  the  influvac  spray 
does  cause  a  significant  increase  in  antibody  levels 
(P  =  0.1/0.005)  The  geometric  mean  titre  rises  from  10  to  42. 
When  subjects  are  chosen  with  low  initial  secretory  antibody 
levels  as  measured  by  both  methods  (Table  11)  no  subject 
seroconverted  in  the  placebo  group  whereas  5/8  seroconverted 
in  the  influvae  spray  group.  This  is  statistically  significant 
(P  =  0.1/0.05)  After  challenge  a  further  8  subjects 
seroconverted  (6  In  the  placebo  group  and  2  in  the  spray  group) 
2/8 
Protection  rate  =  (1  -  6/11)  x  100%  =  54% 
When  subjects  are  examined  with  high  initial  secretory 
antibody  levels  as  measured  by  both  methods  (table  12) 
there  were  too  few  samples  to  analyse  statistically. 70 
When  the  subjects,  with  differing  values  for  initial 
secretory  antibody,  are  examined  the  pattern  is  that  if  the 
Quantitative  haemadsorption  method  gives  a  high  value  the 
subjects  respond  to  the  influvac  spray  and  are  immune  to 
challenge  whereas  if  the  Haemagglutination  inhibition  method 
gives  a  high  value  the  subjects  show  no  response  to  the 
inactivated  influvac  spray  vaccine  but  show  a  good  response 
to  the  attenuated  challenge  vaccine. 71 
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3.1.2  ANALYSIS  OF  SPECIFIC  SECRETORY  ANTIBODY  LEVELS 
The  specific  secretory  antibody  levels  by  the 
Haemagglutination_Inhibition  test  are  shown  in  table  14  and 
the  same  group,  with  the  exclusion  of  those  subjects  who  were 
serologically  demonstrated  to  have  contracted  influenza  during 
the  course  of  the  study,  are  shown  in  table  15. 
In  the  placebo  group  4/13  subjects  showed  a  significant 
rise  in  titre  6  weeks  post  vaccination  as  did  5/17  subjects 
in  the  Influvac  spray  group. 
Table  16  shows  subjects  with  low  initial  levels  of  secretory 
N.  I.  antibodies.  Following  vaccination  with  Influvac  spray 
the  geometric  mean  antibody  titre  rose  from  6  to  21.6 
(P  =  0.05/0.02)  and  in  the  placebo  group  the  geometric  mean 
titre  rose  from  4  to  11.2  (P  =  0.02). 
Table  17  shows  subjects  with  moderate  to  high  initial  levels 
of  secretory  H.  I.  antibodies.  There  is  little  or  no  response 
in  either  group  to  the  initial  vaccination  however  both  groups 
show  a  slight  response  to  the  challenge  vaccine.  In  neither 
groun  is  this  response  significant  (P  '  0.5). 
The  secretory  antibody  response  corresponds  to  the  serum 
antibody  response  when  moderate  to  high  initial  levels  of 
secretory  H.  I.  antibodies  are  examined.  (cf.  Table  7). 
Tables  18  through  21  show  the  secretory  antibody  titres 
measured  by  the  Quantitative  Haemadsorption  test.  There 
is  little  response  to  either  vaccine  or  placebo. 77 
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3.1.3  ANALYSIS  OF  TOTAL  LOCAL  ANTIBODY  LEVELS 
Total  local  IgG  and  IgA  antibody  levels  were  measured 
by  Radloimmunoassay  and  the  results  shown  in  tables  22  and 
23  .  The  results  confirm  the  presence  of  local  IgA  and 
IgG.  The  base-line  antibody  levels  exhibit  the  expected 
ratio  of  IgA:  IgG  (le  5:  1). 
Figure  5  shows  the  secretory  antibody  levels  measured 
both  by  the  Quantitative  Haemadsorption  test  and  by  the  Haem- 
agglutination  Inhibition  test  compared  with  levels  of  total 
local  IgA  measured  by  Radioimmunoassay.  To  facilitate 
analysis  the  results  have  been  divided  into  three  categories: 
Influvac  spray  group,  Placebo  group  and  subjects  naturally 
infected  by  influenza  virus. 
All  three  groups  show  a  response  to  the  initial  stimulus. 
The  two  trial  groups  show  a  fall  in  the  four  month  period  between 
specimens  II  and  III2  the  Influvac  spray  group  showing  a  less 
pronounced  fall  than  the  placebo  group,  whereas  the  group  which 
were  naturally  infected  shows  a  "holding  of  level".  When 
measured  by  the  Haemagglutination  Inhibition  Test  this  group 
shows  a  rise.  Following  challenge  all  three  groups  show  a 
small  rise. 
3.1.4  ANALYSIS  OF  TOTAL  SERUM  ISA  and  IgM  ANTIBODY  LEVELS 
Total  serum  IgA  and  IgM  antibody  levels  were  measured  by 
single  radial  immunodiffusion  and  the  results  are  shown  in 
tables  24  and  25 
The  range  of  base-line  serum  IgA  was  90  -  500  mg/dl  with 
a  mean  of  254  mg/dl  and  a  standard  deviation  of  93  mg/dl. 
The  coefficient  of  variation  was  4.3%. 
The  range  of  base-line  IgM  concentrations  was  found  to 
be  36  -  210  mg/dl  with  a  mean  of  108  mg/dl  and  a  standard 
deviation  of  43  mg/dl.  The  coefficient  of  variation  was  6.5%. 86 
3.1.5  ANALYSIS  OF  SPECIFIC  SERUM  ISG  ANTIBODY  LEVELS 
Specific  serum  IgG  against  Influenza  A/Victoria/3/75 
was  measured  by  the  Fluorescent  Antibody  Technique  and 
the  results  are  shown  in  table  26. 
These  results  indicate  that  this  technique  is  useful 
for  detecting  Infection.  It  does  not,  however,  appear  to 
detect  antibody  changes  produced  by  the  vaccine.  (cf  table  2). 87 
ro 
N 
N 
ro 
0 
c 
M 
to 
.  92 
cm 
U 
.  -1 
td 
N 
a) 
rý1 
. 
Ll 
ro  F- 
O 
N 
U 
td 
-1 
CL 
N 
b 
CL 
U 
H 
C'%  rn  ON  rn  U*%  -4  (7%  CN  C>  CO  >  P.  4  NN  co  co  co  W  -a  tt1  ÖN 
O0  6000x-10 
C)  10  C)  r- 
HONO  r-  CID 
r 
NC\j 
^NN 
HLO488888O 
I  -*  Lf1  'O  1M 
N  (n  (\I 
64  ;O 
Cc)  tl%  N  y-  1!  ß 
MN  ON  rr  rr 
OO8  r10 
-d*  -t  cr%  -t  I  cc 
GOMtf\N  N 
OOO  '-1  O 
1  %Dr-I1'.  co  1  O% 
r-1  r-i  O  ON 
m000  O 
-t  '"I  u4  Q1'.  0ON  fVM  t'.  0  Q\0  MM0  N\0tVc'M  IN  t*-  Ln  .  --I  .  -I  .  -1  -NMOO  t-  NO  Ir1  -4  M  CD  \0  I-k 
ON.  --IN  OLA  .  --10170  O 
0dM  '0  .  -4  4  Ch  \0  NOIO  fN  ON  tf  .  -4  0  0\  O\  NIO  H-1  -t  -4  -'  of  a0  r-1  OO  "4  '-i  N  '-I  LnM  '--I  NOOO  u--I  N 
OOOOONOOÖo  888468u;  668 
O 
.Q 
W 
_W 
4'  co  -4MZ''0N  0  -IN  LM  %OcDO\.  -INt'nO%ON,  y-\O  C  000.  -4-A  --I,  -.  V-4  fqNNNNNNMMen  M-t  ý  -t  rN  NNNNN  I-  NN  t-  r-  t-  NN  tl%  N  t-  r-  r-  t-  t-  t- 
v 
0 
U 
110  1-  m  1ý  %.  O  p  ul  ri  01  ONO-ý  t'º  9  (\J  11N 
CO  d-0  oz  mco  0cc1,  H  fýOý  tOD  mGo  00 
H  NON8  t+1.  --INýO0 
ie  nzt  rnZt  cool,  .  - 
0000  ooý 
1  1ý  1f1  O  1-  an  N  R1  \O  co 
-zt  -2  J  Cr  N  -e 
x-10  0000  OOO 
4- 
oö 
1L1e 
Na 
00 
H 
(hMNNO1-%00N%0 
1  r-Iý  O,  r-10  M1  NLI  O  H  --"-2  Ocý  ￿y'O-2  1  IO  fr11  1  u1111'O  A.  --1  OOOtnOOln00  NOOpp0,.  ý0,.  ý  000 
H 
O.  'ch  M--3C\  0a  Nt  O-i_:  t  aDOh  ON  r-I  N  a00  1  aD0%0  O  MU1N0Lnri  M.  -If-CD  0.  -1%0\Oac)  ('  0  to  O  .-4O  ,  --1  ,  -i  O  t,  r1  OO  OOOOr10c;  000 
w 
z  .  --1N  Lf%  .  ON  ONU  a0  M  NO  d-  i$,  o  p,  to-1Mu1N  OOO00  O^  nnnnnnnnnnnnnnnnn 
"ý  '-i  /-i  .  -1  rl 
^ý 
ri  .  -4  O 
U 88 
b N 
N 
ro 
O 
c 
E 
E 
-I 
O 
ü 
b 
.a 
E 
rn 
H 
r--I 
U 
0 
.  -4 
+1 
0  F- 
N 
.  -1 
ro 
O 
.a 
U 
ro 
N 
N 
C 
CL 
V) 
U 
td 
C 
H 
Ln  %0  r-  00c,  %  i  Co  :t  (N  dNu.  O  .  --  GC  4-  ON 
ýo  tnLs  fJu  -;  fß.  -1 
0  Lr%  -4  0%  %0  Co  r_  e  CD  it  0COMNCh  0%0  C)  r'10' 
H  -nýýDýrnaDHýý  O 
t1%  O,  1'  -4  O  Ln  1-  O  0h  tf%  1  O%  N  O\  0ý,  0%  C)  0,  n  CC)  Ch  1  to  Hn 
12Il1"Im  .  -icm  H^LA  p.  -,  WICZ  OCONd-  .  -I  HO  c'n  QO  CO  Qý  r-1  "1  .  -i  -1 
ý 
-'  I,  t!  1  N  LA  rý  d'  to  fý 
H 
v%CNLnC  LM  -1aDN0%0  1  8O'O0  a000o%0%0  n1O  .  --1  M  .  -1  0,  mM  r4  MNp  0%  tr%  rl  M  0%  %0  ri  %.  0  CD  '0 
.  -I  ri  ýNM  Iý  NO  .  -ý  OM  .  -ý  OMN  .  -I  O  ýO  ON  .  -1 
i  a'  rr  1  rn  1-t  r-  Lr%  m81 
Co  d-  o0  v\  O  aD  e 
ON  +ý  Pß'1  N  rn  Pý1  .  -ý  .  --1 
1  110  .  -1  N4  0'ý  1N  1-  COO  t  .  -1  1-  M  Lr%  -i  Lr%  "0  aD  1ý  N  p:  .......... 
N  .  --1 .  -i  N  ýO  NO  .  -1 
94 
Z  w_ 
C 
aDG"  r--44'  %0I-C) 
(\JtV 
to"0a00%.  -INr+1  ON  ý-  00  4'  r-4ý"ýý  ý,  ".  ýNN  NNNNNýrrlýtrlß 
-4  -4  -1  -1  . 
^-4 
rn-1  0 
N  Lt%  L  r%  co  Juo  .  -I  LrN  QO  Mu10ý  CO  Nrº00 
HN0  0ý  r-1  ý0  1  ap  ;M  Lf; 
aD  "O  O  1.0  O  t-  d-  ON  Qh  U-%  d  OºnM\0dNMOD 
LAM  M  LA  -1  .  d- 
MH 
ý"-INdfNL,  p-  (NJ  O 
ri  N  ý4  ON%.  D  O 
aD  Co  LA 
t  0DNON  Oh  -I  -t  CO  N.  -1  N%0O'%  Np%  QOLm  4'' 
Lý  O64  CJ 
6 
C414,6  a; 
1  c\  1  0's 
" 
ý  rl 
1  rf  1  4- 
th  'p 
ý'  O 
O  ý.  -1ýý0ý  ýONNd  1  OGocomNr 
't%,  o0  1'o  -.  -  ý 
um  NO  r-.  C)  1-4  N  "--l  N  -4  ýn  N4riýO 
"-4  NCOA0  ýn  '0  00 
.1  .  -ý 
a)  C)  'O  tnN  Itz  m  CO  rn  '0  4  a%  1  (z)  %  tr1 
nao-ý  wntnrnOnn  rnOLn000 
u,  rn.  a  al)  .  -t  %O  .-4  i--1  """....... 
NN  ýO"-1  M1Ný.  -IýýOoDd  t!  ý  ON  O 
cý 
a) 
W 
I--,  NMV'.  O  1N  0  tV  L(  )  C'.  M-r,  C  .*  t+  ý  ýD  1ý  aD  .  -I  rn  u'.  N 
CO  0O^00-4_4 
_4  l4  'J  Nm  rv1Mr,  nt., 
r. 
t% 
r-4  wq  Fm4  -,  P-4  w-4  9-4  f-f  -4  -4  -4  r.  4 
0 89 
i  H!  -  ýF-  11  _  ... 
O4j 
"  -1'  R1  .  +i 
C  G)  r 
"'-  >  (1)  i-) 
J-)  ".  1  ) 
0 
g  O'  Jr 
.ý 
i!  uj  U 
>  In 
>  >,  ýCi 
"" 
H!  0O!  0  H;  I  >v  rý  ýo  i 
-1  "rl  ,p,  ^-I 
> 
""4J 
-P  c 
.00 
11 
. 0I  Ö 
'-I  Q'. 
'r{  ,  aý  roI 
ýI  1 
°!  ° 
v-.  ' 
bH 
ail  a   9' 
01 
c 
bi  b 
Ü  ý'  I 
ýI  IIC 
LL, 
H  4-) 
= 
C 
O 
4  Co 
Co 
1  $q 
ý_`ý'  I. 
ý_. 
ý..  i 
i  i 
f--ý--" 
ý. 
1 
4/- 
-;  - 
. 
j 
L 
I 
i  f. 
._ 
- 
! 
-+- 
ý 
y  j 
L  1  _ 
I.. 
I. 
:  m  i 
H 
f 
i 
t 
OO  ýj 
U) 
.4 
C 
O 
.,  4 
U 
4) 
O 
U 
C 
- 
U 
a N 90 
0) E 
0 
N 
4- 
0 
C 
E 
.  -I 
ro 
.,  I 
ro 
0-1 
C 
N 
U) 
1-4  Q) 
rn 
H 
E 
c) 
N 
b 
Fý- 
rn 
0 
U 
a 
0 N 
C 
F4 
N 
U 
rd 
V- 
H 
> 
H 
0N  N04OCD  O4-1N  1  -4  N0  1O  1  N0I  .U  II  N  4N 
mMcr%  1N  3'N 
-4  M(V 
r  1-4  rNnrvrlm4 
Mj 
N 
H 
Lr%  ^Ul%  ^4-LIN  00  Cl  It  N 
0  1.04-  \00  a%r'10N  m 
1  Lr%Ull0 
OOOC'. 
1  (V 
' 
1  C)Lr%L'.  O  I1  CO 
I--1  NNM  .  -1  tº1  r+1  N  u1  .  -i  en  N  M% 
4 
'--1 
LI'.  IS'.  U)  N 
NN  t+l  Cr'. 
t\ 
N 
H 
H 
0  l!  1  r-1  r-1  ýO  "-i  tf\  fV 
4-  '--1  X11  t!  A  CO  -1  0%  Lr%  N  L11% 
I  0\  NO  I  N.  I  t!  '.  1N  LLf'.  1-  II 
.  -1NNNN1'x..  -14N-4 
QO  4-01 
,..  tN  rn 
\0 
.  -I 
rn  -*  CON 
NNf''.  N  It 
N 
H  V%  O  u1  .  -4  4-  O  a)  Lr%  (7% 
"-1  N  4-  u1  1-  _-l  N  %D  O  ao 
1  rl  NO 
r  -  ' 
1N  INO  to  tt'.  1O  0\ 
NNt'r1NNPº1NtY'.  1".  --I 
C  '.  Q  0  % 
(\INer'.  .  -1 
N 
(ID  O  NN 
' 
\0  N 
1  (  nn  (  M 
94 
w  V 
w  E=z 
7  4CIDM  -IM4$Dor"0  1Cq  r%kOODON  P-4  NMO\0  N4*,  0  cO  r-  rl.  r-  OO^r-r-r  (\j  C4 
Ckj  rj  (%J  (\J  r4  nP- 
rte.  r~  "-ý  -i  -4  -i  r-1  .  -1  r-1  r-1  .  --ý  .  --ý  ý--4  ý--I  .  --I  .  -I  r-1  .  --I  ý-I  -i  "-1  .  -4  .  -1  '  -ý  ý--i 
0  U 
> 
H 
Lm  Ou1NN1-.  to  rAOIr% 
C\  LA  N  -4  fN  N  -t  %O  ON  C. 
1  Ou-INOOOOOa0 
Om  "-i  to  0  00  to  .t  %D 
1N11  co 
1  .  -i  r-1  P-4  P^  .  -i  m  r4  r-I  N  to  '--1  N  -'  111  r-1  (V  p.  4 
N 
N 
H 
H 
LAOLAýNNLAN  LA  r-  -t  N  r-  (NJ  N'--INN  GO 
1  0MWNC)0000N 
00  tor1 
1  to  I1  0 
H  fV  -4-4  cA.  -IMN  N  -1  (4-1N(4LAO. 
-i-1(4.  -I-1 
(0 
N 
H 
H 
LA0VN  O-Ic0Pr1N0 
%D  LA  NO  v\  tV  co  'O  u1  LrA 
1  OONIN00LA  AN 
*  I  u1  II  N 
"4  "-1  -4  P-4  (N  "-4  (\j  N  -1  -4 
O\  N  ,D  fV  O  CO  O  O\  LAA 
M  -4  NA  to  .  --1  N  "--1 
rn 
N 
a% 
.4 
0  Ov\a00  NOt"1O-4 
O\  10  N0  \0\ONN\0\0-1  1  O.  -1cm  tr\CD  al  0tr\CO  I  tr\  II  N 
.  -1  -4  .  -1  i--1  N  r4  NN  .  -i  N  -:  t  rn  %,  Ur'r100\  "ONTO 
fn  .qN  .t  LA  .  -i  N  .  -1 
cV  O 
N  N 
0 
EZ 
7  r-1NM  tr1"D  1.  ONLncx)0\m 
-t  1,  pýLr\  sof.  CO-4enLr%  N.  C  000000. 
-Ir-1-4-4r-1(%j  r*1MMýýý  I- 
4)  -I 
-4 
-  -4  -4  --1  '-I  '-I  ý4  -4-4  .^  -I  - 
-4 
-4 
-4 
-4  .  -I  r-4  p-4  r-1  14  4-  rn4  -4  . 
^i 
C.  7 
0 
-1- 
C 
0 
4) 
r0 
"1 
94 
0 
C 
U 
4- 
G) 
0 
V 91 
> 
H 
n'1  04  '00NN400001%  LI%N-  1  MOB  htNI 
.  -t'0.  t  1N  0M  .  -1  00  1-  -4  't  't  Lf%  U0  a0  i'  It  r-  -4  1-  It  C'  -4  "-I  H  .  -i  r-1  NH  r-I  r-q  P-I  1-4 
H 
H 
0  %0%0r-ILf'%  00  'AD  J0r'n  I  fm  r'º1tl%OM  I  N-  '000  IN  0  "-4  '"1  tlt  .  -1  N  ap  00  h  tn  r-1  '  l  01  p'  Lt  0  '0  -4  h  4-  Q'  0% 
`-' 
H 
H 
.  -i  NM0DCl  4N  KOMM  I  M.  -1.  -ION  I  O\  WOO'  IN  N-  C'  -0'0in  ý4  *  4'O-4  iC 
'O 
c  C) 
L  tr\-11-0  O'  co 
O 
"^4  11 
7 
4-- 
C 
1.  H  M  aD  M  U)  N  QO  O  \0  OMI  C\  fn  r-I  O  C'  IC  'O  O  r-I  1N  0'%  u1  O%  1-  O\  N-  r,  t  \O  0  t,  r%  4-  O 
.0  94 
N  '  H  %  tt%  O  tt1  "-i  U)  p%  p\ 
C 
41) 
U 
a) 
.0 
WW 
E 
ro 
^-  1 
CL  C 
4.0)C  r-IM4-  O0NOr-INtn00)C'. 
--INM0%0  NZ  CO  OO-1.  -i.  -1.  -1...  INNNNNN 
H 
NMMMCM  N-  NNNhi  N-  N  N-  -NN  N-  N-  N-  N-  N-  N-  -NN  N-  i--1  P-4  -i  _-1  -4 
I- 
.  n4  -4  -4  --1  r-4  '-'4  .  -'4  -4  r-4  r-1  -4  -4  -4 
ro 
O 
v 
0 
0  > 
H 
\O  110  %0  Ln  Ln  OD)  Irt  It  -14.  UD  N  .  -1  4-  0  \0  NINI  N-  ('  It  N  OD  co  00'NGo  'p  H 
(U 
Nco  C\.  -4oo'--IMF  n1  N  "-1  1--1  .  -4  .  -4  C' 
.0 
H 
H 
'004-m  rf\  -C\J'-4  4-  1  CD  4-  O4'-0%ß'N  INIh  M40  00%4  M  %D  C4  0\  4 
N  i. 
H  N  ODN  N  \0ODLr\"14-  MN  -4  r-1  r-1  "-1  r-4  -4  .  -I  - 
ON 
-4  -4 
1  1  r-1  .1 
a)  N 
>  11 
0  C  H 
H 
0  '0  4-  m4M4  t/%  tn  aD  1  y'  M  4'  O  4.4-  N-  Lr%  M4-00c)  %0CN0C'  iN1  1-  h  NONtll\0NNL/\M 
M  fV  1  1-4 
.  -1  .  -4  .  --1  -4 
O' 
.  -4 
H 
H  \0-,  o  4-  GD.  -14.4-  u,  00  I  %00\-1-0ao04-co  tr\  1  tV  1  v1  .  7t  co  h\O  0'0  --1  -4 
i  4  V 
ý 
.  -INL\\0\Da0O\  tMM  pj  N  r-1  .  -i  P-4  .  -i  .  -1  -1  r-1  --I 
O 
y 
to 
>  .  .  --I  P-1 
H 
4- 
s4 
Q) 
tf1 
H 
'0  E 
W 
N 
0  C 
r1NM  U1\0hO(-,  i  N(OQ\  0)  r-%  C)  tl-%  \0hOD  .  -IMU1h  000000. 
--1.  -4-4-4-4IN  NN  MrnMMMM 
-f  tt  nlýt  N-N-NNN-NNNhhhNNNNN 
r-  r-  -  -1  -1  .  -1  "4  r-I  --1  .  -I  r-I  .  -1  i 
F.. 
.0  b 
'D  -  r--I  .  -1  .  -1  .  -i  r-  I  .  -i  .  -1  .  -1  ý1  .  -1  .  -1  .  --i  .  -1  r4  C7  O 
\0 
C 
0 
ro 
ro 
4- 
0 
4-3 
c 
U 
k-I 
4- 
4- 
O 
O 
U 92 
v 
c 
s 
U 
a)  H 
'D  O 
C 
C 
a) 
U 
N 
4) 
O 
LL- 
L 
4--) 
.0 
Lf1 
N 
fn 
f0 
0 
U 
N 
C 
fd 
Q1 
N 
a) 
C, 
p1 
I--4 
E 
0 
4) 
.0 
F- 
N 
0 
U 
r-I 
a 
N 
Q 
N 
U 
tp 
4- 
>  \O  %0  1110  %D  %0  %0  %D  Ik0  10  I  %D  '0  40  N  %0 
I 
%O  'N  NO  t  %0  H  1--I  r-1  .  -1  i--1 
`-, 
1  %0  .  --I  ý--1  -1  '--1  .  -1  .  --I  r--I  M  .  -i,  r-i  .  -i  R1  P-4  r-1  NIV  VVVH 
rl  -4 
vvVVJVV 
Vv,  zV  v 
1--4  IQ  N%0%D%04%D%0  '0  1  40%DNO  '0'0  1  'O%0N'0  I  %D  HvM  ý-4  '-i  -1  ý0  .  --1  -4  r-4  .4  -1  1-4  -4  .  -I  -4  r-1  1-4  M  .  -4  -4 
-4 
VVV 
, _..  i  ,,..  i  VVVVV  \)  VvVV  4v  '/ 
LL. 
F-1  k0  %D  'O  "O  0O  NO  %D  '0  *,  O  'O  t  '0  'O  %D  %.  o  No  '.  D  '.  O  '.  O  N  '0  I  %o  I--I  -4  .q  r-i  -4  r4  .  -I  .  -1  -4  4  .  -1  -4  ri  r-1  r-1  .  -4  r-i  .  -i  M  -4  r-1  V  VVVVV,  ZVVV  Vv\Jv  VVýJ/  V 
I-I  %O  \D  \O'0'O  \D  IO'0'D'0  1  \O'0  %D  %0  \O'O  \o  %D  N'0  1  %m  .  -i  .  -1  .  --  .  --  .I  .  -1  -1  r-I  .  -1  .  -r  r-4  -4  r-1  -4  _I  r-I  .  -1  .  -4  m  .  --1  -1  V  NVvvv,  '*VVV  V  VVVV  V\OV,;;  V  V 
-° 
Zw 
a0\01N0"--INU1"DaOQ%r-INc*10ý 
ONýýO  000.  "-f--4C\jNNNNNN  en  fn  en  en  -t 
nnnnnnnnnnnnnnnn 
ný  ný  nnn  .  -I  `4  --4  --4  r-4  -I  0 
U 
>  'O  \O  \O  %o  N  '0  \O  00  NtNdd  \O  0O  %D  \O  %0  \0  1  '0  1  %o  H  r-1  ý-1  ýO  .  -ý  .  -1  f  ý1  .  -1  r-1  .  -i  Pn  f  /º  ýO  ýO  r-1 
, 
ý-I1  ri  ri  '-i  rl  H- 
-0  ý0 
%0 
-0  NO  N  rO  WNIN4  ý0  ý0 
4 
%0  ýO  ý0  1  ýp  t  ý0  -1  "--1ýO  .  -4  r-1  r1  r-1  .  -I  r-1  f+'1  M  'O  %D  r-I  VV  ,vV,  ýVV  V4  -4.  -,.  ýVv  -,  iVN  VV 
U-  LL-  LL. 
S'4  '0  \O%Z%0'0%D'0\0%0  %0  1  \Oý0'0'0%0\O'0'0\O 
1  -,  0\O'O  H  P-4  r-1  r-1  r-1  º-1  '-1  -4  -1  -1  -i  r-4  '-i  -1  r-1  r-f  r-1  r-1  .  -1  -4  .  -i  r-1  --1  Vv  uVyVVvvv  V  \%vvuVN  v\i  VVV 
I-i  ýO*lO%0'0\O\O%0\0%0'0 
1  %0%O'0%0%0%0'0'0'0 
1  ýO%0%,  O  F--1  r-i  r-i  vi  -4  -4  -I  r--1  r-1  r--1  -1  rl  r-1  ri  ,  --1  r-I  VVVVV\JVV  VV  VVV.  VVV  VvV  VVV 
sý 
Q) 
'n  W 
"-1  N  fn  L(  %O  1ý  ON  try  ap  Oh  N1  I.  O  .*L  ýO  N.  OD  .  -1  m  u1  N.  C  Or  00000( 
n  ýý4  rºrýMMý  r.  r"  n  r.  ýr",  nýr-  nr-  t-  r-  nºýrý-  r-  F,  Fý  n 
0  u 93 
3.2  GENERAL  PRACTICE  STUDY 
3.2.1  IDENTIFICATION  OF  RESPIRATORY  PATHOGENS. 
These  results  are  shown  in  tables  27,28  and  figures 
6  to  9. 
Winter  1  (November,  1977-  April,  1978  ). 
146  patients  were  included  in  the  survey  and  292  swabs 
were  examined.  125  swabs  from  96  patients  (65%)  yielded  bacteria 
and  21  swabs  from  149  patients  (7%)  gave  viruses.  11  swabs  (6%) 
gave  both  bacterial  and  viral  growth. 
The  majority  of  viruses  (81%)  were  isolated  from  the  first 
swab.  Bacteria  were  isolated  from  both  swabs  in  21%  of  patients. 
Of  these,  37%  had  the  same  bacteria  isolated  from  each  swab  and 
in  63%,  the  bacteria  isolated  were  different.  In  37%  of  patients 
neither  bacteria  nor  viruses  were  grown.  This  high  failure  rate  might 
be  due  to  the  swab  being  taken  at  too  late  a  stage  in  the  infection, 
the  type  of  infecting  agent  not  being  within  the  range  screened  for 
(  eg.  certain  types  of  Rhinovirus),  or  an  alternative  causative  agent 
(  eg.  respiratory  allergy). 
Some  of  the  most  commonly  isolated  bacteria  have  doubtful 
pathogenicity.  A  comparison  was  made  between  the  bacteria  isolated 
from  nasal  swabs  taken  from  staff  at  Belvidere  Hospital  and  swabs 
taken  from  the  General  Practice  patients.  The  hospital  staff,  with 
an  age  range  of  16  to  60  years,  presented  at  the  Hospital  "  Staff  Health 
Department  "  with  an  assortment  of  ailments,  not  necessarily 
respiratory.  In  this  group,  Staphylococcus  aureus  and  Staphylococcus 
albus  were  most  commonly  isolated.  In  the  General  Practice  cases 
there  was,  in  addition  to  the  bacteria  mentioned,  an  increase  in  the 
isolation  rate  of  Diplococcus  pneumonia,  Haemophilus  influenza, 
Streptococcus  pyogenes  and  Candida  species. 94 
Winter  2.  (November,  1978-  April,  1979) 
93  patients  took  part  in  the  2nd.  year  of  the  survey 
and  93  swabs  were  examined.  It  was  decided  to  concentrate 
on  Viral  studies  on  the  1st.  specimen  only  and  no  Bacteriology 
was  carried  out. 
The  virus  isolation  rate  was  12%. 
The  viral  studies  show  that,  during  both  winters, 
Influenza  Type  A  virus  was  the  most  common  respiratory  pathogen 
identified  during  the  periods  of  the  study.  The  low  isolation 
rate  for  Respiratory  Syncytial  virus  (R.  S.  V.  )  probably  reflects 
the  relatively  small  number  of  infants  encountered  in  the 
General  Practice  situation  compared  to  the  hospital  population. 
There  was  difficulty  in  finding  an  alternative  host  cell  line 
to  Rhesus  Monkey  Kidney  for  the  isolation  of  R.  S.  V.  (  Rhesus  monkey 
exports  from  India  have  now  been  banned.  As  a  result  kidney  cells 
from  these  monkeys,  which  were  for  many  years  the  main  cell  line 
used  to  show  respiratory  viruses,  are  no  longer  available.  ) 
The  viruses  isolated  are  presented  in  figures  6  to  9. 
Charts  have  also  been  included  to  show  how  these  results  compare 
with  laboratory  evidence  of  viral  infections  at  the  Virus 
Laboratory,  Belvidere  Hospital,  Glasgow  and  throughout  Scotland. 
It  should  be  noted  that  the  latter  two  groups  include  viruses 
identified  by  serological  techniques. 95 
Table  27  -  Laboratory  Evidence  of  Bacterial  Infections  -  Winter  1. 
Total  number  of  swabs  examined  =  292 
Total  number  of  subjects  =  146 
Isolate  No.  of  Isolates 
Staph.  aureus  30 
Staph.  albus  27 
Neisseria  catarrhalis  2 
Dip.  pneumoniae  15 
Strep.  viridans  9 
Strep.  pyogenes  (  Lancefield  A)  2 
Haemophilus  influenza  13 
Candida  sp.  15 
Commensal  diptheroids  14 
No  growth  obtained  108 
Not  examined  57 
2  92 96 
TABLE  28.  A  comparison  of  bacterial  isolates  obtained  from  nasal 
swabs  from  hospital  staff,  and  specimens  of  nasal  swabs  from 
patients  in  a  general  practice. 
Hospital  General  Practice 
Isolate  No.  of  isolates(%  total)  No.  of  isolates(%  total) 
Staph.  aureus  23  (23)  7  (9.3) 
Staph.  albus  50  (50)  8  (10.6) 
Neisseria  catarrhalis  2  (2)  4  (5.3) 
Dip.  pneumoniae  2  (2)  9  (12.0) 
H.  influenzae  -  -  5  (6.6) 
Diptheroids  5  (5)  1  (1.3) 
Strep.  viridans  4  (4)  1  (1.3) 
Strep.  pyogenes  -  -  2  (2.6) 
Klebsiella  sp.  1  (1)  -  - 
Proteus  sp.  2  (2)  -  - 
Candida  sp.  -  -  6  (8.0) 
No  growth  15  (15)  32  (42.6) 
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3.2.2  ANALYSIS  OF  SECRETORY  I  Aý  PRODUCTION 
In  Winter  1,92  patients  and  in  Winter  2,54  patients 
were  examined  by  Rocket  Electrophoresis  (Plate  1).  All 
relevant  information  about  each  patient  has  been  presented 
In  table  29. 
In  both  study  periods  the  amount  of  sIgA  found  varied 
significantly  between  the  acute  and  convalescent  phase 
specimens  during  respiratory  infection  (Winter  1,  P=0.05/ 
0.025  and  Winter  2,  P=0.0005). 
The  range  of  sIgA  was  from  0-  11mm.  (rocket  height) 
which  is  approximately  0-  250mg/d1. 
In  Winter  1,24  specimens  had  undetectable  sIgA  in  at 
least  one  specimen  whereas  in  Winter  2,  sIgA  was  present  in 
all  specimens. 
Six  patients  had  no  detectable  sIgA  in  either  acute  or 
convalescent  specimens  in  the  first  winter.  Serum  specimens 
were  taken  from  4  of  these  patients  and  they  were  found  to  have 
normal  levels  of  serum  IgG,  IgA  and  IgM.  Unfortunately  it 
was  not  possible  to  obtain  serum  samples  from  the  other  two 
patients. 
In  Winter  1,42  patients  (45.7%)  showed  a  rise  in  sIgA 
concentration  during  the  episode  of  respiratory  infection; 
31  patients  (35.7%)  showed  a  fall  and  18  patients  (19.6%) 
showed  no  change  in  concentration. 
In  Winter  2,33  patients  (61%)  showed  a  rise  in  sIgA 
concentration,  8  patients  (14.8%)  showed  a  fall  and  13  patients 
(24%)  showed  no  change  in  concentration. 102 
Protein  concentrations  were  measured  using  a  modification 
of  the  Lowry  technique. 
The  difference  in  protein  concentration  between  acute  and 
convalescent  specimens  was  not  significant  during  either 
study  period.  (Winter  1P>0.1  and  Winter  2  P-.  -0.1). 
In  Winter  1,  the  range  of  protein  concentration  was  from 
5-  273  mg/di.  The  mean  protein  concentrations  for  the  85 
patients  examined  were  :  acute  specimens,  56.88  +  38.35  mg/dl; 
convalescent  specimens,  53.82  +  37.67  mg/dl. 
In  Winter  2,  the  range  of  protein  concentration  was  from 
14  -  384  mg/dl.  The  mean  protein  concentrations  for  the  47 
patients  examined  were  :  acute  specimens,  51.82  +  59.17  mg/dl; 
convalescent  specimens,  51.22  +  53.65  mg/dl. 
To  facilitate  description  the  patients  have  been  separated 
into  3  age  bands  (0-15;  16-29  and  3  30  years),  and  the  sIgA 
levels  found  in  'acute'  and  'convalescent'  mucus  samples  for 
each  age  band  are  shown  in  figures  10  and  11  for  Winter  periods 
1and2. 
In  Winter  1  the  highest  percentage  of  infections  is  in  the 
expected  age  band  of  0-15  years,  followed  by  the  over  30's  group 
and  a  small  percentage  of  infections  in  the  16-29  year  old  group. 
Winter  2  shows  the  highest  percentage  of  infection  in  the  over 
30's  group. 
The  mean  difference  in  sIgA  concentration  in  each  age  band 
is  very  small.  Nevertheless  the  amount  of  sIgA  shows  an 
increase  in  each  group  during  both  winters. 
Expansions  of  these  results  are  shown  in  figures  12  to  17 
and  demonstrate  the  variation  of  sIgA  between  acute  and 
convalescent  specimens  for  each  individual  patient. 103 
Secretory  IgA  levels  from  acute  and  convalescent  specimens 
of  patients  over  60  years  old  in  the  two  winter  periods 
combined  are  presented  in  figure  18. 
Having  established  that  the  difference  in  sIgA  concentration 
between  'acute'  and  'convalescent'  specimens  was  statistically 
significant,  the  factors  affects  sIgA  production  were  examined. 
1.  sIgA  production  in  patients  from  whom  a  respiratory 
pathogen  has  been  isolated.  (Table  30,  a)  through  d)  ). 
In  Winter  1,31  pathogens  were  isolated  from  92  patients: 
seventeen  bacteria  (18.5%)  and  fourteen  viruses  (15.2%). 
Streptococcus  viridans  and  Haemophilus  influenzae  were 
the  most  commonly  isolated  bacterial  respiratory  pathogens 
in  Winter  1.  Bacteria  were  isolated  equally  well  from  acute 
or  convalescent  specimens.  Three  patients  also  show  infection 
with  Influenza  type  A.  The  overall  difference  in  sIgA 
concentration  is  approaching  significance  (P  =  0.1/0.05). 
Twelve  out  of  the  seventeen  patients  (70.6%)  showed  a  difference 
in  sIgA  concentration,  7  patients  (41.2%)  showing  a  rise  and 
5  patients  (29.4%)  showing  a  fall.  Five  patients  (29.4%) 
showed  no  difference  in  sIgA  concentration. 
Influenza  type  A  and  Rhinoviruses  were  the  most  commonly 
isolated  viral  respiratory  pathogens  in  Winter  1.  In  this 
group  the  difference  in  sIgA  concentration  between  specimens 
is  not  significant.  The  viruses  tended  to  be  isolated  from 
the  acute  specimens  (85.7%).  Twelve  out  of  14  patients  (85.7%) 
from  whom  a  virus  was  isolated  showed  a  difference  in  sIgA 
concentration,  8  (57.1%)  showed  a  rise,  4  (28.6%)  showed  a 
fall  and  2  (14.3%)  showed  no  difference  in  sIgA  concentration. 
When  the  above  two  sets  of  results  are  combined  to  indicate 
sIgA  production  when  a  respiratory  pathogen  has  been  isolated, 
the  difference  in  sIgA  concentration  is  approaching  significance. 
(P  =  0.1/0.05). 104 
A  wider  range  of  viruses  was  isolated  in  Winter  2. 
The  difference  in  slgA  concentration  between  specimens  Is 
significant.  (P  =  0.05/0.025).  Eight  viruses  were 
isolated  from  54  patients  (14.8%).  Forty-one  (75.9%) 
showed  a  difference  in  sIgA  concentration,  33  (61%)  showed 
a  rise  and  8  (14.8%)  showed  a  fall.  Thirteen  patients 
(24%)  showed  no  change  in  slgA  concentration. 
2.  sIgA  production  with  respect  to  Initial  sIgA  levels 
(Table  31).  Both  winters  show  that  if  the  initial  level 
of  sIgA  shows  a  rocket  height  of  5mm.  then  the  difference 
In  sIgA  concentration  between  acute  and  convalescent  phase 
specimens  is  significant.  In  Winter  1,  the  range  of  Initial 
sIgA  was  0-  12mm  and  5  patients  showed  no  detectable  sIgA 
in  either  specimen.  In  Winter  2,  the  range  of  initial  sIgA 
was  2-7.5mm  and  all  patients  had  detectable  levels  of  sIgA. 
3.  slgA  production  with  respect  to  the  number  of  days 
after  the  onset  of  symptoms  to  collection  of  the  'acute' 
specimen  (Table  32) 
In  Winter  1  if  the  acute  specimen  is  taken  2-3  days  after 
the  onset  of  symptoms,  the  difference  in  sIgA  between  the 
acute  and  convalescent  specimens  is  significant.  Specimens 
taken  at  more  than  7  days  post  onset  also  show  a  significant 
difference  but  care  must  be  taken  in  interpreting  statistical 
values  on  such  a  small  'number  of  specimens. 
In  Winter  2  the  results  appear  to  agree.  Again  a  small 
number  of  specimens  taken  at  5  days  post  onset  show  a 
significant  difference  in  sIgA  concentration. 105 
4.  sIgA  production  with  respect  to  both  the  number  of 
days  after  onset  and  the  height  of  the  initial  rocket 
(Table  33) 
Although  the  groups  tend  to  be  small  the  figures  for 
both  winter  periods  correspond.  The  results  suggest  that 
specimens  with  an  initial  level  of  sIgA  giving  a  rocket  height 
of  3-  5mm  and  taken  2-3  days  after  the  onset  of  symptoms 
will  show  a  significant  difference  in  sIgA  concentration  when 
a  convalescent  phase  specimen  is  examined  about  7  days  later. 
5.  sIgAproduction  with  respect  to  the  age  of  the  patient 
(Table  34) 
In  Winter  1,  only  specimens  taken  from  the  under  4  year  olds 
show  a  significant  difference  between  specimens.  In  Winter  2, 
all  age  groups  show  a  significant  difference. 
6.  Duration  of  secretory  antibody  production 
During  the  two  winter  periods,  14  patients  required 
medical  attention  on  at  least  two  occasions  and  an  acute  and 
convalescent  specimen  was  taken  at  each  episode  of  respiratory 
infection.  The  sIgA  concentrations  and  protein  concentrations 
are  shown  in  figure  19  together  with  the  time  interval  between 
respiratory  infections.  Despite  the  fact  that  sIgA  and 
protein  levels  follow  an  individual  pattern,  generally  the 
production  of  protein  follows  a  similar  pattern  to  that  of 
sIgA  and  this  is  confirmed  in  figures  20  and  21  which  are 
combined  graphs  for  the  14  patients.  Both  sIgA  and  protein 
concentrations  fall  steadily  towards  baseline  levels  over  an 
eight  month  period  but  rise  again  rapidly  following  re-infection. 106 
7.  Dynamics  of  sIgAproduction 
The  accumulation  of  sIgA  and  protein  In  the  acute  and 
convalescent  specimens  is  shown  in  figures  22  and  23  for  both 
Winters.  In  both  periods  sIgA  accumulation  initiated  very 
quickly  and  the  majority  of  patients  had  detectable  sIgA 
one  day  after  the  onset  of  symptoms.  However,  the 
magnitude  of  the  sIgA  response  is  not  great.  The  protein 
concentrations  varied  considerably. 
3.2.3  ANALYSIS  OF  PATIENTS  WITH  FREQUENT  RESPIRATORY 
INFECTIONS  AND/OR  ALLERGIES 
When  the  sIgA  and  protein  concentrations  are  examined  with 
regard  to  whether  the  levels  rise,  fall  or  show  no  change, 
the  results  are  shown  in  Tables  35  and  36.  Over  the  two 
winter  periods  the  majority  of  patients  showed  a  rise  in 
sIgA  production.  Protein  concentrations  do  not  show  a  similar 
pattern. 
When  the  sIgA  and  protein  concentrations  are  examined 
in  patients  with  a  history  of  frequent  respiratory  infections 
and/or  allergies  the  results  are  shown  in  tables  37  and  38. 
A  graphical  comparison  is  shown  In  figures  24  and  25.  From 
these  results  it  can  be  seen  that  respiratory  tract  sufferers 
show  a  very  similar  pattern  of  sIga  and  protein  production  to 
the  overall  group  studied. 107 
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KEY  FOR  TABLE  29  -  30. 
A  Acute  specimen 
C  Convalescent  specimen 
F  Female 
M  Male 
N.  K.  Not  known 
N.  T.  Not  tested 
occ.  Occasional 
chron.  Chronic 
Resp.  infs.  Respiratory  Infections 
URTI  Upper  respiratory  tract  infections 
Note  :  In  the  Pathogen  column,  the  numbers  In  parenthesis 
indicate  the  specimen  from  which  the  pathogen  was  isolated. ö 
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Table  30  sIgA  production  in  patients  from  whom  a  respiratory 
pathogen  has  been  isolated 
a)  Winter  1  Bacterial  Isolates 
Patient  A  C  Difference  Bacterium  isolated 
4  4.5  4.5  0  Haemophilus  influenzae(c) 
11  2  10  +8  Streptococcus  pyogenes(A) 
19  3  6  +3  H.  influenzae  (c) 
40  4  6  +2  H.  influenzae  (c) 
43  11  8.5  -2.5  Step.  viridans  (A) 
44  5  5  0  Strep.  viridans(A) 
45  5.5  8.5  +3  H.  influenzae*  (A) 
46  8  8  0  H.  Influenzae  (c) 
53  5  4  -1  H.  influenzae  (c) 
54  3  0  -3  Strep.  viridans  (A) 
56  6  6  0  H.  inf  luenzae  (A) 
61  6  4.5  -1.5  Strep.  viridans  (A) 
66  5  4  -1  H.  influenzae  (A) 
70  5  7  +2  H.  influenzae  (A) 
72  5  5  0  Strep.  viridans*  (c) 
88  0  4.5  +4.5  Strep.  viridans  (c) 
57  6  11  +5  H.  influenzae*  (c) 
N=  17  d=1.09 
SD  =  2.9 
SE  =  0.7 
t=1.56 
P=0.1/0.05 
degrees  of  freedom  =  16 
Difference  is  approaching  significance 
Influenza  type  A  was  also  Isolated  from  these  patients 125 
Table  30  (  continued  ). 
b)  Winter  1  Viral  isolates 
Patient  A  C  Difference  Virus  isolated 
8  5  2  -3  Rhinovirus  (c) 
16  6  10  +4  Rhinovirus  (A) 
22  3  7  +4  Rhinovirus  (A) 
26  8  5  -3  Herpes  simplex  (c) 
27  5  6.5  +1.5  Rhinovirus  (A) 
45  5.5  8.5  +3  Influenza  type  A*(A) 
47  0  8  +8  Parainfluenza  type  3(A) 
57  6  11  +5  Influenza  type  A*(A) 
60  8  9.5  +1.5  Influenza  type  A(A) 
71  7.5  5  -2.5  Herpes  simplex  (A) 
72  5  5  0  Influenza  type  A*(A) 
73  3  6  +3  Influenza  type  A(A) 
75  9  3  -6  Influenza  type  A  (A) 
89  2  0  -2  Influenza  type  A  (A) 
N=  14  d=0.96 
SD  =  3.87 
SE  =  1.03 
t=0.932 
P=0.2/0.15 
Difference  is  not  significant 
degrees  of  freedom  =  13 
*Pathogenic  bacteria  also  isolated  from  these  patients 126 
Table  30  (  continued  ). 
c)  Winter  1  Respiratory  Pathogen  (combination  of 
tables  a  and  b) 
N=  28  d  0.86 
SD  =  3.378 
SE  =  0.638 
t=1.35 
P=0.1/0.05 
degrees  of  freedom  =  27 
Difference  is  approaching  significance. 127 
Table  30  (  continued  ). 
d)  Winter  2  Viral  Isolates 
Rocket  HT  (mm) 
Patient  A  C  difference  Virus  isolated 
1  5  5  0  Echovirus  type  22 
9  3  6  +3  Parainfluenza  type  1 
20  4  8  +4  Parainfluenza  type  3 
21  5  6.5  +1.5  Influenza  type  A 
25  5.5  7  +1.5  Parainfluenza  type  3 
26  6  7  +1  Parainfluenza  type  1 
47  3  4.5  +1.5  Influenza  type  A 
49  5.5  4  -1.5  Influenza  type  A 
N=8  d=  1.375 
SD  =  1.685 
SE  =  0.596 
t=  2.31 
-'degrees  of  freedom  =7 
P=0.05/0.025 
Difference  is  significant 
NB  All  specimens  were  isolated  from  the  first  specimen 128 
Table  31  slgA  production  with  respect  to  initial  sIgA  levels 
Winter  1 
Rocket  Ht  (mm)  N  d  SD  SE  t  d  of  f  p 
3.5  30  2.82  2.74  0.5  5.64  29  0.0005 
4  1.0  -0.6  2.66  0.32  1.8  9  0.05 
5  19  0.74  2.51  0.58  1.28  18  >0.1 
6  13  0.15  2.99  0.86  0.17  12  >0.1 
7  7  -0.21  2.16  0.88  0.24  6  >  0.1 
8  5  -1.9  1.95  0.97  1.96  4  >  0.1 
9  6  NT 
Winter  2 
Rocket  Ht  (mm)  N  d  SD  SE  t  d  of  f  P 
3.5  13  1  1.17  0.33  3.03  12  0.01/0.005 
4  12  1.71  1.42  0.43  3.89  11  0.01/0.005 
5  15  0.83  1.48  0.4  2.08  14  0.05/0.025 
6  10  0.15  1.29  0.43  0.35  9  >0.1 
7  4  0.13  2.32  1.34  0.1  3  '  0.1 129 
Table  32  sIgA  production  with  respect  to  the  number  of  days 
after  the  onset  of  symptoms  that  the'acute'  specimen 
was  taken. 
Winter  1 
No.  of  days 
after  onset 
1 
2 
3 
4 
5 
6 
ý7 
Winter  2 
No.  of  days 
after  onset 
1 
2 
3 
4 
5 
6 
N  d  SD  SE  td  of  f 
14  0.68  3.3  0.88  0.77  13 
17  0.94  2.87  0.695  1.35  16 
13  -1.04  2.88  0.22  4.73  12 
13  0.62  3.25  0.90  0.69  12 
6  -1.5  3.07  1.25  1.2  5 
1 
6  1.75  1.6  0.71  2.46  5 
N  d  SD  SE  T  d  of  f 
11  0.45  1.72  0.57  0.79  10 
17  0.76  1.03  0.25  3.04  16 
8  0.94  1.43  0.54  1.74  7 
6  0.75  1.47  0.66  1.14  5 
5  1.3  0.97  0.49  2.65  4 
4  1  2.58  1.49  0.67  3 
P 
>  0.1 
0.1 
4  0.0005 
0.1 
7  0.1 
NT 
0.05/0.025 
P 
X0.1 
0.05/0.0025 
0.1/0.05 
a0.1 
0.05/0.025 
>  0.1 130 
Table  33  sIgA  production  with  respect  to  the  number  of  days  after 
onset  and  the  height  of  the  initial  rocket 
Winter  1 
Rocket 
No.  of 
Ht  (mm) 
days 
0-  2mm  3-  5mm  6-  8mm  9mm 
1  N=4  P=  0.1  N=7  P=  0.1  N=5  P=  0.1  - 
N=11  P=0.1 
2  N=3  P=  0.1  N=8  P=  0.1  N=6  P=  0.1  N=1 
N=11  P=0.1/0:  05 
3  N=1  ND  N=8  P=  0.1  N=5  P=  0.1  - 
H=9  P=0.05 
4  N=3  P=  0.1  N=5  P=0.1  N=4  P  0.1  N=2 
N=8  P=0.1/0.05 
5  - 
P 
N=5 
=  0.01/0.005  N=9  P=  0.1  N=1 131 
Table  33  (  continued). 
Winter  2 
0-  2mm  3  -5mm  6-  8mm  9mm 
1  -  N=7  P=0.1  N=3  P-0.1  - 
2  N=2  N=13  P=0.125/ 
0.01  N=2 
3  -  N=7  P=0.1/ 
0.05  N=1  - 
4  -  N=14  P=0.1  N=3  P=0.1  - 
5  N=1  N=3  P=0.1  - 
6  -  N=3  P=0.1  - 132 
Table  34  slgA  production  with  respect  to  the  age  of  the  patient 
Winter  1 
Age(years)  N  d  SD  SE  d  of  f  t  P 
iE  4  28  0.804  3.18  0.602  27  1.33  0.1/0.05 
5-12  10  0.35  2.91  0.91  9  0.38  >0.1 
13-21  5  0.9  3.47  1.55  4  0.58  >0.1 
}  21  44  0.46  3.06  0.48  40  0.96  >  0.1 
60  5  1.25  4.36  1.95  4  0.64  70.1 
Winter  2 
Age  (years) 
4  11  1  1.72  0.54  10  1.85  0.05/0.025 
5-12  16  1.03  1.64  0.41  15  2.51  0.125/0.01 
13-21  6  1.5  1.22  0.55  5  2.73  0.025/0.0125 
21  19  0.55  1.29  0.3  18  1.83  0.05/0.025 
60  2  -  -  -  -  -  NT 133 
Table  35  Summary  of  sIgA  levels  (Rocket  heights) 
Winter  1 
sIgA  concentration 
Age  range  Number  Rise  Fall  No  change 
0-15years  38  16  11  11 
16-29years  21  13  6  2 
30years  33  12  13  7 
Total  92  41  30  20  (ND=1) 
(44.6%)  (32.6%)  (21.8%) 
Mean  base-line  level  of  sIgA  =  4.6  mm 
Winter  2 
Age  range 
0-15years  29  19  5  5 
16-29years  18  12  1  5 
>-,  30years  7  4  2  1 
Total  54  25  8  11 
(61%)  (14.8%)  (24%) 
Mean  base-line  level  of  sIgA  =  4.8  mm 134 
Table  36  Summary  of  Protein  levels  (mg/dl) 
Winter  1  Protein  concentration 
Age  range  Number  Rise  Fall  No  change 
0-15  years 
38  15  12  9 
16-29  years  21  8  6  7 
30  years  33  7  13  9 
Total  92  30  31  25  (ND=6) 
(32.6%)  (33.7%)  (27.2%) 
Winter  2 
Age  range 
0-15  years  29  10  9  8 
16-29  years  18  3  3  12 
30  years  7  0  4  3 
Total  54  13  16  23 
(24%)  (29.6%)  (42.6%) 135 
Table  37  Analysis  of  sIgA  levels  (rocket  heights)  in  patients 
with  frequent  respiratory  infections  and/or  allergies 
Winter  1 
Age  range  Number  Rise  Fall  No  change 
0-1.5  years  15/38  8  4  3 
16-29  years  1/21  1  0  0 
30  years  7/33  2  4  1 
Total  23/92  11  8  4 
(47.8%)  (34.8%)  (17.4%) 
Mean  base-line  level  of  sIgA  =  4.8 
Winter  2 
Age  range 
0-15  years  12/29  5  2  5 
16-29  years  3/18  3  0  0 
30  years  0/7  0  0  0 
Total  15/34  8  2  5 
(53.3%)  (13.3%)  (33.3%) 
Mean  base-line  level  of  sIgA  =  4.7 136 
Table  38  Analysis  of  protein  levels  (mg/dl)  in  patients  with 
frequent  respiratory  infections  and/or  allergies 
Winter  1 
Age  range  Number  Rise  Fall  No  change 
0-15  years  15/38  6  3  5 
16-29  years  1/21  1  0  0 
30  years  7/33  2  3  2 
Total  23/92  9  6  7  (ND  =  1) 
(39%)  (26%)  (30.4%) 
Winter  2 
Age  range 
0-15  years  11/29  4  5  2 
16-29  years  4/18  1  1  2 
30  years  0/7  0  0  0 
Total  15/54  5  6  4 
(33.3%)  (40%)  (26.7%) 137 138 
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Figure  13.  Paired  sIgA  Levels.  (  Age  range  16-29  years  ).  Winter  1. 
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Figure  14.  Paired  sIgA  Levels.  (  Age  range  30+  years  ).  Winter  1. 
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Figure  15.  Paired  slgA  Levels.  (  Age  range  0-15  years  ).  Winter  2. 
Rocket  Acute.  Convalescent. 
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Figure  16. 
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Paired  sIgA  Levels.  (  Age  range  16-29  years  ).  Winter  2. 
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Figure  17.  Paired  sIgA  Levels.  (  Age  range  30+  years  ).  Winter  2. 
Rocket  Acute.  Convalescent. 
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Figure  19.  Duration  of  Antibody  Production. 
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Figure  19  (continued).  Duration  of  Antibody  Production. 
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Figure  19  (  continued  ).  Duration  of  Antibody  Production. 
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Figure  20. 
___ 
Duration  of  Antibody  Production.  (N=  14) 
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CHAPTER  4 
DISCUSSION 
Two  important  aspects  of  Influenza  vaccination  require 
further  consideration.  Firstly,  which  of  the  available 
vaccines  is  most  efficacious  and  secondly,  what  is  the 
duration  of  the  immunity  provided  by  the  different  vaccines? 
Of  the  currently  available  vaccines,  the  main  vaccine 
in  routine  use  both  in  the  United  Kingdom  and  the  United 
States  is  one  in  which  the  infectivity  of  the  virus  is 
destroyed  chemically  before  the  vaccine  is  injected 
subcutaneously  or  intramuscularly.  Live  virus  vaccines 
made  from  attenuated  strains  remain  experimental  in  most 
countries  although  they  are  used  on  a  considerable  scale 
in  the  U.  S.  S.  R  and  Yugoslavia.  Their  merits  relative  to 
those  of  inactivated  vaccine  are  still  uncertain.  A  third 
possibility  exists  when  inactivated  vaccine  is  given  as 
an  intranasal  spray.  This  method  has  been  used  in  a 
number  of  Influenza  vaccine  trials  in  recent  years  and 
is  under  study  in  this  thesis. 
In  the  first  part  of  this  study  an  attempt  has  been 
made  to  evaluate  the  efficacy  of  an  inactivated  Influenza 
virus  vaccine  (  Influvac  Spray  )  administered  intranasally 
by  the  third  route  i.  e.  by  aerosol,  and  to  assess  the 
duration  of  protection  induced.  In  addition,  an  evaluation 
has  been  made  of  the  correlation  between  levels  of  local 
and  serum  antibodies  and  patient's  response  to  subsequent 
artificial  infection.  A  natural  Influenza  outbreak 
which  occurred  during  the  course  of  the  study  allowed  some 
comparisons  to  be  made  of  antibody  responses  to  natural 
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The  long-accepted  criterion  for  selection  of 
volunteers  to  participate  in  vaccine  trials  has  been  the 
detection  of  very  low  levels  of  H-I  antibody  against 
Influenza  virus.  H-I  antibody  levels  are  not  now  thought 
to  be  the  sole  indication  of  protection  and  therefore  can 
selection  of  volunteers  on  this  basis  still  be  justified? 
In  the  present  study  evidence  has  been  presented  to  show 
how  different  initial  levels  of  secretory  antibody  affect 
the  response  to  the  vaccine.  The  serological  response 
in  terms  of  H-I  antibody  will  be  examined  first. 
I  have  shown  that  subjects  with  low  initial  levels 
of  secretory  antibody,  as  measured  by  the  H-I  test,  will 
develop  a  significant  response  following  intranasal  Spray 
vaccination  (  tables  4-6  ).  If  initial  levels  of 
secretory  antibody  are  moderate  to  high  the  serological 
response  to  Spray  vaccine  is  not  significant.  Secretory 
antibody  is  therefore  necessary  for  protection. 
In  the  group  of  subjects  found  to  have  moderate  to 
high  levels  of  secretory  antibody  before  challenge  (  table  7) 
there  are  three  who  seroconverted  after  challenge  (  two 
in  the  Spray  group  and  one  in  the  placebo  group  ).  If 
immunity  has  been  induced  by  the  Spray  vaccine  why  are 
there  any  seroconversions  in  this  group?  These  conversions 
may  have  been  due  to  the  use  of  an  attenuated  challenge 
vaccine  causing  a  'boosting'  effect  of  antibody  production. 
Alternatively,  the  immunity  conferred  by  the  Spray  vaccine 
has  not  lasted  for  the  four  month  test  period. 
Subject  1723  (  table  2)  shows  a  four-fold  rise  in 
serum  H-I  antibody  levels  both  six  weeks  post-vaccination 
(  II  )  and  four  months  later,  pre-challenge  (  III  ).  If 
thiswas  due  to  natural  infection  why  were  no  symptoms 
reported  during  the  study  ?  It  seems  reasonable  to 
suggest  that  the  accompanying  moderate  to  high  levels  of 
secretory  antibody  were  reducing  the  severity  of  the 
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The  presence  of  initial  levels  of  neutralising 
antibody  as  measured  by  the  Q-H  assay  do  not  prevent 
subjects  producing  a  serological  response  to  the  Spray 
vaccine,  but  this  response  appears  to  protect  against 
the  attenuated  challenge  vaccine  (  tables  8-10  ). 
If  subjects  have  low  levels  of  secretory  antibody 
by  both  methods  of  measurement,  there  is  a  significant 
response  to  the  Spray  vaccine  and  no  response  to 
placebo.  Unfortunately,  in  the  group  with  moderate 
to  high  initial  secretory  antibody  levels  by  both 
methods  of  measurement,  there  are  too  few  subjects 
to  analyse. 
A  small  group  of  study  subjects  have  levels  of 
secretory  antibody  which  varied  according  to  the 
method  of  measurement.  If  Influenza  neutralising 
antibodies,  as  measured  by  the  0-H  test,  are  high 
and  antibodies  against  the  Haemagglutinin  (  HA  ),  as 
measured  by  the  H-I  test  are  low,  the  subjects  will 
respond  to  Spray  vaccine  and  are  immune  to  challenge; 
If  antibodies  against  the  HA  are  high  and  neutralising 
antibodies  are  low  there  Is  no  response  to  Spray  vaccine 
but  a  response  does  occur  to  the  attenuated  challenge 
vaccine. 
The  two  tests  must  therefore  be  measuring 
different  functional  subgroups  of  secretory  antibodies. 
If  HA  antibodies  are  high  they  appear  to  protect 
against  the  inactivated  Influenza  virus  vaccine  but 
this  protection  is  short-lived  and  a  response  is 
elicited  by  the  attenuated  challenge  vaccine.  If 
neutralising  antibodies  are  high  the  subjects  can 
respond  to  the  Spray  vaccine  but  are  immune  to 
challenge.  Neutralising  antibodies  do  not  give 
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Why  there  should  be  a  difference  in  the  responses  is 
unclear  because  neutralising  antibody  should,  in  theory, 
be  directed  against  the  Haemagglutinin  (H.  A.  )  and  should 
therefore  be  comparable  with  H-I  antibody.  Neutralising 
antibody  must  also  have  a  component  which  is  active  against 
the  Neuraminidase  (N.  A.  )  antigen.  This  is  also  present 
on  the  virus  surface. 
In  making  this  distinction  it  is  important  to  realise 
that  antibody  measurement  is  dependent  on  the  type  of  assay 
system  used.  Yanagihara  and  McIntosh  (1980)  found  that 
local  antibody  to  Respiratory  Syncytial  Virus  (R.  S.  V.  )  and 
Parainfluenza  viruses,  post  natural  infection,  was 
detected  by  the  Fluorescent  Antibody  Test  (F.  A.  T.  )  but 
not  by  neutralising  antibody  assays.  This  suggests  a 
dissociation  between  functional  antibody  measured  In  the 
neutralisation  test  and  antibody  detected  by  assays  for 
antigen-antibody  binding.  Murphy  et  al.  (1982)  showed 
that  IgA  antibodies  measured  by  the  Enzyme  Linked 
Immunosorbent  Assay  (E.  L.  I.  S.  A.  )  correlate  with  neutralising 
antibody. 
The  present  observation  that  antibody  against  H.  A. 
must  be  present  for  protection  confirms  previous  studies. 
Slepushkin  d  o.  \  (t  '%t)  showed  that  antibody  against  the  H.  A. 
was  necessary  for  protection  against  the  same  Influenza 
serotype  and  that  antibody  against  the  N.  A.  does  not 
protect.  Schulman  (1969)  thought  that  anti  N.  A.  antibody 
was  important  shortly  after  an  epidemic  in  reducing  the 
severity  of  infection  and  affecting  transmission  but  less 
important  thereafter  in  terms  of  protection. 
In  the  present  study  the  subjects  who  suffered  from 
natural  Influenza  infection  show  a  sustained  rise  in  both 
serum  and  secretory  antibodies  (  tables  2,14,18  ). 
Since  the  time  of  infection  was  unknown  it  is  not  possible 
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In  this  section  I  have  been  dealing  with  the 
serological  response  to  intranasal  spray  vaccination  when 
an  inactivated  virus  is  used.  The  vaccine  is  eliciting 
a  significant  serological  response  and,  in  addition,  it  is 
clear  that  the  initial  levels  of  secretory  antibody  affect 
the  response  to  the  vaccine.  This  lends  weight  to  the 
suggestion  that  initial  levels  of  secretory  antibody 
should  also  be  used  as  a  criterion  for  acceptability  into 
vaccine  trials. 
The  secretory  responses  to  the  inactivated  Spray 
vaccine  are  puzzling.  When  they  are  measured  by  the  H-I 
test,  I  have  shown  that,  although  a  significant  response 
is  produced  in  patients  in  the  Spray  group,  a  comparable 
response  is  also  produced  in  the  placebo  group  (  tables 
14-  17  ).  Of  the  subjects  in  the  Spray  group  who  show 
a  four-fold  rise  In  secretory  antibody  post  Spray  vaccine 
(  II  )  all  but  one  also  show  a  four-fold  serological  rise. 
In  addition,  the  secretory  antibody  rise  is  sustained  for 
the  four  months  of  the  test  period.  Of  the  subjects  in 
the  placebo  group  who  show  a  four-fold  rise  in  secretory 
antibody  in  the  same  period,  none  developed  a  comparable 
serological  response  and  the  rises  in  secretory  antibody 
are  not  sustained  for  four  months. 
It  seems  that  subjects  who  are  vaccinated  with 
Spray  vaccine  are  producing  a  genuine  response  whereas 
those  vaccinated  with  a  placebo  may  only  be  responding 
to  the  irritation  of  intranasal  aerosol  treatment  which, 
in  turn,  promotes  both  the  non-specific  activation  of  the 
secretory  immune  response  and  mucus  production.  As  all 
the  subjects  are  adults  it  is  highly  likely  that  they 
will  have  been  'primed'  against  Influenza  type  A(H3N2) 
strains  which  have  been  active  since  the  pandemic  of 
1968  and  it  is  fortuitous  that  specific  antibody  is 
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It  is  also  reasonable  to  suggest  that  the  subjects 
who  have  responded  in  the  placebo  group  are  reflecting 
the  fact  that  Influenza  virus  is  present  in  the  community. 
It  has  been  suggested  recently  by  several  workers  (Ganguly 
and  Waldman  (1977),  Schvartsman  and  Crigorieva  (1979)) 
that  secretory  immunity  is  more  important  in  protecting 
against  the  different  strains.  of  Influenza  virus  (drifts) 
than  in  protection  against  new  variants  (shifts).  In 
this  latter  case  the  serological  response  is  more  important. 
The  placebo  group  response  may  well  represent  a  'boosting' 
of  herd  immunity. 
Evidence  for  IgA  memory  has  been  published  recently. 
(  Wright  et  al.  (1983)  ).  These  authors  found  that  live, 
attenuated  Influenza  vaccine  administered  10  to  18  months 
before  challenge  with  inactivated  vaccine  clearly  primed 
the  secretory  immune  system  for  local  memory  and  caused  an 
'anamnestic'  response  on  re-exposure.  Neither  serum  nor 
local  antibody  was  seen  before  two  weeks  from  primary 
exposure.  Local  response  was  demonstrated  however  at 
one  week  after  re-exposure. 
This  postulated  combined  effect  of  systemic  and  local 
immunity  emphasises  the  importance  for  current  vaccines 
to  stimulate  both  systems.  Clearly  in  inter-pandemic 
years  the  more  important  antibody  response  to  stimulate 
is  the  secretory  response. 
A  higher  percentage  of  the  Spray  group  (35%) 
compared  with  the  placebo  group  (19%)  have  moderate  to 
high  initial  levels  of  secretory  antibody  (  figure  5  ). 
Since  the  presence  of  secretory  antibody  protects  against 
both  vaccine  and  challenge,  this  factor  may  cause  the  Spray 
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When  the  secretory  responses  (  measured  by  the 
Q.  H.  test  )  are  examined  (  tables  18-  21  )  the  overall 
response  is  smaller  than  that  demonstrated  by  the  H-I  test. 
The  pattern  is  similar  however  and  the  above  reasons  also 
apply. 
The  duration  of  complete  resistance  to  Influenza  A 
in  the  absence  of  antigenic  shift  and  following  recovery 
from  the  natural  disease  is  unknown.  It  is  believed  to 
last  only  two  years  (  Lennette  (1981)  ).  Some  workers, 
however,  indicate  that  immunity  persists  for  at  least 
twice  this  time  and  that  significant  resistance  to 
Influenza  A  virus  may  last  for  at  least  21  years  (Chanock  and  Murphy 
(1979)).  Because  of  the  uncertainties  which  still  surround 
the  duration  of  naturally  acquired  immunity,  frequent 
vaccination  is  generally  advised.  In  theory,  at  least, 
mass  immunisation  against  Influenza  should  serve  either 
to  prevent  epidemics  or  to  halt  their  speed  of  spread. 
The  phenomena  of  antigenic  drift  and  shift  require  that 
immunisation  be  against  those  viral  strains  that  are 
currently  in  circulation  in  the  population  at  risk.  For 
this  reason  the  antigenic  composition  of  vaccines  must  be 
constantly  under  review. 
In  this  study  the  duration  of  Spray  vaccine  induced 
immunity  was  examined  for  four  months  (  le.  over  the  peak 
period  of  exposure  to  Influenza  virus  ). 
Figure  5  shows  the  total  and  specific  mean  secretory 
antibody  titres  during  the  four  month  test  period  for  the 
Spray  vaccine,  placebo  and  naturally  infected  groups.  The 
naturally  infected  group  show  a  sustained  rise  in  local 
antibody  whereas  the  vaccine  and  placebo  groups  show  a 
drop  in  titre  after  an  initial  rise  over  the  four  month 
period.  Duration  of  the  secretory  antibody  response  in 
nasal  washings  was  therefore  higher  after  natural  infection 
than  following  vaccination.  In  1979,  Schvartsman 
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that  the  duration  of  the  secretory  antibody  response  was 
higher  after  severe  forms  than  after  mild  forms  of  Influenza. 
Concentrations  of  secretory  antibodies  (  ie.  1:  4  by  the 
Indirect  Haemagglutination  test  (  I.  H.  T.  )),  which  in 
volunteers  had  been  correlated  with  the  decrease  in  virus 
isolation  in  nasal  secretions,  persisted  for  four  to  eight 
months  in  both  adults  and  children  who  had  mild  courses 
of  disease  and  for  more  than  eight  months  in  persons  who 
had  severe  forms  of  the  infection. 
The  present  study  in  which  Influvac  Spray)intranasal, 
inactivated  vaccine  was  used  is  a  'follow-up'  study  to  an 
earlier  one  carried  out  in  Rome  (  Chezzi  et  al.  (1976) 
unpublished).  The  strain  of  virus  used  in  the  vaccine 
was  Influenza  A/England/42/72  (H3N2).  The  results  of  the 
Rome  placebo-controlled  comparative  study,  which  involved 
157-volunteers,  on  the  local  and  systemic  antibody  responses 
after  Inoculation  of  inactivated  Influenza  vaccine  administered 
either  by  the  inhalation  or  subcutaneous  route  are  as  follows: 
Administration  of  vaccine  by  inhalation  (  Influvac  Spray  ) 
significantly  increased  the  levels  of  neutralising  antibodies 
but  had  no  effect  on  the  level  of  serum  antibodies.  On 
the  other  hand,  inoculation  of  a  similar  vaccine  (  Influvac 
Plain  )  at  a  slightly  higher  dose  by  the  subcutaneous  route, 
stimulated  circulating  H-I  antibodies  but  not  neutralising 
local  antibodies. 
These  findings  contrast  with  the  present  study  where 
serological  and  local  responses  occur.  A  different  strain 
of  Influenza  was  used  in  this  study.  (  Influenza  A/Victoria/ 
3/75  (H3N2)  ).  Also,  placebo  and  Spray  were  administered 
intranasally  whereas  in  the  Rome  study  a  parenterally 
administered  vaccine  was  being  tested  at  the  same  time 
(  Influvac  Plain  )  and  the  placebo  was  also  administered 
parenterally.  A  third  difference  was  that  initial  levels 
of  secretory  antibody  were  lower  in  the  placebo  group  than 
in  the  Spray  group  in  the  Rome  trial.  The  reverse  is  true 
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In  the  analysis  of  the  results  of  Vaccine  trials  it 
is  important  to  know  why  an  effective  or  ineffective  result 
was  obtained.  (  Couch,  R.  B.  cited  in  Kilbourne  et  al.  (1973)). 
Like  must  be  compared  with  like  or  incorrect  conclusions  may 
be  reached.  For  example,  in  a  study  carried  out  in  volunteers 
by  Couch,  one  group  received  inactivated  vaccine  intranasally 
and  the  other  received  the  vaccine  intramuscularly.  When 
the  volunteers  were  subsequently  challenged  with  infectious 
virus,  the  results  in  neither  vaccinated  group  were  significantly 
different  from  those  in  control  groups.  However,  when  formation 
of  antibody  after  vaccination  was  assessed,  it  was  noted  that 
not  all  individuals  responded  to  the  vaccination  procedure 
with  formation  of  antibody.  When  only  those  who  actually 
developed  antibody  were  compared  with  controls,  significant 
protection  was  noted  in  both  vaccinated  groups.  In  addition, 
both  vaccinated  groups  developed  approximately  equal  antibody 
responses  in  serum  and  nasal  secretions,  and  the  degree  of 
protection  was  approximately  the  same.  Had  the  antibody 
response  not  been  assessed  in  this  way,  the  conclusion  would 
have  been  that  vaccines  given  by  any  route  are  ineffective 
in  producing  protection,  whereas  in  reality,  the  immune  response 
to  the  particular  preparation  used  and  the  method  of  vaccination 
was  less  than  optimal.  These  considerations  suggest  that 
vaccine  failures  may  be  attributed  frequently  to  failure  of  a 
vaccine  preparation  or  method  of  vaccination  to  elicit  an  immune 
response  rather  than  to  failure  of  an  elicited  immune  response 
to  protect  against  disease. 
There  is  ample  recorded  evidence  attesting  to  the 
protective  capacity  of  killed  Influenza  virus  vaccines.  Their 
protective  efficacy  averages  70-  90%  and  is  sufficiently  high 
to  find  practical  application  in  Public  Health.  Such 
application,  however,  has  been  directed  primarily  at  selected 
population  groups,  'in'particular  the  elderly  and  other 
individuals  who  are  immunologically  compromised  or  suffering 
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accorded  to  key  industrial  workers  in  an  effort  to  reduce 
absenteeism  and  the  attendant  losses  in  productivity. 
(  Lennette  (1981)  ).  Because  immunity  following  vaccination 
is  of  uncertain  duration  and  since  Influenza  type  A  viruses 
are  undergoing  continuous  antigenic  modification,  re-vaccination 
on  an  annual  basis  is  recommended. 
Inactivated  whole-virus  vaccines  administered  parenterally 
give  rise  to  a  low  incidence  of  local  or  systemic  reactions. 
Because  of  these,  children,  who  form  an  important  part  of  the 
population  at  risk,  have  generally  been  excluded  from  immun- 
isation  programmes.  However,  increased  realisation  that 
Influenza  A  virus  is  a  cause  of  serious  disease  in  infants  and 
young  children  has  led  to  increased  research  into  alternative 
methods  of  administration  of  vaccine.  (Glezen  et  al.  (1977)  ). 
Resistance  to  Influenza  represents  a  complex  and  subtle 
Interaction  of  humoral  and  cellular  factors.  In  consequence, 
a  more  effective  state  of  resistance  might  be  achieved  through 
the  use  of  a  live,  attenuated  virus  vaccine  which  mimics  natural 
infection  more  closely  than  the  Immunity  induced  by  inactivated 
virus  vaccine. 
Conventionally,  live,  attenuated  vaccines  are  administered 
to  the  upper  respiratory  tract  by  the  intranasal  route.  In 
adults  and  children  these  vaccines  have  been  shown  to  be  highly 
immunogenic  with  an  acceptable  rate  of  reactogenicity  (Tyrrell  et  al. 
(1981)  ).  However,  the  major  fear  of  attenuated  vaccines  is 
their  possible  reversion  to  virulence  in  an  unprotected 
population  because  of  the  risk  of  genetic  recombination. 
Another  curious  fact  which  has  emerged  from  recent  studies 
is  that  mammalian  cells,  infected  by  Influenza  type  A(  as 
well  as'by  other  viruses  )  show  an  increased  binding-of 
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superinfection.  It  has  been  suggested  that  the  use  of 
attenuated  vaccines  in  children  may  lead  to  an  increased 
incidence  of  bacterial  upper  respiratory  tract  infections. 
For  example,  otitis  media  and/or  pharyngitis  may  be  more 
common  in  these  situations  and  these  two  diseases  should 
probably  be  considered  as  potential  vaccine  complications. 
These  complications  may  not  yet  be  significant  in  the  United 
Kingdom  or  United  States  but  are  of  potential  significance 
in  countries  such  as  Japan  or  the  U.  S.  S.  R.  where  the  major 
emphasis  of  Influenza  immunisation  is  in  children  and  where 
attenuated  Influenza  virus  vaccines  are  currently  in  use. 
(  Kessler  (1980)  ). 
Meanwhile,  for  as  long  as  inactivated  Influenza  virus 
vaccines  are  in  use  in  this  country,  it  will  be  necessary  to 
keep  trying  to  complete  the  picture  of  anti-Influenza  Immunity 
both  local  and  systemic  so  that  current  vaccines  can  be  made 
more  effective 
In  the  second  part  of  this  thesis  an  attempt  has  been 
made  to  study  secretory  immunity  following  naturally  acquired 
Influenza  and  other  respiratory  bacterial  and  viral  diseases. 
The  dynamics  of  secretory  antibody  production  have  been 
investigated  in  terms  of  time  of  initiation,  variation  in 
total  duration  and  quantity  of  production  during  infection 
with  different  recognised  bacterial  and  viral  pathogens. 
Particular  attention  has  been  given  to  the  patient's  previous 
history  of  respiratory  infection  and  to  the  possibility  of 
malfunctions  in  the  secretory  system  as  may  happen  in  chronic 
bronchitis  and  emphysema. 
The  Initial  results  in  this  section  have  confirmed  that 
there  is  a  significant  response  in  terms  of  secretory  IgA 
production  following  natural  infection  with  a  bacterial  or 
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It  should  be  noted  that  in  Winter  1  there  were  five 
patients  with  no  detectable  sIgA.  The  possibility  arises 
that  these  patients  may  have  been  IgA  deficient. 
Serum  IgA  deficiency  is  commonly  defined  as  an  IgA 
level  below  0.02mg/ml.  (  being  the  detection  limit  of  the 
S.  R.  I.  D.  ).  When  the  concentrations  of  IgG  and  IgM  in  the 
serum  are  normal  or  increased,  the  designation  '  selective 
IgA  deficiency'  is  used.  Selective  IgA  deficiency  can 
occur  without  clinical  manifestations  :  in  patients  the 
symptoms  are  mainly  those  of  gastrointestinal  and/or 
respiratory  infections.  Since  serum  IgA  is  mostly  (  but 
not  always  )  associated  with  secretory  IgA  deficiency,  the 
clinical  symptoms  reflect  the  latter  deficiency  rather  than 
the  former.  The  incidence  of  selective  IgA  deficiency  in 
a  normal  population  has  been  estimated  to  be  between  0.03 
to  0.28%  and  an  occurrence  of  various  autoimmune  phenomena 
in  these  Individuals  is  well  known. 
In  addition,  the  occurence  of  transient  IgA  deficiency 
as  well  as  partial  IgA  deficiency  occurs.  Transient  IgA 
deficiency  has  been  observed  in  children  who  were  slow  to 
form  serum  IgA,  or  following  tonsillectomy  or  following  the 
use  of  certain  drugs  such  as  penicillamine  and  phenytoin. 
Slow  maturation  of  IgA  synthesis  early  in  life  may  lead  to 
the  development  of  allergic  disease.  (Review  of  IgA  Defiency, 
Schuurman  and  Zegers  (1980)). 
Three  of  the  five  patients  with  no  detectable  IgA  had 
normal  levels  of  serum  Immunoglobulins  (  the  other  two 
patients  could  not  be  traced.  )  This  suggests  that  they 
are  unlikely  to  be  IgA  deficient.  In  addition,  three 
patients  gave  no  history  of  frequent  respiratory  infections 
and/or  allergies.  In  one  the  history  was  unknown;  the 
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In  all  but  one  patient  the  levels  of  protein  detected  In 
the  nasal  swabs  were  normal.  This  excluded  incorrect  sampling. 
The  fifth  patient's  sample  had  a  very  low  protein  content, 
presumably  because  only  a  small  amount  of  mucus  had  been 
collected  instead  of  the  correct  sample.  It  is  also  possible 
that  a  highly  mucold  sample  might  'trap'  the  sIgA  and  render  it 
undetectable  In  the  electrophoresis  gel  system. 
In  several  specimens  the  sIgA  concentration  fell  to  zero 
during  the  seven  day  interval  between  specimens.  This  is 
highly  unlikely  to  happen  and  these  specimens  must  be  viewed 
with  suspicion.  It  is  possible  that  the  sIgA  Is  being  bound 
by  the  replicating  pathogen  and  is  therefore  not  free  to  react 
in  the  detection  system.  (  Ogra  and  Karzon  (1971)  ).  Alternatively, 
sIgA  may  have  fallen  to  a  level  below  the  sensitivity  if  the 
electrophoresis  test.  These  possible  explanations  for  falls  in 
sIgA  concentration  are  more  likely  to  be  correct  when  a  live 
pathogen  Is  replicating  than  when  an  Inactivated  vaccine  is 
administered. 
Variation  In  mucus  production  occurring  during  the  course 
of  a  respiratory  infection  will  also  affect  the  amount  of  sIgA 
detectable. 
Bacterial  pathogens  were  isolated  equally  often  from 
either  'acute'  or  'convalescent'  specimens  whereas  all  but  two 
of  the  viral  pathogens  were  isolated  from  the  'acute'  phase 
specimen. 
In  a  recent  article  in  The  Lancet  (  Editorial,  February 
27th.,  1982  )  the  possibility  that  viruses  may  Impair  the  immune 
response  against  bacteria  is  discussed.  As  well  as  damaging 
bronchial  and  alveolar  epithelium,  Influenza  viruses  often 
interfere  with  chemotaxis  of  polymorphs  and  macrophages  and 
probably  also  depress  immune  T-cell  function.  In  addition, 
there  Is  the  previously  mentioned  problem  that  Infection  with 
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increased  bacterial  adhesion  which  results  in  non-specific 
binding  with  increased  susceptibility  to  bacterial  super- 
infection.  Adenovirus  infections,  for  example,  are  seldom 
complicated  by  bacterial  pneumonia. 
Certain  micro-organisms  of  importance  in  human  disease 
such  as  Neisseria  sp.,  Candida  sp.  and  Vibrio  sp.  have  been 
shown  to  produce  proteolytic  enzymes  whose  only  known  substrate 
is  human  IgA.  These  IgA  proteases  impair  the  antibody 
function  of  IgA  even  though  these  enzymes  do  not  directly  affect 
the  primary  structure  of  the  antigen-binding  (F-ab)  region  of 
the  molecule.  Such  interference  with  the  local  defence  mech- 
anisms  is  likely  to  play  an  important  role  in  pathogenesis. 
(  Plaut  (1978)  ). 
Bacterial  supcrinfection  may  therefore  be  a  reason  for 
the  higher  incidence  of  'convalescent'  phase  bacterial  isolates. 
Local  defence  mechanisms  may  be  impaired  for  the  reasons  given 
above.  Interferon  production  may  also  be  important. 
The  'initial'  level  of  sIgA  depends  on  several  factors. 
The  duration  of  the'latent  period'  of  secretory  antibody 
processing  and  accumulation,  the  level  of  sensitisation  of 
the  secretory  immune  system  to  the  pathogen  and  the  intensity 
of  development  of  the  infectious  process  (  le.  the  length  of 
time  after  the  onset  of  infection  )  are  all  important. 
During  the  first  few  days  after  the  onset  of  respiratory 
infection  the  accumulation  of  sIgA  in  secretions  is  higher  in 
patients  with  low  initial  levels  of  sIgA.  This  suggests  that 
the  build-up  in  concentration  of  antibody  may  be  happening 
early  in  patients,  just  after  the  first  clinical  symptoms  appear. 
i 168 
The  suggestion  confirms  the  findings  of  Nf^uscova  et  al  (1976) 
but  contrasts  with  those  of  Schvartsman  and  Grigorieva  (1979) 
and  Rossen  et  al.  (1970)  who  showed  that  the  duration  of  the 
latent  period  of  sIgA  production  in  Influenza  A  varied  from 
3-  21  days  and  in  some  cases  was  even  longer. 
Rapid  build-up  in  concentration  of  sIgA  may  be 
attributed  to  factors  such  as  the  problems  involved  in 
pinpointing  the  time  of  onset  of  infection.  Unlike  the 
administration  of  vaccine  the  time  of  onset  of  natural  infection 
is  arrived  at  as  an  assessment  between  patients  and  doctor. 
It  is  important  to  realise  that  the  time  may  be  several  days 
before  the  onset  of  symptoms,  also  the  size  of  the  infecting 
dose  is  unknown  and  this  too  affects  sIgA  production. 
(Schvartsman  and  Zykov.  (1976)  ). 
Only  a  small  amount  of  IgA  is  present  in  the  sera  of 
newborn  babies  (Tomasi  and  Gray  (1972))and  in  a6  month  old 
child  levels  of  serum  IgA  are  equal  to  only  25%  of  the  amount 
formed  In  a  healthy  adult.  (Uffelman  et  al  (1970)).  However, 
in  the  child  sIgA  reaches  adult  levels  by  the  end  of  the  first 
month.  In  this  study,  during  both  winter  periods,  children 
under  the  age  of  4  years  showed  a  significant  sIgA  response 
to  respiratory  infection  and  appeared  to  be  synthesising 
antibodies  more  actively  than  adults.  This  finding  confirms 
reports  from  a  recent  Influenza  workshop  (Kilbourne  et  al  (1973)) 
but  contradicts  observations  by  Waldman  et  al,  1971  who  suggests 
that  secretory  antibodies  are  not  formed  as  actively  in  small 
children  as  In  adults  apparently  due  to  what  the  authors 
described  as  children's  less  intensive  production  of  sIgA. 
The  duration  of  antibody  production  following  natural 
infection  was  studied  in  14  patients.  Each  showed  an 
individual  pattern  of  sIgA  production.  This  individual  response 
caused  difficulty  in  assessing  the  duration  of  the  response 
because  no  clear  pattern  emerged. 169 
In  some  patients  detectable  sIgA  was  maintained  for  up  to 
12  months;  in  others  the  levels  dropped  but  were  re-stimulated 
rapidly  following  re-infection. 
Wright  et  al  (1983)  have  shown  that  secretory  antibody 
formed  after  natural  infection  with  Influenza  is  rather  persistent. 
Antibody  was  observed  in  8/8  children  for  3-6  months  post 
primary  infection. 
When  the  patients  in  this  study  were  examined  as  a  group 
it  became  clear  that  although  levels  of  sIgA  were  falling,  they 
were  maintained  at  a  rocket  height  of  3  mm  for  at  least  9  months. 
By  the  10th  month,  presumably,  the  respiratory  pathogens  were 
again  becoming  active  in  the  community  and  secretory  Immunity 
was  boosted.  Total  protein  production  followed  a  similar 
pattern. 
Information  about  the  influence  of  respiratory  infectious 
diseases  on  the  formation  of  secretory  antibodies  is  scanty  and 
often  contradictory.  In  adults  and  children  who  are  ill  with 
different  forms  of  bronchial  asthma,  secretory  antibodies 
are  formed  in  response  to  the  aerosol  administration  of 
inactivated  Influenza  vaccine  exactly  as  in  healthy  people 
(Newcomb  and  Eller(1971),  Waldman  et  al.  (1971)).  On  the  other  hand, 
patients  with  bronchopulmonary  disorders  had  weak  reactions  to 
the  same  vaccine.  It  is  possible  that  bronchitis  lessens  the 
intensity  of  antigen  sorption  and  therefore  also  lessens  the 
intensity  of  'trigger'  action.  (Shore  et  al.  (1973)).  South  et  al, 
(1968)  have  shown  that  in  infants  a  correlation  can  be  demonstrated 
between  the  absence  of  sIgA  and  repeated  episodes  of  acute  and 
susceptibility  to  chronic  respiratory  tract  infections,  regardless 
of  levels  of  serum  immunoglobulins. 
In  this  study  ,  patients  with  a  history  of  repeated  respiratory 
infections  and/or  allergies  showed  a  similar  sIgA  response  to  the 
study  group  as  a  whole  (ie.  no  deficiencies  in  sIgA  production 
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The  sIgA  and  total  protein  variations  are  remarkably  similar 
over  both  winter  periods.  In  addition,  no  correlation  was 
observed  between  base-line  levels  of  sIgA  and  the  frequency 
of  respiratory  infections.  This  confirms  the  work  of 
Yodfat  and  Silivan(1977).  They  found  that  children  who  responded 
to  infection  by  producing  higher  levels  of  sIgA  had  a  lower 
incidence  of  respiratory  tract  infection  than  those  who  did  not. 
This  finding,  in  turn,  supports  the  hypothesis  that  the 
responsiveness  of  the  host  in  the  production  os  sIgA  during 
Infection  is  important  in  protection  against  mucosal  infections. 171 
CHAPTER  5 
AREAS  FOR  FUTURE  DEVELOPMENTS 
Recent  technological  advances  have  brought  new,  rapid 
antibody-detecting  tests  to  the  laboratory.  Sensitive  tests 
such  as  F.  A.  T.  (  Fluorescent  Antibody  Test  ),  E.  L.  I.  S.  A. 
(  Enzyme-Linked  Immunosorbent  Assay  )  and  R.  I.  A.  (  Radio- 
immunoassay  )  have  great  implications  in  vaccine  research. 
sIgA  testing  is  no  longer  a  laborious,  time-consuming  problem 
and  large  numbers  of  secretions  can  be  screened  quickly  and 
easily. 
The  detection  and  quantitation  of  specific  slgA  also 
has  applications  in  the  Diagnostic  Laboratory.  Using  E.  L.  I.  S.  A., 
Grauballe  et  al.  (1981),  have  shown  that  Rotavirus  infections 
can  be  diagnosed  by  finding  specific  sIgA  in  serum.  The 
detection  and  quantitation  of  specific  sIgA  in  serum  and  In 
secretions  for  other  viruses  will  require  evaluation  but,  in 
time,  will  surely  become  an  accepted  method  for  diagnosis  of 
virus  infections. 
sIgA  is  important  in  protection  from;  infection  but  its 
role  in  recovery  is  still  unclear.  sIgA  production  during 
recovery  Is  part  of  a  more  complex  immunological  process  and  is 
subject  to  extensive  variations  within  a  group  of  individuals. 
The  Importance  of  T-dell  immunity  in  recovery  from  Influenza 
has  only  been  recognised  recently.  (  Wells  et  al.  (1981  a&  b); 
Yap  et  al.  (1978)  ).  The  mechanism  of  action  of  the  T-cells 
is  not  fully  understood.  However,  they  also  are  obviously 
only  a  part  of  a  very  complex  immune  system  for  they  initiate 
the  antibody  response  by  priming  B  -lymphocytes  and  they  also 
act  Independently.  T-cell  immunity  on  its  own  does  not  confer 
complete  immunity  but  is  likely  to  be  part  of  the  recovery 
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During  the  same  time  period  as  the  vaccine  trial  presented 
in  this  thesis  (1977  -  78),  large  scale  clinical  trials  were 
being  undertaken  in  USA  to  determine  the  safety  and  optimum  dosage 
of  inactivated  influenza  virus  vaccine  administered  parenterally. 
The  results  of  these  trials  demonstrated  that  the  test  vaccines 
were  safe  and  that  optimum  serological  responses  could  be  achieved 
when  the  vaccines  were  standardised  with  respect  to  their 
haemagglutinin  content.  (Galasso  et  al  (1977)).  In  1979,  four 
different  inactivated  influenza  virus  vaccines  were  tested  for  their 
reactogenicity,  immunogenicity  and  for  the  subsequent  persistence 
of  induced  antibody  in  adults.  The  results,  confirmed  the  American 
studies  but  still  left  unanswered  questions  about  the  degree  and 
duration  of  protection  offered  by  the  various  vaccine  schedules. 
(Cate  et  al  (1983)). 
Inactivated  influenza  virus  vaccines  are  usually  administered 
subcutaneously.  Given  this  way  they  can  elicit  both  local  and  serum 
antibody  responses  (Dowd  le  (1973)).  Their  use  by  the  intranasal 
route  has  not  received  much  support  presumably  because  their 
effectiveness  by  this  route  has  not  been  shown  to  be  superior. 
Despite  improvements  such  as  the  development  of  'subunit' 
Influenza  vaccines  the  protection  conferred  is  not  complete. 
As  a  consequence  there  is  renewed  interest  in  live,  attenuated 
vaccines  which  would  mimic  natural  infection  in  its  'broader'  and 
more  durable  immunity.  Murphy  et  al  (1982)  and  Wright  et  al  (1983) 
have  shown  recently  that  stimulation  of  secretory  immunity  by  the 
use  of  live  virus  is  important  in  protection  following  influenza 
vaccination. 
Only  when  the  total  complexity  of  the  immune  response  to 
influenza  is  elucidated  will  it  be  possible  to  devise  completely 
effective  vaccines.  The  eradication  of  respiratory  disease  will 
then  be  a  realistic  goal. 173 
APPENDIX  I 
Contractions  used  in  this  Thesis. 
Ab.  Antibody 
Ag.  Antigen 
AgMK  :  African  Green  Monkey  Kidney 
B.  A.  L.  T.  Bronchus  Associated  Lymphoid  Tissue 
C.  D.  S.  :  Communicable  Diseases  Scotland, 
Ruchill  Hospital,  Glasgow. 
C.  F.  :  Complement  Fixation 
d  or  x  Mean 
d.  of  f.  Degrees  of  Freedom 
E.  I.  D.  50  Egg  Infective  Dose  (50%) 
ie.  the  dose  of  virus  which  Infects 
50%  of  the  eggs  under  test. 
E.  L.  I.  S.  A.  Enzyme  Linked  Immunosorbent  Assay 
F.  A.  T.  :  Fluorescent  Antibody  Test 
F.  I.  T.  C.  :  Fluorescein  Isothiocyanate 
F  (ab)  Antigen  binding  region  of  immunoglobulin 
F  (c)  :  Complement  fixing  region  of  immunoglobulin 
G.  A.  L.  T.  Gut  Associated  Lymphoid  Tissue 
G.  I.  tract  :  Gastro-intestinal  tract 
G.  U.  tract  :  Genito-urinary  tract 
G.  M.  T.  Geometric  Mean  Titre 
'd-globulin  :  Immunoglobulin 
H.  A.  :  Haemagglutinin 
H.  A.  unit  Haemagglutinating  unit 
H-I  :  Haemagglutination-Inhibition 
IgA  :  Immunoglobulin  type  A 
IgE  type  E 
IgG  type  G 
IgM  type  M 
I.  D.  D.  :  Immuno  Double  Diffusion 
I.  E.  :  Immunoelectrophoresis 
Infs.  :  Infections 
I.  U.  :  International  Units 174 
L  :  Lymphocyte 
M.  E.  M.  :  Minimal  Essential  Medium 
H  Population  number 
N.  A.  :  Neuraminidase 
O.  D.  :  Optical  Density 
P.  B.  S.  :  Phosphate  Buffered  Saline 
P.  P.  :  Peyer's  Patches 
Q.  H.  :  Quantitative  Haemadsorption 
r.  b.  c.  :  Red  blood  cells 
R.  D.  E.  :  Receptor  Destroying  Enzyme 
R.  I.  A.  :  Radloimmunoassay 
S.  C.  Secretory  Component 
S.  D.  :  Standard  Deviation 
S.  E.  :  Standard  Error 
sIgA  Secretory  Immunoglobulin  type  A 
S.  R.  D.  Single  Radial  Diffusion 
S.  R.  H.  Single  Radial  Haemolysis 
U.  R.  T.  I.  :  Upper  Respiratory  Tract  Infection 175 
APPENDIX  II 
PROTOCOL  FOR  A  DOUBLE-BLIND  PLACEBO-CONTROLLED  STUDY  OF  LOCAL 
AND  SERUM  ANTIBODY  RESPONSES  OVER  A  PERIOD  OF  FOUR  MONTHS 
AFTER  INTRANASAL  ADMINISTRATION  OF  INACTIVATED  INFLUENZA  VIRUS 
VACCINE  AND  OF  THE  IMMUNITY  CONFERRED  AS  ASSESSED  BY  ARTIFICIAL 
INFECTION  WITH  AN  ATTENUATED  LIVE  VIRUS  VACCINE  STRAIN. 
Product  Influvac  Spray 
Kind  of  Study 
.  1.  Antibody  response  (local  and  serum) 
over  4  months 
2.  Protection  against  challenge  with 
Gripovax  RIT  4050 
Country  :  United  Kingdom 
Route  of  Administration  :  Intranasal  (Influvac  Spray  and  Gripovax) 
Dosage  :  Influvac  Spray  : 
400  I.  U.  A/Victoria/3/75  (H3N2) 
400  I.  U.  B/Hong  Kong/8/73 
Gripovax  107  EID  50 
No.  of  Subjects  about  40  pre-selected  from  150. 176 
Composition  of  Vaccines. 
The  antigenic  composition  of  the  vaccines  used  in  this  study 
will  be  as  follows  per  dose 
1.  Influvac  Spray  :  A/Victoria/3/75  (H3N2)  400  I.  U. 
B/Hong  Kong/8/73  400  I.  U. 
1  dose  =4  "puffs"  intranasally. 
2.  Gripovax  :  A/Victoria/3/75  (H3N2)  strain  RIT4050 
1  dose  =5  drops  of  reconstituted  vaccine 
Into  each  nostril.  (107  EID50)' 
3.  Placebo  material  :  an  aerosol  with  the  same  appearance  and 
composition  as  Influvac  Spray  except  that 
it  does  not  contain  virus. 
The  above  vaccines  are  registered  in  the  United  Kingdom  and  are 
approved  by  the  National  Institute  for  Biological  Standards  and 
Control. 
Selection  of  Study  Subects. 
About  150  previously  unvaccinated  healthy  subjects  will  be  initially 
invited  by  an  explanatory  circular  letter  to  participate  in  the 
investigation.  They  will  be  informed  of  the  need  to  collect  blood 
samples  and  nasal  washings  on  several  occasions  during  the  course 
of  the  study  which  will  cover  a  period  of  about  6  months.  Volunteers 
will  be  told  that  an  Investigation  of  the  efficiency  of  an  Inactivated 
spray  vaccine  will  take  place  during  the  vaccination  programme  which 
will  also  involve  Inoculation  of  a  live  attenuated  Influenza  vaccine. 
An  outline  of  the  study  will  be  given.  They  will  be  asked  to  sign 
a  consent  form.  Volunteers  will  of  course  be  completely  free  to 
withdraw  from  the  study  at  any  time. 177 
Excluded  from  this  Study  will  be  : 
-  all  subjects  who  are  known  to  be  hypersensitive  to  : 
.  egg  products,  chicken  meat  or  feathers 
.  neomycin 
-  all  subjects  who  at  the  time  of  the  vaccination  show 
symptoms  of  acute  or  chronic  respiratory  disease 
-  all  subjects  who  show  pre-vaccination  serum  H-I  titres 
>40  against  Influenza  A/Victoria/3/75. 
Allocation  to  Study  Groups  and  Vaccination  Scheme. 
Subjects  included  in  the  study  will  be  divided  at  random  in 
2  equal  groups  according  to  a  pre-determined  scheme.  It 
is  hoped  that  at  least  40  subjects  (le.  20  subjects  per 
group)  will  be  recruited. 
Vaccination  with  a  freeze-dried,  bivalent,  aerosol, 
inactivated  Influenza  vaccine  (  Influvac  Spray  )  and  a 
placebo  preparation  will  be  done  on  a  double-blind  basis. 
Four  months  after  vaccination  all  subjects  will  receive 
one  dose  of  a  live  monovalent  vaccine  (le.  A/Victoria/3/75 
(H3t12)  :  Cripovax). 
Mode  of  Administration  of  Vaccines. 
Influvac  Spray  and  the  spray  placebo  will  be  administered 
into  both  nostrils  during  deep  and  slow  inhalation.  A 
single  dose  of  the  vaccine  (le.  4  "puffs",  2  into  each 
nostril  )  will  be  administered. 
Cripovax  will  be  administered  by  instilling  5  drops  of  the 
reconstituted  vaccine  into  each  nostril  with  the  subject 
lying  supine  with  head  extended  and  eyes  closed  (  as 
recommended  by  the  manufacturer  ). 178 
Collection  of  Specimens. 
A.  Blood  Sampling 
Blood  (I) 
From  all  volunteers  (  potential  participants)  blood  samples 
(8  ml.  )  will  be  collected  before  (  on  Day  -14)  the  start  of 
the  study  (  vaccination  on  Day  0). 
Blood  (II) 
From  all  study  participants,  a  second  blood  sample  (8  ml.  ) 
will  be  collected  6  weeks  after  vaccination  (  on  Day  42). 
Blood  (III) 
Before  administration  of  live  vaccine  (  on  Day  112)  a  new 
blood  sample  (6  ml.  )  will  be  taken  from  all  subjects. 
Blood  (IV) 
From  all  participants  a  final  blood  (8  ml.  )  sample  will  be 
taken  6  weeks  after  vaccination  with  live  vaccine. 
B.  Nasal  Washings 
These  will  be  collected  from  all  subjects  on  the  day  of 
vaccination  (  1/2  hour  before)  and  subsequently  6  and  16 
weeks  after  vaccination  and  again  6  weeks  after  inoculation 
of  the  live  Influenza  vaccine. 
Labelling  of  Samples 
The  blood  samples  and  nasal  washings  should  be  labelled 
with  the  white  labels  supplied  by  Duphar. 
On  the  label  should  be  clearly  mentioned  I,  II,  III  or  IV 
with  the  date  of  taking  the  sample  and  the  code  number  of 
the  subject. 179 
Storage  and  Transport  of  Serum. 
Separation  of  serum  from  the  collected  blood  samples  should 
be  performed  on  the  day  of  collection.  The  first  batch  of 
sera  (  about  150  )  will  be  titrated  for  H-I  antibodies  against 
A/Victoria/3/75  (  H3N2  ).  After  titrations,  the  remaining 
sera  will  be  stored  at  -20  C.  The  set  of  sera  from  the 
second,  third  and  fourth  blood  collected  will  be  stored  at 
-20  C  until  used. 
Titration  of  Sera. 
This  will  be  done  by  the  standard  Haemagglutination-inhibition 
(  H-I  )  titration  techniques  in  routine  use  in  Belvidere  Hospital 
Laboratory.  The  first  batch  of  sera  will  be  titrated  directly 
on  arrival  in  order  to  select  those  subjects  who  will  be  admitted 
to  the  study.  At  the  end  of  the  study  all  collected  sera  from 
each  subject  will  be  titrated  simultaneously,  using  the  vaccine 
strains  as  antigens. 
Titration  of  Nasal  Washings. 
All  nasal  washings  will  be  titrated  at  the  end  of  the  study  for 
total  and  specific  sIgA  by  the  techniques  in  current  use  in  the 
Belvidere  Hospital  Laboratory.  Until  used  they  will  be  stored 
In  the  frozen  state. 
Material  and  Coding. 
Influvac  Spray  and  the  placebo  material  will  be  prepared  by 
Philips-Duphar  B.  V.  and  provided  in  code  numbered  vials  of 
identical  appearance. 
The  coding  will  be  done  by  the  Statistical  Department  of 
Philips-Duphar  B.  V. 
The  live  attenuated  vaccine  (  Gripovax  )  will  be  imported 
from  Belgium. 180 
Evaluation  of  Results. 
Infection  with  the  live  vaccine  will  be  diagnosed  by  serology. 
A  4-fold  or  greater  rise  in  serum  H-I  and/or  C.  F.  'titre  against 
A/Victoria/3/75  and/or  a  significant  local  specific  antibody 
response  will  be  taken  as  diagnostic. 
Safety  Precautions. 
It  is  important  that  all  Physicians  involved  in  this  study 
follow  the  protocol  exactly  and  remember  that  some  of  the 
exclusions  in  the  patient  selection  scheme  are  designed  to 
avoid  Inclusion  of  patients  who  may  react  adversely  to  one  or 
more  agents  administered  during  the  study  or  to  Inclusion  in  a 
clinical  study  of  this  type. 
Very  few  therapeutic  agents  are  completely  devoid  of  all 
possible  risks  of  causing  side  effects.  The  Physicians 
involved  in  the  execution  of  this  study  should  adhere  to  the 
protocol  and  should  be  aware  of  what  are  the  main  possible 
side  effects  of  the  drugs  used  in  this  study  and  the 
investigator  should  ensure  that  any  drugs  or  equipment 
required  to  handle  such  situations  are  reasonably  accessible 
during  the  study. 
Date  of  Start  of  Study. 
October,  1977  (  Ist.  blood  sample). 
End  of  Study. 
April,  1978. 
It  Is  important  that  the  investigator  and  his  trained  colleagues, 
whom  he  selects  to  assist  him  in  this  study,  adhere  strictly  to 
this  2rotocol. 181 
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APPENDIX  III 
Statistical  Analyses 
1.  Geometric  Mean  Titres 
The  Geometric  mean  is  obtained  by  multiplying  all  the 
values  together  and  taking  the  Nth'  root  of  the  product 
where  there  are  tJ  values  in  the  sample. 
This  may  be  expressed 
tJ  ,N  gF  (x)  =  x1t  x2.  x3.....  xN 
where  g  is  the  geometric  mean  and  P  (x)  is  the  product 
of  all  the  values  of  x.  It  is  most  easily  calculated  by 
using  logarithms.  If  the  logarithms  of  all  the  numbers 
are  added  together,  the  sum  of  the  logarithms  will  be  the 
logarithm  of  the  product  of  the  numbers.  If  this  sum 
is  divided  by  N,  it  will  give  the  logarithm  of  the  Nth. 
root  of  the  product,  that  is  the  logarithm  of  the 
geometric  mean.  Therefore  the  antilog  of  this  mean 
value  is  the  Geometric  mean  value. 
2.  Coefficient  of  Variance..  (  C.  V.  = 
S'D' 
x  100%  ) 
X 
The  coefficient  of  variance  is  a  percentage  of  the 
standard  deviation  divided  by  the  mean  of  a  set  of  data. 
It  is  a  measure  of  the  variability  of  the  data. 183 
3.  The  Student  't'  Test. 
The  't'  test  was  used  to  determine  whether  there  was  a 
significant  difference  between  the  values  found  in  two 
discrete  sets  of  data.  This  analysis  compares  the  means 
and  standard  deviations  obtained  from  both  populations  using 
the  following  formula  : 
xl  -  x2  where  an 
j! 
Dl2+SDj2  SD  =  standard  deviation 
Nl  2N= 
population  size 
The  't'  value  is  then  compared  with  the  't'  distribution 
table.  (  Fisher  and  Yates  (  1963  ))  at  (n1-1)  +  (n2-1)  degrees 
of  freedom  and  aP  value  is  obtained  which  indicates  the 
probability  that  two  sets  of  data  are  related,  assuming  the 
normal  distribution.  A  significant  difference  is  one  which 
has  a  probability  of  less  than  or  equal  to  5%  which 
corresponds  to  1.96  times  the  standard  error.  If  the 
probability  is  less  than  or  equal  to  1%,  the  difference  is 
highly  significant. 184 
APPENDIX  IV 
Buffers  and  Reagents. 
1.  Buffers  : 
Phosphate  Buffered  Saline 
B.  Og  Sodium  chloride 
0.2g  Potassium  dihydrogen  orthophosphate 
2.9g  Di-sodium  hydrogen  orthophosphate 
0.2g  Potassium  chloride 
1  Litre  Distilled  water. 
Michaelis'  Buffer  (  for  Immunoelectrophoresis  ) 
19.43g  Sodium  acetate 
29.43g  Barbital  sodium  Solution  A 
1  Litre  Distilled  water 
8.5%  Sodium  chloride  solution  Solution  B 
0.114  Hydrochloride  sulution  Solution  C 
Add  50m1.  of  solution  A  to  20m1.  Of  solution  B. 
Adjust  pH.  to  8.6  with  solution  C.  Make  up  volume 
to  250m1.  with  distilled  water. 185 
2.  Media  : 
Monkey  Kidney  Medium 
(  for  the  growth  and  maintenance  of  monkey  kidney  cells  ) 
M.  E.  M.  medium  and  Earles  Salts  containing 
0.85g/litre  Sodium  bicarbonate 
10%  Foetal  Bovine  Serum  (Growth  medium) 
2%  (Maintenance  medium) 
100  units/ml.  Penicillin 
l0ug/ml.  Streptomycin 
25  units/ml.  Nystatin 
300ug/ml.  Glutamine 
Monkey  Kidney  Serum-Free  Medium 
(  for  Quantitative  Haemadsorption  Test  ) 
199  medium  and  Earles  Salts  containing 
2%  Hepes 
0.15%  Sodium  bicarbonate 
100  units/ml.  Penicillin 
l0ug/ml.  Streptomycin 
25  units/ml.  Nystatin 
300ug/ml.  Glutamine 186 
3.  Immunoelectrophoresis  Reagents  : 
Coomassie  Stainer 
5g 
450m1. 
l00m1. 
450m1. 
Coomassie  Brilliant  Blue 
Ethanol  (96%) 
Acetic  acid 
Deionised  water 
Add  Coomassie  dye  to  Ethanol/  Acetic  acid  mixture  and  leave 
at  room  temperature  overnight.  Filter  the  solution  before 
adding  the  water. 
Destalner 
250m1.  Ethanol  (96%) 
100ml.  Acetic  acid 
450ml.  Deionised  water. 187 
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